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Abstract 
Bypassing all the research advances made in the last decades, cancer remains as 
a major public health problem affecting millions of people worldwide. The most recent 
advance in the tumor biology field was the discovery of cancer stem cells (CSCs) and of 
their implication in the metastatic disease, the main cause of cancer patients’ mortality. 
CSCs were shown to drive tumorigenesis and differentiation, contributing to tumors’ 
heterogeneity and to their chemo- and radiotherapy resistance and eventually relapse. 
Although targeted therapeutic approaches have been developed to abolish them, CSCs 
managed to reemerge through dedifferentiation of other tumor cells, condemning these 
therapies. The mechanisms behind dedifferentiation process are still unclear and were 
part of the main focus of this project. 
Lung cancer is one of the most common neoplasias worldwide. Its prevalence is 
increasing due to the widespread smoking habits and increasing accumulation of at-
mosphere pollutants. In this work hexavalent chromium [Cr(VI)] was selected as a model 
for lung carcinogenesis mainly due to is increasing occupational relevance. The non-
malignant human bronchial epithelial airway system 2B (BEAS-2B) was malignantly 
transformed into the RenG2 cell line using low density culture in the presence of Cr(VI). 
A parallel control cellular system (Cont1) was produced under the same conditions, 
though, in the absence of Cr(VI). Two additional derivative cell lines were attained fol-
lowing serial rounds of injection in immunocompromised mice, and named DRenG2 and 
DDRenG2, respectively. A panoply of techniques was then used to characterize the at-
tained cellular systems leading to the hypothesis of CSCs involvement in Cr(VI)-driven 
BEAS-2B malignant transformation. The sphere-formation assay tested this hypothesis 
and allowed the isolation of CSC spheres (SC-DRenG2 and SC-DDRenG2 cells, respective-
ly), but only from the derivative cell lines. These results suggested that a dedifferentia-
tion process featured CSCs’ formation during RenG2 derivation in nude mice. 
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The involvement of the mouse stroma in the dedifferentiation process was un-
covered by surgical isolation of lumbar stromal cells (FR fibroblasts) from the subcuta-
neous compartment and their subsequent co-culture with RenG2 cells. Following two 
months, RenG2 cells were isolated from the upper compartment (iRenG2) and tested for 
their ability to form spheres. Gene and protein expression analysis were used to com-
pare iRenG2 cells’ signature with those of RenG2, DRenG2 and SC-DRenG2, showing that 
iRenG2 cells were no longer similar to RenG2 but rather more close to both DRenG2 and 
SC-DRenG2. Finally, the study of the conditioned media from co-cultured cells identified 
interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF) and Activin-A as the 
potential paracrine orchestrators of this stromal-induced dedifferentiation process. 
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Resumo 
Contornando os avanços científicos feitos nas últimas décadas, o cancro prevalece 
como um grande problema de saúde pública que afeta milhões de pessoas por todo o 
mundo. O avanço mais recente feito no campo da oncobiologia foi a descoberta das 
células estaminais tumorais (CETs) e do seu envolvimento na doença metastática, a 
principal causa de morte em doentes oncológicos. Subsequentemente ficou demonstra-
do que as CETs regulam a tumorigenicidade e o grau de diferenciação tumoral, sendo 
ainda responsáveis pela resistência às terapias convencionais e pelas recidivas. Mais 
recentemente foram desenvolvidas terapias direcionadas especificamente a estas célu-
las que, no entanto, não surtiram o efeito esperado, uma vez as CETs conseguem rege-
nerar-se por dediferenciação a partir de outras células do tumor. Os mecanismos subja-
centes ao processo de dediferenciação são ainda desconhecidos, constituindo a sua 
caracterização parte dos objetivos deste trabalho. 
 O cancro do pulmão é uma das neoplasias mais frequentes. A sua prevalência 
tem aumentado nos últimos anos, principalmente devido ao acréscimo dos hábitos 
tabágicos e à acumulação de poluentes atmosféricos. Neste trabalho utilizou-se o cró-
mio hexavalente [Cr(VI)], um agente carcinogénico cujos níveis atmosféricos e relevân-
cia ocupacional têm aumentado significativamente nos últimos anos. Para os nossos 
estudos selecionámos uma linha celular não maligna de epitélio bronquial humano 
(BEAS-2B), a qual foi malignizada por cultura a baixa densidade na presença de Cr(VI), 
originando a linha celular RenG2. Em paralelo, uma linha controlo cultivada a baixa den-
sidade na ausência de Cr(VI) (Cont1) foi também estabelecida. Visando aumentar o seu 
potencial maligno, as células RenG2 foram injetadas em murganhos imunocomprometi-
dos e uma nova linha celular (DRenG2) foi estabelecida a partir do tumor formado. Este 
processo foi repetido com as células DRenG2, tendo-se obtido as células DDRenG2. 
Diversas técnicas de biologia celular e molecular foram então utilizadas para caracterizar 
os vários sistemas celulares, tendo os resultados obtidos sugerido o envolvimento de 
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CETs na malignização das células BEAS-2B. Esta hipótese foi testada usando o ensaio de 
formação de esferas, no qual se observou a formação de colónias SC-DRenG2 e            
SC-DDRenG2, apenas nos dois sistemas derivados, DRenG2 e DDRenG2, respetivamente. 
Os resultados obtidos sugeriram que a formação de CETs na população de RenG2 inje-
tada em murganhos imunocomprometidos decorreu de um processo de dediferencia-
ção, provavelmente orquestrado pelas células do estroma do compartimento subcutâ-
neo do animal. Para testar esta teoria, foram isoladas cirurgicamente células da região 
lombar de murganhos singénicos aos anteriores, e uma linha primária de fibroblastos 
(FR) foi estabelecida. A sua subsequente co-cultura com as células RenG2 durante dois 
meses levou à formação de uma população de CETs no seio das células RenG2 isoladas 
(iRenG2), cuja posterior caracterização mostrou serem mais semelhantes às DRenG2 e 
SC-DRenG2 do que às suas progenitoras RenG2. Por fim, o estudo dos meios condicio-
nados das células em co-cultura identificou a Interleucina-6 (IL-6), o Factor estimulador 
de colónias derivado de granulócitos (G-CSF) e a Activina-A como potenciais mediadores 
parácrinos do processo de dediferenciação induzido pelas células do estroma do murga-
nho. 
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Chapter 1  
Cancer 
Cancer is probably one of the most intriguing mysteries of biology and medicine. 
With its intricate pathways and deceiving strategies, it has always managed to defeat its 
aggressors and win the battle against cure. Acting as a professional spy, cancer keeps 
evading the tremendous amount of knowledge that has been acquired on the biology of 
tumors, avoiding even the most elegant and fine-tuned therapeutic approach. 
1.1 From Pre-historic times to the XXI century: 
an historic perspective  
Paleopathological reports indicate that tumors could be found in animals 
that inhabited Earth long before men, during the pre-historic times (Haddow, 
1936). The first evidence of tumors in men’s evolutionary lineage came out this 
year by the hand of an American anthropologist who reported the discovery of a 
Neanderthal skeleton in Croatia with a rib that preserves bony indications of a fi-
brous dysplastic tumor (Monge et al., 2013). The next references to malignant 
growths in men appear in the Edwin Smith Papyrus, dated from 3000 BC, where 
breast tumor was described as a grave disease to which no treatment was avail-
able (Hajdu, 2011a). After that, the next reference came from the Ebers Papyrus, 
dated from circa 1500 BC, mentioning an ulcerative soft-tissue tumor, treated at 
the time with the Egyptian ointment, an arsenical paste used until the XIX centu-
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ry (Garrison, 1926; Hajdu, 2011a). This second papyrus also referred to the iden-
tification of skin, uterus, stomach, and rectum tumors (Hajdu, 2011a). 
Tumor treatment was firstly approached by the Egyptians. Besides the ar-
senical past, Egyptians tried to use salts to prevent the malignant growth (Hajdu, 
2011a). Afterwards, Indians introduced the use of knifes to surgically resect the 
more exuberant and localized malignant masses (Garrison, 1926), followed again 
by Egyptians who redesigned the surgical technique by introducing the cautery 
and describing specific surgical protocols very alike to the ones still practiced to-
day (Hajdu, 2011a; Papavramidou et al., 2010; Sudhakar, 2009). At the same 
time, other oriental civilizations like Indian, Hebrew and Chinese also contributed 
with their insights to the malignant growth prevention by introducing some 
herbal remedies like tea, figs, boiled cabbage, and fruit juices, as well as  pastes 
of iron, copper, sulfur, and mercury in more extreme cases (Hajdu, 2011a). 
The advent of Greek civilization was accompanied by profound changes in 
the way that life was seen by ancient populations. Disease started to be learned 
as a natural biological process and not as a mere God punishment for improper 
conduct or the result of dark magic, as a consequence, major important advanc-
es occurred in the fields of pathophysiology and therapy. Hippocrates (460-375 
BC) was the first personality of history to use the words carcinoma and cancer to 
differentiate between malignant and ulcerative malignant tumors, respectively 
(Hajdu, 2011a). These words root from the Greek word karkinos that means crab, 
highlighting the similarities that Hippocrates found between the growth of a tu-
mor throughout the human body and the movement of a crab in the sand. In his 
works, he also introduced the term scirrhus or hard tumor, to depict tumors with 
uncertain malignant potential, and described anorectal condylomas and polyps 
aided by the use of a speculum (Hajdu, 2011a). Regarding therapy, Hippocrates 
introduced the notion and practice of palliative cares for tumors he classified un-
treatable and surgical removal for the others. He also advised lotions and cautery 
use for superficial lesions and knife extraction for deep tumors (Hajdu, 2011a). 
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After the decline of the Greek empire, Romans ascended to the power. 
Roman physicians essentially continued the traditions of the Greek colleagues, 
despite introducing their own new philosophies, one being the change of the sci-
entific language to Latin. Aulus Celsus (25 BC-50 AD), the first eminent roman 
physician working on cancer, made reference to tumors of visceral and paren-
chymal organs and described a wide range of superficial cancers (Haddow, 1936). 
He also differentiated cancer from other non-malignant cellular proliferations 
and highlighted the involvement of the axillary glands in mammary carcinoma 
(Garrison, 1926). Even though already aware of metastatic dissemination of pri-
mary tumors, particularly of the breast, Celsus kept on with the Hippocratic as-
sumption that cancer resulted from an excess or deprivation of blood, mucus, 
bile, and/or other body secretions (the humors), particularly at old age, the so 
called Humoral Theory (Sudhakar, 2009). In agreement, Claudius Galen (130-200 
AD), another physician of Rome, declared cancer as disease of the sick that 
should be treated with purgatives to diminish the accumulation of black bile 
(Hajdu, 2011a). He also agreed with the cancer denomination attributed by Hip-
pocrates, as he once said that “as a crab is furnished with claws on both sides of 
its body, so, in this disease, the veins which extend from the tumor represent 
with it a figure much like that of a crab” (Haddow, 1936). This Greek physician 
was also responsible for the attribution of the name sarcoma to the tumors with 
the appearance of raw meat (in Greek sarkos) (Garrison, 1926).  
Following the decline of the Western Roman Empire, progress of medi-
cine was left in the hands of the Byzantine Empire. By combining oriental medi-
cine principles with the theoretical knowledge propagated from Greece, this 
population produced a great deal of knowledge regarding the different tumor 
types. The first insights into the cancer of the uterus were done by Aretaeus (81-
138 AD), who made a comprehensive description of signs and symptoms com-
monly associated to these tumors. Later on, Oribasius of Baghdad (325-403) ob-
served that cancers were not as red as inflammatory lesions and were habitually 
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painless. Aetius (527-565) introduced the treatment of breast cancer by amputa-
tion of the entire breast and established that ulcerated cancers should be given 
no treatment. Simultaneously, the cancer of the esophagus was approached by 
Avenzoar (1070-1162). Lanfranc (1252-1315) firstly described how to differenti-
ate benign tumors of the breast from cancer and proclaimed that cancer “could 
only be cured by entire removal, along with its roots” (Garrison, 1926; Hajdu, 
2011a). 
The almost 1000-year-old theory of the humors of Galen was publically 
rejected for the first time by Henri de Mondeville (1260-1320), who stressed that 
scirrhus and carcinoma mean the same and that both of them were cancer. The 
French physician was responsible for introducing some organization in the field 
of oncology. He realized that the history of prior lesions was essential for the un-
derstanding of tumors and proposed a classification of cancers based on their 
size, anatomic site, and whether the tumors were superficial or deep in location. 
On break with the prevailing paradigm, Mondeville firstly introduced the idea of 
external carcinogens which according to the author could make their way to the 
body through the orifices of the glands (Hajdu, 2011a).  
In 1315, in Bologna, Italy, the first public postmortem dissection of two 
human cadavers took place and the first steps for autopsy studies were taken. 
Nearly a century later, in 1450, Johannes Guttenberg (1395-1468) developed the 
movable-type printing. These two independent events marked the beginning of 
the Renascence, a period that was marked by an intense knowledge production, 
mainly based on experimental science (Hajdu, 2011b). The introduction of autop-
sies as current practice rendered the cause of many deaths and highly increased 
the knowledge on anatomy, allowing a better understanding of cancer in its dif-
ferent perspectives, as, for instance, epidemiology. In agreement, Ambroise Paré 
(1510-1590) in his cadaver dissection studies observed that malignant tumors 
were far more common and more dangerous in women than in men (Garrison, 
1926). 
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By the early 1600s, anatomic dissections and scientific illustration had 
been so perfected that very few anatomic details remained undisclosed. The il-
lustration of tumors in particular was pioneered by Marco Aurelio Severino 
(1580-1656) who made dozens of images depicting some of the largest carcino-
mas and sarcomas he had operated on (Hajdu, 2011b). The movable-type print-
ing turned out a very professional way of diffusing this knowledge among the 
scientific community in a fast and efficient manner. 
The microscopy studies and the establishment of the cellular theory by 
Robert Hook (1635-1703), pretty much influenced by the work of other contem-
porary microscopists, led Marie Xavier Bichat (1771-1802) to reveal the lobular 
nature of cancer, which he ascribed to the proliferation of the connective tissue, 
and also to differentiate between the tumor parenchyma, or nutritive base, and 
its stroma, or degenerated element (Garrison, 1926). As a consequence of these 
observation, the microscope was introduced as a tool for diagnosis of tumors by 
Michael Etmullerus (1644-1683) and Bichat postulated that cancer forms as the 
result of pathologic changes in the tissues (Hajdu, 2011b). This observation was 
further corroborated by Johannes Müller (1801-1858) who demonstrated that 
rather of being made of lymph, cancer was made of cells grouped within the 
connective tissue of an organ with profound affection or infection of whole sys-
tem through vascular dissemination – the Blastema Theory (Garrison, 1926; 
Sudhakar, 2009). He was the first author to demonstrate a nuclear epithelium in 
cancerous tissues and to establish a classification of the different carcinomas 
based on detailed microscopic observation of tumor samples (Hajdu, 2012a). As 
a disciple of Müller, Rudolph Virchow (1821-1902) continued to study the cellular 
origins of cancer and postulated a new theory according to which tumors are the 
result of the proliferation of connective tissue’s cells in response to a chronic irri-
tating element or secretion – The Chronic Irritation Theory (Garrison, 1926; 
Sudhakar, 2009).   
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The term metastasis to describe the dissemination of the primary tumor 
to other locations in the body was first introduced by Joseph Recamier (1774-
1852) (Hajdu, 2012a). At the time it was believed that some unidentified fluid 
and not cells conducted the metastatic process (Sudhakar, 2009), and that the 
lymphatic system played a crucial role in the process (Garrison, 1926). Later on, 
Karl Thiersch (1822-1895) showed that cancers metastasize through the spread 
of malignant cells and subsequently, Theodor Billroth (1829-1894) first recogniz-
ing that carcinomas spread preferentially through the lymphatic vessels while 
sarcomas preferably use blood vessels. John Birkett (1815-1904) observed for 
the first time malignant epithelial cells breaking through the basement mem-
brane of an epithelium to initiate the metastatic process, a step called 
microinvasion (Hajdu, 2012a).  
The XX century was a period during which the knowledge on oncology 
sciences grew exponentially. In accordance, Steven Hajdu and Farbod Darvishian 
recently stated that “in the three decades from 1910 to 1940, more progress 
took place in cancer research and the diagnosis and treatment of cancers than 
during the prior centuries combined” (Hajdu and Darvishian, 2013). As a matter 
of fact, the technological boom observed at the time greatly propelled scientific 
advance as new and better cell laboratory conditions and techniques were estab-
lished. Alexis Carrel (1873-1944) gave the first steps in the culture of tumor cells 
while Theodor Boveri (1862-1915) set the basis for the Chromosomal Theory of 
Cancer by evidencing that cancer can be triggered by chromosomal mutations 
(Hajdu and Darvishian, 2013). Animals started to be used to xenotransplant tu-
mors which resulted in the observation that some tumors are specie-specific 
while others are not. Also chemical- and radiation-induced tumors were discov-
ered as were some biological agents capable of inducing neoplastic growth. Dur-
ing the 20’s, James Ewing (1866-1943) reconfirmed inflammation as a main cause 
of cancer and advised early diagnosis as the better approach to treat cancer, 
which should be done using a multidisciplinary approach combining radiological 
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screening with clinical examination and microscopic observation of tumor biop-
sies. Ewing was the first to indicate that large number of tumor cells in mitosis, 
cellular pleomorphism, hypervascularity, and tumor necrosis were biomarkers of 
increased malignancy (Hajdu and Darvishian, 2013). 
Following the discovery of the DNA structure by James Watson and Fran-
cis Crick in 1953, the unspoken world of molecular biology started to gain form 
and the field of genetics prospered. The concept of gene introduced in the be-
ginning of the century by the botanist Wilhelm Johannsen (1857-1927) acquired 
a new dimension, and the works on heredity made by Gregor Mendel (1822-
1884) were finally accepted, as consequently were the rumors of the hereditary 
behavior of some tumors. One of the last big discoveries on the field was made 
when the genetic basis of cancer were established. In 1969, Robert Huebner and 
George Todaro identified genes that were normally activated (sometimes 
hyperactivated) in cancer and highlighted their malignant potential by calling 
them oncogenes (Huebner and Todaro, 1969). The first oncogene to be discov-
ered was the sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (SRC), by 
Steve Martin in a chicken retrovirus (Martin, 2004).  Some years later, a group of 
scientists from the University of California observed that oncogenes were acti-
vated genes that pre-existed in the normal cellular genome and as such termed 
them proto-oncogenes (Stehelin et al., 1976). Conversely, genes with tumor sup-
pressive ability, predictably underexpressed in tumors, were also found. The first 
of those called tumor suppressor genes to be discovered was the retinoblasto-
ma-1 (RB1) which plays a key role in cell cycle progression from G1 to S phase 
(Murphree and Benedict, 1984). 
The implication of mutations as key players in the tumorigenic process 
opened the hunt period for new cancer-related mutations. Several oncogenes 
and proto-oncogenes were identified, as was a plethora of tumor suppressors. As 
a consequence, a big paradigm shift was made and the Somatic Mutation Theory 
for cancer origin, also known as stochastic or clonal evolution model, was postu-
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lated. According to this theory, cancer derives from a single somatic cell that ac-
cumulated multiple DNA mutations. These mutations often affect genes that 
control proliferation and cell cycle, thus inducing hyperproliferation (Soto and 
Sonnenschein, 2004). 
The last three decades of cancer research were marked by an extraordi-
nary increase in the input of scientific knowledge on the different aspects of can-
cer biology. Every day new genes are discovered as are new features and abilities 
of cancer cells. Tumor stroma fired from being a mere supporter of tumor cells to 
adopt a key function in either tumor cells’ survival or metastization. The velocity 
at which information is generated long overcame our capacity of overall integra-
tion and in the apogee of the genomic era integrative strategies and multidisci-
plinary teams are still scarce in cancer research. 
1.1.1 Cancer Epidemiology and Etiologies 
Bernardino Ramazzini (1633-1714) was the first to seed the roots of 
cancer epidemiology. The Italian physician, considered the father of occu-
pational medicine, established the first correlation between individual life-
styles and cancer development when he realized that celibate nuns almost 
never develop cervical cancer while breast cancer was a common malig-
nancy among them (Felton, 1997). Almost fifty years later, Percival Pott 
(1714-1788) highlighted the enormous incidence of cancer of the scrotum 
in chimney sweeps, caused by soot accumulation in the skin folds of the 
scrotum (Brown and Thornton, 1957). These two studies lighted the fuse 
for the search and identification of new occupational carcinogens and vari-
ous reports came out in the scientific literature at the time. 
The industrial revolution repainted the skies of the metropolitan 
centers of the epoch. With the use of coal as the source of energy for the 
new designed machines, black smoke started to deposit in the atmosphere 
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above the industrialized cities and cancer incidence increased (Firket, 1958; 
Hajdu, 2012b). Literature reports indicate that despite the higher preva-
lence of lung and skin cancers, malignant processes were documented in 
most of the human tissues and organs as a consequence of chemical pollu-
tion (Ames and Gold, 1997). The most popular human carcinogen in the 
late nineties was the tobacco, whose recently discovered prejudices to 
health largely overcame the benefices predicted in the previous decades 
(Loeb, 1989). 
Parasitic origins of cancer were proposed during the advent of mi-
crobiology back in XIX century. Reginald Harrison (1838-1908) was the first 
to establish a correlation between parasitic infections, in this case the uri-
nary system parasite Schistosoma haematobium, and an extraordinary ele-
vated frequency of bladder carcinoma. The second parasite associated with 
cancer was the Clonorchis sinensis, whose infection was correlated with the 
bile ducts’ tumors (Hajdu, 2012b). Over the last decades many other mi-
croorganisms including virus and bacteria were correlated with cancer de-
velopment, being the most recent the Nobel laureate association between 
Helicobacter pylori and gastric cancer (Marshall and Warren, 1984). 
The view of cancer as a hereditary disease appeared with Recamier 
who believed that disposition to breast and many other cancers might de-
rive from family predisposition, even though he could not identify the exact 
source. Later on, Virchow also unrevealed the hereditary nature of some 
gastric tumors (Hajdu, 2012a). With the discovery of oncogenes and tumor 
suppressor genes, the hereditary nature of cancer was better understood. 
Retinoblastoma was definitely established as a hereditary tumor that 
needs two mutations to develop, but in which the presence of an inherited 
mutation already predisposes to the development of the second, and con-
sequently, to the onset of the disease (Murphree and Benedict, 1984). 
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More recently, cancer was also proposed to result from endoge-
nous homeostasis dysregulation. The first evidence on this endogenous 
origin of cancer was implicit in the Ramazzini observations of nuns’ higher 
incidence of breast cancer. As a corollary of his observations, the author 
hypothesized that sexual hormones and hormonal cycles in females may 
predispose them, somehow, to the development of breast cancer (Felton, 
1997). From there on, many other endogenous carcinogens capable of in-
ducing mutations in the DNA have been discovered (Loeb, 1989). For in-
stance, the disequilibrium of oxidant and anti-oxidant species as a result of 
excessive reactive oxygen species (ROS) production may cause DNA dam-
age, which, if unrepaired, can drive cell’s malignant transformation (Ralph 
et al., 2010). 
Nowadays, despite the huge increase in the number and availability 
of carcinogenic agents produced, the etiologies of cancer remain essential-
ly the same, with proportional differences between developed and devel-
oping countries (Figure 1.1). Tobacco and dietary habits account for the 
major slice of all cancers worldwide, followed by other unspecified sources 
and microorganism infections (American Cancer Society, 2011). 
 
 
Figure 1.1 - Graphic representation of the proportions of 
the different cancer causes and their correlation with 
economic development. In developing countries microorgan-
ism infections represent a major risk factor for cancer develop-
ment, while in developed countries dietary habits and tobacco 
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are responsible for almost 50% of all tumors. Adapted from 
American Cancer Society, 2011. 
1.1.2 Cancer Statistics  
For a disease like cancer that affects so many people all over the 
world and so many tissues and/or organs in the human body, statistical 
analysis is a complicated task. Trying to shed some light in the subject, the 
American Cancer Society (ACS) organized a council that estimates roughly 
every year the numbers of new cancer cases and the expected cancer-
related deaths for the United States, and published an annual public report 
on the collected data (Siegel et al., 2013). However, no such a thing exists 
at a planet scale and consequently, the data on worldwide cancer statistics 
is scarce.  
In an attempt to fulfill the need for cancer statistical information, 
international consortiums were established to scrutinize the available data 
on cancer incidence, etiologies and survival in as much countries of the 
world as possible. One of the first consortiums was the Cancer Incidence in 
Five Continents (CI5), whose main aim was to make available comparable 
data on cancer incidence from a wide range of geographical locations. Lat-
er on, in early 2000’s, information from a group of 184 countries was com-
bined and used to build an online database under the control of interna-
tional project GLOBOCAN. The aim of the project was to provide contem-
porary estimates of the incidence of cancer, and the mortality, prevalence 
and disability-adjusted life years (DALYs) from the major cancer types at 
the national level. Nowadays it represents a very helpful open-access web 
tool that allows researchers from all over the world to perform several sta-
tistical combinations according to their specific needs. All these databases 
are now grouped and available online at the CANCERMondial webpage, su-
pervised by the International Agency for Research on Cancer (IARC). 
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Through the compilation of some information from GLOBOCAN 
2008 the IARC, working with the Cancer Research UK, constructed a map 
depicting the worldwide incidence of cancer (Figure 1.2). Through its analy-
sis it becomes evident that cancer incidence still correlates with the higher 
industrialized or polluted countries. In agreement, the countries with high-
er cancer incidence are Australia and EUA, while the lower rates are placed 
in Northern and Middle Africa and in the South Central Asia. 
 
 
Figure 1.2 - Worldwide incidence of cancer. Cancer has a higher incidence 
Australia and North America and a lower incidence in Northern and Middle Africa. 
Adapted from Cancer Research UK website. 
 
According to a publication from the ACS, the rate of cancer inci-
dence is increasing worldwide, with particular emphasis on developed 
countries (American Cancer Society, 2011). This regionalized behavior of 
cancer incidence seems to depend upon the adoption of the so-called 
western lifestyle. In fact, the popularized smoking and poor-diet habits are 
directly correlated with higher cancer development rates, as are some re-
productive factors like the increased medium age for first pregnancy. 
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The risk of being diagnosed with cancer seams to increase substan-
tially with age. In agreement, 78% of all newly diagnosed cancer cases in 
developed countries occur at age 55 and older. Also true is the fact that 
men seem to have more susceptibility for cancer than women, as higher 
rates of almost all the different tumor types are observed in men (Figure 
1.3). Epidemiological studies also revealed a higher mortality rate among 
men (American Cancer Society, 2011). 
 
 
Figure 1.3 - Cancer incidence in men ver-
sus women. Cancer is normally more com-
mon among men, either when analyzed in 
general or each type in particular. Adapted from 
American Cancer Society, 2011. 
 
Cancer should now be regarded as an epidemic disease. In fact, it is 
spread for all over the planet and affects all kinds of animals reaping more 
lives than any other disease. The costs of cancer are tremendous; a report 
from the ACS indicated that cancer has the most devastating economic im-
pact of any cause of death worldwide (American Cancer Society and 
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Livestrong, 2010). Of note is the fact that these costs are not only due to 
the treatments at health institutions, but also due to the loss of economic 
output as a consequence of a decrease in work production by the affected 
population. 
1.1.3 The hallmarks of cancer: an overview of the 
transformation process 
Cancer biology is a vast and active field of research that receives in-
put from virtually all the other scientific areas. As a matter of fact, cancer 
can be approached from different perspectives such as immunology, genet-
ics or cellular biology; however the attained results and deduced outlines 
should not be left imprisoned in their own fields but for contrarily, they 
should be included into the other’s attainments in order to complete the 
full picture of cancer. 
In an attempt to provide cancer field with some consensus and clari-
fy several uncorrelated results, Hanahan and Weinberg published a review 
article in which they ruled out six hallmarks all cancer cells have and which 
are responsible for their malignant properties (Hanahan and Weinberg, 
2000). More recently, two additional hallmarks were added to the list, as 
were two enabling characteristics (Figure 1.4) (Hanahan and Weinberg, 
2011). 
The most prominent characteristics of tumor cells are their sus-
tained proliferative signaling and their ability to resist cell death, which 
combined confer cells replicative immortality. Some tumors acquire these 
hallmarks solely by the loss-of-function of the tumor suppressor tumor pro-
tein P53 (TP53), while others depend upon the collaboration of two or 
more independent genetic changes to attain the same features (Hanahan 
and Weinberg, 2000). This observation implies that there is not a rigid pro-
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gramme followed by a cell in its rout for malignancy, or in other words, the 
acquisition of the hallmark capabilities in the different tumor types hap-
pens by distinct means and at various times along the multistep 
tumorigenesis (Hanahan and Weinberg, 2011). 
 
 
Figure 1.4 - The hallmarks of cancer and their en-
abling characteristics proposed by Hanahan and 
Weinberg. The eight hallmarks and the two enabling 
characteristics are transversal to almost all tumors and 
largely contribute for the understanding of the tumors’ 
biology. Adapted with permission from Hanahan and 
Weinberg, 2011. 
 
Successive rounds of genetic alterations must happen in the ge-
nome of pre-malignant cells in order to provide them with the full set of 
the cancer hallmarks. Between rounds, natural selection acts over the mu-
tated cells selecting the clones with higher survival potential (Khong and 
Restifo, 2002). As a consequence, tumors become comprised of heteroge-
neous cell populations, each of them with a different arsenal of mutations, 
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and the prominent cell clone within the tumor may vary along time in tune 
with changes in the environment.  
A good and diverse arsenal of mutations may, in periods of stress, 
represent a backup escape for keeping cellular integrity. For instance, while 
a primary tumor is growing and angiogenesis has not yet been triggered in 
the tumor bed, or when the vasculature of the tumor is leaky and did not 
ensure cell’s needs, genomic instability (GI) may hide the exit for an oxy-
gen-independent metabolism, thus allowing cells to survive oxygen depri-
vation. In accordance, activated oncogenes such as the rat sarcoma (RAS) 
and the myelocytomatosis viral oncogene homolog (MYC), or silenced tu-
mor suppressors like TP53, have been implicated in potentiating glycolysis 
under such conditions (DeBerardinis et al., 2008; Kamphorst et al., 2013). 
Hypoxia response system is also implicated by upregulating glucose trans-
porters at cell’s surface in response to low oxygen pressures (Semenza, 
2010; Fakhrejahani and Toi, 2012). Recent reports further confirmed that 
when these actions are blocked, the metabolic switch did not take place 
and tumor’s progression is abrogated (Kim et al., 2013a; Zirath et al., 2013). 
The establishment of a tumor-dedicated vascular web is essential to 
ensure malignant cells’ energetic needs and to appropriately remove the 
byproducts of their metabolism. This net originates from both angiogene-
sis, i.e., the sprouting of pre-existing vessels, and vasculogenesis, stating 
for the in situ formation of blood vessels by the recruitment of bone mar-
row (BM)-derived endothelial precursor cells (EPCs) (Figure 1.5) (Carmeliet 
and Jain, 2011; Lyden et al., 2001). However, the activation of these pro-
grams seems to differ considerably among different tumors, apparently in 
a type-specific manner (De Palma and Hanahan, 2012). 
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Figure 1.5 - Angiogenesis versus Vasculogenesis. Tumor 
angiogenesis is based on the sprouting of pre-existing vessels 
driven by a tip cell that was chemically selected to be so (left). 
Vasculogenesis represents the formation of vessels through 
the recruitment of BM-derived EPCs. Adapted with permission 
from Weis and Cheresh, 2011. 
 
Contrarily to what may be thought tumor vascularization is induced 
very early during the tumorigenic process in a process called angiogenic 
switch (Hanahan and Folkman, 1996). In accordance to this observation, 
Vivek Mittal’s group showed that green fluorescent protein (GFP)+ BM-
derived cells infiltrate subcutaneous tumors implanted in GFP+ BM-
replaced mice as soon as 4-6 days after tumor implantation (Nolan et al., 
2007). The observed cellular mobilization resulted from a breakdown of 
the balance between pro- and anti-angiogenic factors in the tumor bed 
which triggers the hyperproliferation of tumor cells and the formation of 
hypervascularized tumors (Baeriswyl and Christofori, 2009). The mobilized 
GFP+ cells documented in Mittal’s work, characterized as being vascular 
endothelial growth factor receptor 2 (VEGFR2+), vascular endothelium cad-
herin (VE-cadherin)+ and CD31low, incorporate into the initially sprouting 
vessels and differentiate into mature endothelial cells (ECs), albeit their 
overall small percentage (5-10%) in the tumor vasculature. This observa-
tion led to the understanding that EPCs’ action is critical during the initia-
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tion of the angiogenesis, providing structural support and guidance for the 
nascent vessels, but less important in the subsequent growth of the stubs, 
which is ascribed to other cellular populations (Nolan et al., 2007; Okazaki 
et al., 2006).  
Vascular endothelial growth factor (VEGF) is by far the most com-
mon angiogenic switch trigger; however, some tumors revealed less de-
pendent upon VEGF and use noncanonical pathways to activate vascular 
growth and fulfill their needs. Such is the case of tumors arising in very vas-
cularized tissues, like brain gliomas (Holash, 1999) or melanomas in the 
skin (Hillen and Griffioen, 2007). In these tumors, cells divide and grow 
along pre-existing tissue vessels without evoking an angiogenic response, 
in a process called vascular co-option (Holash, 1999). Alternatively, tumor 
cells can also mimic endothelial cells by altering their gene expression pro-
file, and integrating themselves into the tumor vasculature. This process of 
vascular mimicry is common among more undifferentiated tissue tumors 
like glioblastomas and melanomas (Maniotis et al., 1999; Soda et al., 2011). 
Finally, one last alternative is the induction of CSCs differentiation into en-
dothelial cells. These cells then embody the tumor vasculature even though 
they normally carry some cytogenetic abnormalities (Wang et al., 2010). 
The role of this specific cell population will be dissected in detail in Chapter 
3. Figure 1.6 highlights the main differences between the aforementioned 
strategies that tumors can use to access vascular supply.  
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Figure 1.6 - Different strategies used by tumors to access 
vascular supply. A. Sprouting angiogenesis based upon a tip 
cell differentiation from an endothelial cell of a pre-existing 
vessel. B. Vasculogenesis dependent on BM-derived cells, 
namely EPCs. C. Vessel co-option by tumors growing in the 
neighborhoods of pre-existing vessels. This strategy did not in-
volve an angiogenic response. D. Vascular mimicry portrayed 
by tumor cells that attempt to differentiate into endothelial 
cells. E. Endothelial cell differentiated form CSCs, which carry 
chromosomal mutations and integrate tumor vasculature. 
Adapted with permission from Carmeliet and Jain, 2011. 
 
The activation of the migration and metastases programme is 
commonly assumed as the last pace in the process of multistep carcino-
genesis. Contrary to this belief, research made over the last decade indi-
cates that at least dissemination may not occur as late as predicted, but in-
stead very early during tumor establishment (Joyce and Pollard, 2009). In-
vasive niches, comprised of a mixture of cancer and tumor-co-opted mi-
croenvironment cells called tumor microenvironment of metastases 
(TMEM), were observed to form within the primary tumor prompting them 
for dissemination (Robinson et al., 2009). The increased density of these 
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niches over time, along with their ability to paracrinely communicate with 
neighbor endothelial cells, facilitate migrating cells’ intravasation and can 
be directly correlated with the appearance of circulating tumor cells (CTCs) 
(Joyce and Pollard, 2009).  
Nowadays the metastatic disease is the main cause of cancer-
related deaths, accounting for more than 90% of the mortality rate of this 
disease. The main reason for our inability to target metastases relies on 
their systemic nature and on the increased chemo- and radioresistance of 
CTCs (Valastyan and Weinberg, 2011).  
The collection of the cellular and molecular events driving the for-
mation of metastases by carcinomas, meaning the human tumors of epi-
thelial nature, is theoretically divided into seven steps, in a process termed 
invasive-metastasis-cascade. These steps encompass: (1) invasion of the 
local microenvironment and breakdown of the basement membrane, (2) 
intravasation, (3) survival in the bloodstream, (4) arrest at distant organs, 
(5) extravasation, (6) survival in a foreign territory and (7) reactivation of 
the proliferative programs and subsequent metastatic growth (Valastyan 
and Weinberg, 2011). 
As reviewed by Joyce and Pollard, “tens of thousands of cancer cells 
can be shed into circulation every day, yet less than 0.01% will survive to 
produce metastases” (Joyce and Pollard, 2009). This observation, besides 
clearly reflecting the inefficiency of the metastatic process, uncovers the 
difficulties endured by CTCs while in the bloodstream. One of the first se-
lective pressures that CTCs would have to overcome after intravasation is 
the survival to the absence of anchorage. As is widely known normal cells 
die without integrin-mediated adhesion to extracellular matrix (ECM) and 
the consequently activated downstream signaling pathways. The activated 
programmed cell death pathway is characteristic of the metastatic pro-
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gramme and is called “anoikis”. Many strategies adopted by tumor cells to 
avoid anoikis have recently been summarized by Paoli and collaborators 
(Paoli et al., 2013). 
Another main disadvantage of being inhabitant of the bloodstream 
is the omnipresence of immune cells and the continuous need to avoid 
them. As a matter of fact, if it was not for the deceiving strategies that 
CTCs employ to hide from natural killer (NK) cells, for example, through an 
innate immune response, CTCs will be killed within minutes after 
intravasation (Palumbo et al., 2005). One such effective and elaborated 
strategy used by CTCs is the elaboration of a platelet shield. It has been 
demonstrated that CTCs are able to release paracrine factors that act over 
platelets inducing the formation of a platelet shield around them. These 
activated platelets were also shown to release themselves other factors 
that potentiate CTCs’ survival in a paracrine loop communication (Goubran 
et al., 2013). An alternative, albeit most complex, strategy is the fusion of 
CTCs with macrophages, which provides them with myeloid cell traits fa-
voring the success of metastatic process (Lu and Kang, 2009; Pawelek and 
Chakraborty, 2008). 
The leaky and tortuous vasculature and the tumor-associated cells, 
characteristics of the primary tumor sites, are absent at metastatic places 
hampering the extravasation process. As a consequence, CTCs must over-
come alone the physical barrier imposed by the capillaries to access the tis-
sue parenchyma. However, this barrier has not the same composition 
throughout the body, and some places are more prone to metastases than 
others (Figure 1.7). This is the case of BM, where capillaries, specifically 
called sinusoids, are lined with fenestrated endothelium which provides 
virtually none friction to the extravasation of CTCs. In contrast, brain pa-
renchyma is efficiently protected by the blood-brain barrier (BBB) which 
requires specifically adapted strategies to be transposed. 
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Figure 1.7 - Different vascular barriers imposed to extravasating CTCs. 
CTCs lodged at distant organs may encounter different capillary barriers depend-
ing on the organ. In the case of bone, fenestrated capillaries easily allow CTCs to 
extravasate into the bone trabeculae. Lung capillaries, however, are less permis-
sive for metastases due to the presence of a basement membrane (resultant from 
the fusion of the basal lamina of both the endothelium and of the respiratory epi-
thelium). Finally, the brain is the organ that imposed the higher degree of difficul-
ty for metastization due to the presence of the BBB composed by tightly-
connected endothelial cells covered with the foot-processes of the astrocytes. 
Adapted with permission from Nguyen et al., 2009. 
 
In the last decades debate was installed over the tropism of metas-
tases formation. Although it has long been recognized that some tumors 
often metastized to the same organs (Valastyan and Weinberg, 2011), the 
prevailing idea that the dynamics of the circulatory system may justify the 
tropism of metastases lacked robustness and no better idea emerged until 
Stephen Paget first proposed that cancer cells (the seeds) would only colo-
nize tissues or organs (the soils) that allow their growth (Paget, 1889). 
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However, this observation, later known as the “seed and soil theory”, 
while providing the first hint into the organ-specific theory of metastases 
gave no clues about the molecular mechanisms underlying the process.  
Knowledge produced over the last decades indicate that primary 
tumors are able to secrete cytokines into the bloodstream that will influ-
ence the microenvironment of distant organs, eventually inducing vascular 
hyperpermeability (Valastyan and Weinberg, 2011). One such example is 
angiopoitin-like-4 (Angptl4) which besides remodeling the vasculature of 
the lung prompting it for extravasation of CTCs (Gupta et al., 2007), was al-
so shown to promote breast cancer derived CTCs’ extravasation specifically 
to the lung parenchyma (Padua et al., 2008). Erler and collaborators also 
verified that the release of lysyl oxydase (LOX) by the primary tumor in-
duced the production of fibronectin by the fibroblasts at the secondary site 
(Erler et al., 2009), which was shown to increase the survival and prolifera-
tive ability of metastatic cells (Knowles et al., 2013). These and other simi-
lar observations lead David Lyden’s group to propose that primary tumors 
are able to induce changes in the parenchyma of the secondary metastatic 
sites prior to the extravasation of CTCs, thus minimizing the impact of a 
foreign microenvironment over extravasated CTCs. This concept became 
known as the pre-metastatic niche (PMN) formation (Psaila and Lyden, 
2009).  
Much alike to what was done concerning the first steps of the tu-
morigenic process, specific metastases-related genes have been searched 
for. In a review published in the The New England Journal of Medicine, 
Chiang and Massagué divided the known metastatic-related genes into 
three categories: (1) metastases initiation genes, (2) metastases progres-
sion genes and (3) metastases virulence genes (Figure 1.8) (Chiang and 
Massagué, 2008). The action of the two first categories-grouped genes 
could very easily be deduced from their group names; however, expression 
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of genes clustered in the third group has been shown to confer cells the es-
sential features needed for organ-specific metastization (Chiang and 
Massagué, 2008). Because the expression of metastases virulence genes 
can only be found in cancer cells that metastasize to specific tissues, the at-
tainment of such a list of genes would most probably provide markers that 
could help clinicians to predict tumor relapses, and more importantly, or-
gan-specific relapse. 
 
 
Figure 1.8 - Groups of genes involved in the different steps of the tumor-
igenic process. The genes involved in the different steps of tumor progression 
can be separated into different categories. Regarding metastases, there are three 
categories, the third of which containing the genes responsible for tissue-specific 
metastization. Adapted with permission from Chiang and Massagué, 2008. 
1.1.4 The tumor microenvironment: a crowded and 
agitated battlefield 
The assumption that a tumor is not a mere aggregate of homotypic 
cells brought in the necessity of identifying and dissecting as much cell 
populations as possible from the wide diversity that inhabit the tumor bed. 
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As a result, much became known about tumor microenvironment, and in a 
paradigm shift tumors started to be interpreted as organs, perhaps even 
more complex than some anatomical ones.  
During the last decades different cell populations in different stages 
of differentiation were identified within the tumor microenvironment. In a 
recent report, Hanahan and Coussens grouped these warriors into three 
general classes, namely, (1) angiogenic vascular cells (AVCs), (2) infiltrating 
immune cells (IICs) and cancer-associated fibroblasts (CAFs), which are 
fundamental in sustaining the hallmark capabilities of tumors (Hanahan 
and Coussens, 2012). 
As previously discussed, tumor’s vascularization is one of the main 
growth-limiting steps in tumor progression, mainly because adult blood 
vessels are usually in a quiescent state (Carmeliet and Jain, 2011). In fact, 
only during the female menstrual cycle or in certain pathophysiological re-
sponses angiogenesis is triggered in an adult body and this normal physio-
logical answer relays mostly on the same pathways as the angiogenic 
switch in cancer, and invariably involves stromal cells. In the particular case 
of tumors, IICs and CAFs have been implicated.  
Tumor-co-opted IICs produce a wide range of soluble mediators 
that act over endothelial cells inducing angiogenesis. Particular subsets of 
myeloid cells named tumor-associated macrophages (TAMs) have been de-
scribed to have a key role in the overall angiogenic process. In agreement, 
TAMs were shown to directly stimulate angiogenesis via the production of 
VEGF-A, a ligand of the VEGFR2 present in endothelial cells inducing their 
sprouting (Baeriswyl and Christofori, 2009); or indirectly by protease secre-
tion, namely metalloproteinase-9 (MMP-9), that disassemble the ECM and 
release the ECM-sequestered VEGF-A (Carmeliet and Jain, 2011). Mast cells 
represent another important IIC population found in tumor’s stroma that 
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has the ability to trigger angiogenesis. These cells, can also act directly over 
the pre-existing endothelium, by releasing a battery of potent pro-
angiogenic mediators including VEGF, angiotensin-1, histamine, heparin 
and interleukin (IL)-8, also called C-X-C chemokine ligand (CXCL)-8 
(Coussens et al., 1999). Alternatively, recent evidence demonstrated that 
mast cells may also induce angiogenesis by cleaving the protease-activated 
receptor-2 on CAFs, which in turns activates pro-angiogenic pathways 
(Khazaie et al., 2011). 
The most intuitive warriors of the tumor microenvironment would 
be perhaps the IICs, intended to combat infections and cancer. However, 
these cells are very soon co-opted by the tumor, and the factors that they 
then release sustain tumor growth, rather than activating suppressive 
pathways (Hanahan and Weinberg, 2011). According to Peyton Rous, tu-
mors developed from “subthreshold neoplastic states” previously induced 
by viral or chemical carcinogens (Rous and Kidd, 1941), described by Dvo-
rak as ”wounds that never heal” (Dvorak, 1986). Following this first associa-
tion between cancer and inflammation, evidence continued to accumulate 
and no doubt remains regarding the immune system responsibility on iden-
tifying and eliminating emerging tumors (Hanahan and Weinberg, 2011; 
Schiavoni et al., 2013; Schreiber et al., 2011). Moreover, mice models engi-
neered to portray ablated, isolated or combined immune cell populations 
showed increased susceptibility to develop tumors, as recently reviewed by 
Schiavoni and collaborators (Schiavoni et al., 2013). However, pretty much 
contradicting these observations are the increasing body of evidences 
showing that highly immunogenic tumors are able to evade the immune 
system bullets, thus surviving unharmed the immunological traps in a pro-
cess called cancer immunoediting (Vesely and Schreiber, 2013). Among the 
deceiving strategies employed by tumors to avoid the immune surveillance 
is the secretion by the tumor cells of anti-inflammatory cytokines, such as 
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tumor growth factor β(TGF-β), which paralyze tumor-infiltrating CD8+ cyto-
toxic T lymphocytes (CTLs) and NK cells, thus blocking their action (Wilson 
et al., 2011b; Yang et al., 2010). Subsequent studies further corroborated 
this observation by showing that inhibiting TGF-β signaling in fibroblasts 
enhanced the growth and oncogenic potential of adjacent epithelia (Cheng 
et al., 2005).  
Other similar paracrine loops between tumor and microenviron-
ment cells have been shown to influence a wide repertoire of tumor’s ac-
tions. For example, Bose and collaborators recently demonstrated that IL-6 
produced by stromal cells is able to co-opt pericytes from tumor vascula-
ture inducing them to produce negative regulators of CD4+ T effector cells 
(Bose et al., 2013), one of the principal cellular framework of antitumor 
immune response (Hung et al., 1998). Finally, the previously referred tu-
mor recruited myeloid cells also play important roles in mediating immune-
evasion responses as depicted in Figure 1.9 (Pistoia et al., 2013).  
A link between the metabolic switch observed in progressing tu-
mors and the microenvironment has also been established. In a recent re-
view, Pavlides and collaborators highlighted the role o CAFs in mediating 
this switch. According to the authors, CAFs are educated during tumor pro-
gression to shift their metabolism towards the independency from mito-
chondria by favoring glycolysis, while tumor cells keep their oxidative me-
tabolism. This way, the big amounts of L-lactate produced by CAFs as a 
consequence of their anaerobic metabolism, are released to the extracellu-
lar space and enter the tumor cells via monocarboxylate transporters. 
Once inside tumor cells L-lactate is used in the tricarboxilic acid (TCA) cycle, 
which allows its full oxidation and subsequent ATP synthesis. This parasitic 
relation between CAFs and tumor cells was named “Reverse Warburg Ef-
fect” as it opposes the initial idea of Otto Warburg of an increased glyco-
lytic metabolism in tumor cells even in normoxic conditions (Pavlides et al., 
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2012; Warburg, 1956), and seems to relay on the loss of Caveolin-1 (Cav-1) 
by the stromal CAFs during their education by tumor cells (Pavlides et al., 
2012). 
 
 
Figure 1.9 - The role of myeloid-derived cells in tu-
mor immune evasion. Myeloid-derived suppressor cells 
(MDSC) can help cancer immunoediting by acting over the 
immune cells and inhibiting their anti-tumoral activities. 
Adapted with permission from Pistoia et al., 2013. 
 
Strong evidence also supports a connection between microenvi-
ronment and metastases. In a special issue from Nature magazine dedicat-
ed to migration and metastases, Joyce and Pollard dissected the theory of 
the microenvironment-based regulation of metastases formation and high-
lighted the particularly important role played by TAMs in this step of tumor 
progression, mostly due to their ability to produce the aforementioned in-
vasive niches within the primary tumor (Joyce and Pollard, 2009). It has al-
so been hypothesized, yet not completely proved, that TAMs are the 
guides of tumor cells during the intravasation process. As a matter of fact, 
IL-4 produced by metastatic-competent tumor cells was shown to induce 
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TAM-phenotype in the macrophages of the primary tumor stroma, which in 
turn secrete cathepsin. This protease has a potent ECM-degrading activity 
thus favoring the migration of the tumor cells towards the circulatory sys-
tem (Gocheva et al., 2010). Nevertheless, previous results have shown that 
the touristic trip to circulation, rather than being guided by TAMs, is guided 
by CAFs (Gaggioli et al., 2007). 
Regardless of ongoing debates on the role of specific microenvi-
ronment cells in the different tumor progression steps, no arguments are 
raised against their having any role at all. However, future research in the 
field, particularly in the recent field of cancer immunology, is expected to 
substantiate most of the available knowledge on each cell’s task during 
tumor progression, thus allowing redefining and improving therapeutic 
strategies, and consequently better outcomes. 
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Chapter 2  
Lung Cancer  
In the last decades cancer prevailed as one of the most common human diseases 
with lung cancer (LC) on the top 3 ranking (American Cancer Society, 2011). Notwith-
standing the advances made, much is still unknown about the malignant transformation 
of the human bronchial epithelium (HBE) and the number of LC-related deaths is still 
astonishing. 
2.1 Lung Cancer Statistics, Epidemiology,     
Etiology and other relevant facts 
The statistical and epidemiological discussions on LC are hampered by the 
scarceness of recent reports, particularly at the worldwide scale. Nevertheless, 
some things never (or almost never) change, and according to Parkin and collab-
orators, LC has been the most common neoplasia diagnosed each year since 
1985 (Parkin et al., 2005). As to nowadays, it keeps topping the list of tumors di-
agnosed among men and retreats to the fourth place in the case of women (Fig-
ure 3) (American Cancer Society, 2011). 
There is a strong association between LC and smoking habits.  As a matter 
of fact, the geographical distribution of LC, especially among men, can easily be 
interpreted by following the introduction of tobacco as a social habit in the dif-
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ferent countries, as well as following the modifications that tobacco suffered 
over time. Supporting these observations are the higher rates of LC registered 
among men in North America, Australia, New Zealand, and many North-Western 
Europe countries during the eighties (Youlden et al., 2008). Also in agreement 
are the still increasing or tending to plateau LC rates of the emerging economies, 
like the Chinese, the Japanese and the Eastern European countries where tobac-
co is still an habit of the wealthy circles (Devesa et al., 2005). Moreover, the in-
troduction of filters in the cigarettes during the sixties along with the alteration 
of the tobacco’s composition also had a tremendous impact in LC cancer rates 
and histological features (Brooks et al., 2005). These alterations imprinted a 
worldwide unbalance of LC not only in terms of geography but also between 
genders.  
Surprisingly, the introduction of tobacco also changed the landscape of 
prominent LC histological types (Stellman et al., 1997; Wynder and Muscat, 
1995). Classically, lung tumors are divided in two major histological types: small 
cell LC (SCLC) and non-small cell LC (NSCLC) (Walter and Pryce, 1955). The first 
type of tumors encompasses the most aggressive forms of LC which are strongly 
associated with smoking habits (>95% patients). These tumors characteristically 
grow in the hilar region of the lung and have a strong tendency for early dissemi-
nation (Jackman and Johnson, 2005). Conversely, NSCLC is a more heterogene-
ous group of lung tumors that comprise three distinct subtypes, namely, adeno-
carcinomas, squamous cell carcinomas and large cell carcinomas. Large cell car-
cinomas are relatively rare and can differentiate into a neuroendocrine pheno-
type (Harada et al., 2002). The other two subtypes account for the majority of 
NSCLCs and tend to develop at the periphery of the lungs (Goldstraw et al., 
2011).  
Epidemiological data attained between 1998 and 2002 revealed that 
squamous cell carcinoma was the most frequent LC histological subtype among 
men, while adenocarcinomas occupy that position among women (Youlden et 
  
 Chapter 2 
PhD in Biosciences – Specialization in Cellular and Molecular Biology 35 
al., 2008). However, the incidence of lung adenocarcinoma has been increasing 
gradually in most countries, having already displaced squamous cell carcinomas 
from the prime position (Nakamura and Saji, 2013). This tendency has long been 
accepted to be driven by tobacco, in particular by the changes in different physi-
cal and chemical properties of the cigarettes introduced during the past decades 
(Brooks et al., 2005; Thun et al., 1997). The decrease in the concentration of tar 
and nicotine and the introduction of filters in the cigarettes made smokers in-
crease the puff volume, frequency, or duration in order to attain the desired 
stimulation. However, due to the presence of the filters, the particles entering 
the lungs were smaller, thus gaining more access to the periphery of the organs 
where adenocarcinomas normally develop. Finally, the increased nitrosamination 
of the tobacco also predisposes to adenocarcinomas (Gabrielson, 2006; Hecht, 
1998). 
But tobacco is far from being the only human lung carcinogen. Many oth-
er substances have been described over the last century, either chemical or 
physical, natural or artificial, and much more remain unknown. There are, how-
ever, identified endangered populations; for instance, workers of certain profes-
sions or people living in specific environments are known to be more prone to 
develop LC than others. One example would be people living near dust incinera-
tion sites or highways, who are continuously exposed to chemical combustion-
derived smokes and would have a higher incidence of LC than those living near 
the ocean (Brugge et al., 2007; Sharma et al., 2013). Similarly, metallurgic indus-
try workers and airport ground staff are considered very high-risk populations to 
develop LC, and their work conditions are, or at least should be, very strictly con-
trolled (Clapp et al., 2008). Finally, radiation may also induce cancer. The first 
case of radiation-induced cancer was reported in 1902 on the hand of an X-ray 
technician, who died four years after the diagnostic of a metastatic squamous 
cell carcinoma (Hajdu, 2012b). 
  
    
36 Carlos F. D. Rodrigues │ University of Coimbra  
Independently of its etiology, LC is the worldwide leading cause of cancer 
death in men and the second cause in women. This fact mainly reflects the late 
stage of the tumor at the time of diagnosis, when almost no therapeutic options 
are available but palliative care (Spiro and Silvestri, 2005; Youlden et al., 2008). 
Nonetheless, despite still being very elevated, the incidence and mortality rates 
of LC have been slightly decreasing in the last years, with more pronounced de-
cline observed among men (Figure 2.1) (American Cancer Society, 2011).  
 
 
Figure 2.1 - Worldwide lung cancer death rates analyzed by 
sex. Lung cancer-related deaths decreased in the last decades, 
most markedly among men. Adapted from American Cancer Society, 
2011. 
 
The principal reason for the decrease in the incidence and mortality rates 
of LC is believed to relay on the increased awareness of the world population to 
this infirmity which is translated into a reduction in the risk behaviors and in a 
more dedicated medical surveillance. Anti-tobacco campaigns and the elevated 
price of the cigarettes were very helpful on alerting adult populations for this 
disease, and benefits are already visible. As a matter of fact, American States 
that introduced very rigid anti-tobacco policies are viewing the consumption of 
  
 Chapter 2 
PhD in Biosciences – Specialization in Cellular and Molecular Biology 37 
tobacco decreasing at the same time that the rate of LC and other lung patholo-
gies are diminishing. The most ironic subtleness of LC is that among the different 
human neoplasias, it is one of the most preventable (American Cancer Society, 
2011). 
2.2 Hexavalent Chromium and Lung Cancer: a 
view to a kill! 
Chromium is a natural element discovered in 1797 by Louis Vauquelin. It 
is relatively abundant on Earth, being mostly found in the mineral form com-
bined with iron and oxygen (FeCr2O4) (Urbano et al., 2008). Its name derived 
from the Greek word “chroma” which means “color”, mirroring its ability to form 
colored compounds (Kotaś and Stasicka, 2000). 
Ruled by the minimum energy principle, chromium only exists naturally in 
its most stable oxidation states: the trivalent and the hexavalent (Cr(III) and 
Cr(VI), respectively) (Urbano et al., 2012, 2008). Cr(III) is a very stable oxidation 
state for chromium. Under this form it produces large octahedral complexes and 
chelates with other substances, thus hampering its ability to enter the cells and 
reducing its cytotoxicity (Urbano et al., 2012, 2008). In agreement, studies using 
human fibroblasts showed that Cr(III) compounds were one thousand-fold less 
cytotoxic than Cr(VI) compounds (Biedermann and Landolph, 1990). In opposi-
tion, Cr(VI) is normally found in aqueous solutions under the form of chromate 
(CrO4
2-) or dichromate (Cr2O7
2-) oxyanions, being the prominent ion strongly de-
pendent upon the pH of the solution. At normal physiological pH (7.4) there is a 
predominance of the chromate oxyanion which has a tetrahedral structure very 
similar to that of sulphate and phosphate at the same pH (Urbano et al., 2012, 
2008). Provided with this ability to structurally mimic such ubiquitary endoge-
nous anions, Cr(VI) can easily move across the cellular membranes using the 
equally ubiquous non-specific anion-exchangers (Alexander and Aaseth, 1995; 
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O’Brien et al., 2003). Once inside the cells, Cr(VI) is rapidly reduced to Cr(III) 
through mechanisms dependent on the reducing conditions of the medium, 
mainly the concentration of ascorbate (Figure 2.2) (Wong et al., 2012b). Because 
Cr(III) is too large, cells become a playground from where it can no longer exit, 
thus being available to induce damage to the cellular constituents. In support of 
this observation are a wide range of reports in the literature outlining the reper-
toire of lesions induced by Cr(III) trapped inside the cells. Among the more dan-
gerous are the Cr(III)-DNA adducts and protein-crosslinks which may corrupt cells 
function and drive their malignant transformation (Nickens et al., 2010; O’Brien 
et al., 2003). 
 
 
Figure 2.2 - The intracellular reduction of Cr(VI) and the consequent genetic 
lesions. After entering the cells Cr(VI) is immediately reduced by ascorbate to Cr(III). 
Due to its bigger size, Cr(III) can no longer exit the cells and moves to the nucleus 
where is interacts with the DNA, either directly with its bases and/or the phosphate 
backbone or indirectly with DNA-associated proteins. The result of these interactions 
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is the formation of wide panoply of DNA lesions, ranging in size and importance. Also 
of note is the formation of intermediate chromium oxidation states during the reduc-
tion process of Cr(VI), which can also induce genetic lesions. Adapted with permission 
from O’Brien et al., 2003. 
 
The hypothesis of a possible link between Cr(VI) exposition and LC first 
appeared during the late XIX century, when a higher rate of LC was registered 
among the Scottish chrome pigment workers (Barceloux, 1999). This discovery 
triggered the search for the mechanisms of Cr(VI)-induced LC and in the subse-
quent year piles of reports came out in the literature dissecting the pathophysi-
ology and molecular pathways underlying this disease. Currently, Cr(VI) is classi-
fied by both the IACR and the United States Environmental Protection Agency 
(USEPA) as a human lung carcinogen of Group I and Group A, respectively 
(Urbano et al., 2008). 
In the last century the atmospheric levels of Cr(VI) increased, mainly due 
to the release of chromium-containing compounds from industrial waste dis-
posal, Portland cement, concrete pavement, milling, demolition, cigarette 
smoke, fuel combustion and other known, and most probably unknown, sources 
(Urbano et al., 2008). The immediate and drastic consequence of these elevated 
Cr(VI) levels was that the size of the population at risk of developing Cr(VI)-
induced lung cancer increased from just the employees of specific jobs to the 
worldwide population. As a matter of fact Cr(VI)-induced LC have already been 
reported among people unpredictable of being affected by the disease (Kotaś 
and Stasicka, 2000). 
Regardless of the source of Cr(VI), the pathophysiology of the disease is 
essentially the same. After being inhaled, Cr(VI) nanoparticles with a diameter 
ranging from 0.2 to 10 µm fly into the lungs and tend to accumulate at the bron-
chial bifurcations (Ishikawa et al., 1994a, 1994b; Kotaś and Stasicka, 2000). The 
deposited nanoparticles may persist in the lung for decades, slowly releasing 
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Cr(VI) oxyanions to the lung parenchyma and thus promoting a chronic exposi-
tion to the carcinogen (Ishikawa et al., 1994a, 1994b). The majority of the re-
leased ions are immediately reduced to Cr(III) by the ascorbate present in the 
lung interstitial fluid; however, some Cr(VI) bypasses ascorbate-driven reduction 
and enters the cell via the non-specific anion-exchangers, as previously de-
scribed. Microscopic analysis of lungs or biopsy samples from chromate industry 
workers revealed that Cr(VI)-induced LC tends to develop at the sites of chro-
mium accumulation (Kondo et al., 2003). The postmortem studies of Ishikawa 
and collaborators, where autopsies were made to thirteen chromate industry ex-
worker men, further showed that the most frequent histological type of Cr(VI)-
induced LC is the squamous cell carcinoma, and that tumors tend to develop cen-
trally in the lung  (Ishikawa et al., 1994b). 
The plethora of genetic lesions resumed in Figure 11 and described by the 
group of Patierno was unquestionably confirmed to occur both in the lungs’ cells 
of the chromate industry workers and in cultured cells exposed to different con-
centrations of Cr(VI) (Arakawa et al., 2012; Figgitt et al., 2010; Ishikawa et al., 
1994a, 1994b; Kondo et al., 2003; Nickens et al., 2012; O’Brien et al., 2003; 
Reynolds et al., 2012; Thompson et al., 2012; Wise et al., 2010). Moreover, these 
lesions are also established activators of most of the DNA repair systems, in a le-
sion-dependent manner. In agreement, chromium-DNA monoadducts and in-
duced-oxidized DNA are preferably repaired by the Base Excision Repair (BER) 
system in coordination with the Apurinic/Apyrimidinic (AP) site repair system 
(Brooks et al., 2008). The cooperation of these two repair systems results in the 
excision of the damaged base by a DNA glycosylase (normally the 8-oxo-guanine 
DNA glycosylase 1 (OGG1)), with the consequent formation of an AP site. This 
site is then recognized by AP endonuclease (APE) which cleaves the 
phosphodiester backbone forming a transitory single strand break (SSB) that is 
promptly repaired by the cooperative action of the DNA polymerase β (Polβ) and 
the X-ray cross-complementing group 1 (XRCC1) complex (Robertson et al., 
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2009). Major Cr(VI)-induced genetic lesions, such is the case of DNA-protein 
crosslinks (DPCs) and DNA inter/intrastrand crosslinks (ICLs), imply the recruit-
ment of more complex DNA repair systems as is the case of Nucleotide Excision 
Repair (NER) system (O’Brien et al., 2005). Provided with a set of protein groups 
called xeroderma pigmentosum (XP) complementation groups, this system pro-
ceeds with the excision of a fragment of injured DNA and replaces it by a normal 
equivalent polymerized using as a template the intact strand (Shuck et al., 2008). 
Not surprisingly, mutations in key proteins involved in these DNA repair systems 
have been described both in Cr(VI)-induced LC patients and in cultured cells ex-
posed to the oxyanion. One example is the impaired ability to remove chromium-
DNA adducts and the increased sensitivity to Cr(VI) of Chinese hamster ovary 
(CHO) cells engineered to carry an inactive NER system (O’Brien et al., 2005).  
Notwithstanding the unquestionable importance of the role played by 
BER and NER systems in keeping genome’s integrity, it is the Mismatch Repair 
(MMR) system that leads the fight against genetic instability. MMR is a complex 
system that encompasses dozens of heterodimeric proteins acting sequentially 
to repair the mismatched DNA (Figure 2.3). Briefly, the injured DNA is recognized 
by the human MutS-homolog protein (MSH) heterodimeric complex that binds to 
the lesion and recruits the human MutL-homolog protein (MLH) complex. This 
second complex, in turn, recruits the exonuclease 1 (EXO1) that excises the mis-
matched DNA bases along with some adjacent bases at each side of the lesion, 
thus forming a temporary DNA SSB with loss of some genetic material. Finally, 
the same EXO1 resynthesize the gap in the DNA having as template the intact 
DNA strand (Harfe and Jinks-Robertson, 2000; Li, 2008).   
One of the main hallmarks of Cr(VI)-induced lung tumors is their charac-
teristic GI. As a matter of fact, the tumors that relay on Cr(VI) malignant potential 
can be distinguished from the other types of lung squamous cell carcinomas 
through their high incidence of microsatellite instability (MSI), a particular type 
of GI that specifically affects the microsatellites (Hirose et al., 2002; Takahashi et 
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al., 2005; Urbano et al., 2008). Although the exact mechanisms underlying Cr(VI)-
induced GI are still largely unknown, the damage that takes place in the DNA, 
particularly DNA single and double strand breaks (SSB and DSB, respectively), and 
the consequent activation of the DNA repair systems, seem to play an important 
role in this effect. 
 
 
Figure 2.3 - Mismatch Repair System. Following recognition 
of the mismatched bases by the MSH heterocomplex, a scaffold-
ing protein heterocomplex including an exonuclease 1 (EXO1) is 
recruited to remove the injured DNA along with some adjacent 
bases. Subsequently DNA polymerase fills the gap having as 
template the non-injured strand. Adapted with permission from 
Martin and Scharff, 2002. 
 
Following a genomic insult, cells usually trigger a cell cycle arrest, thus 
gaining time to repair the damage. This arrest normally occurs during the S or G2 
phases of the cell cycle and is characterized by an intense activation of the cellu-
lar repair mechanisms. However, when cells immediately sense that the DNA 
damage is extensive, instead of arresting their growth, they promptly block cell 
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cycle progression and eventually trigger apoptosis. In a very accurate work, 
O’Brien and collaborators applied the abovementioned cellular strategies to 
Cr(VI)-expositions and concluded that the cellular response to Cr(VI) depends on 
the concentration of the ion (Figure 2.4) (O’Brien et al., 2003). 
 
 
Figure 2.4 - Cellular responses to different Cr(VI) concentra-
tions. Depending on the dose, Cr(VI)-exposed cells may either acti-
vate a transient cell cycle arrest or block cell cycle progression. 
Adapted with permission from O’Brien et al., 2003. 
 
Cells’ fate after S/G2-cell cycle arrest mainly depends on the extent of the 
induced lesions and on the time needed to repair them. Various in vitro studies 
on Cr(VI)-induced genetic injuries demonstrated that following Cr(VI) exposition, 
MMR is most often the cellular repair system to be activated (Jiang et al., 2010; 
Reynolds and Zhitkovich, 2007; Reynolds et al., 2007). Furthermore, these stud-
ies also showed that lung fibroblasts and epithelial cells exposed to low concen-
trations of Cr(VI) have a higher incidence of DSB formation (identified by the γ-
H2AX foci formation), thus unveiling a potential link between the activation of 
the MMR system and the formation of these lesions (Reynolds et al., 2007, 2009; 
Zecevic et al., 2009). Nonetheless, because the formation of DSB in the Cr(VI)-
exposed cells occurred faster than following alkylating agents exposures, the 
idea that a mechanism rather than the production of persistent SSB following 
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EXO1 mismatch removal may drive the collapse of the DNA replications forks and 
the consequent DSB formation emerged. In confirmation of this idea, studies 
from the Zhitkovich’s laboratory showed that the DSB formation results from a 
replication fork collapse induced by the chromium-ascorbate-DNA-induced bulky 
lesions, rather than from EXO1-promoted SSB formation (Reynolds et al., 2007, 
2009). Moreover, these studies also postulated that DSB formation under physio-
logically relevant Cr(VI) concentrations only requires the progression of the cell 
cycle from late S to early G2 phase and the specific action of MSH3 protein 
(Urbano et al., 2012). 
DSBs’ repair during the S and G2 phases is entrusted to the homologous 
recombination (HR) repair system. This mechanism is described by Urbano and 
collaborators as a series of interrelated molecular pathways that intervene in the 
recovery of stalled or broken replication forks and in the repair of DSBs and ICLs 
(Urbano et al., 2012). In agreement, HR activation is based upon the recognition 
of the γ-H2AX foci by the scaffolding protein 53BPI and ataxia-telangiectasia mu-
tated protein (ATM). The downstream actions of the ATM protein involve the 
crosstalk between different molecular pathways and the consequent induction 
of different cellular responses. As an example, the activation of the HR system 
depends on the activation of the Fanconi anemia (FA) complementation group D 
(FANCD2) protein and on its interplay with RAD51 (Taniguchi et al., 2002). 
In addition to the direct Cr(VI)-induced genetic lesions and to those in-
duced by the action of the repair systems, GI may also result of an uncoupling of 
the cell cycle from centrosome duplication (Urbano et al., 2008; Xie et al., 2005). 
The molecular mechanisms underlying this uncoupling are mostly unknown; 
however it apparently results from a delayed S/G2-induced cell cycle arrest (Fig-
ure 2.5). Wise’s group exhaustively explored this subject and concluded that 
chronic exposure of cells to lead chromate induces centrosome amplification, 
which drives Cr(VI) clastogenic effects, namely the formation of aneuploid cells 
(Holmes et al., 2010). Wise’s laboratory also reported the formation of tetraploid 
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cells following chronic exposures to Cr(VI), which is in line with the theory ex-
plored by Pellman’s laboratory, stating that a link exists between tetraploidy, an-
euploidy and cancer (Ganem et al., 2007; Gordon et al., 2012; Pellman, 2007).  
 
 
Figure 2.5 - Different pathways for genomic instability formation following 
Cr(VI) exposure. Cells with DSBs and SSBs may repair their DNA by the activation of cell 
cycle checkpoints and DNA damage repair systems while cells with extensive damage 
may trigger cell death to be eliminated. Impairment of these systems can lead to ge-
nomic instabilities including chromosomal aberrations. Note should be given to the im-
portant role played by MMR in the formation of genetic instability.  
 
However much became known regarding Cr(VI) carcinogenicity in the last 
decades, the use of inadequate study designs hampered the translation between 
the bench and the clinic and no big advances were done in terms of therapeutics. 
So far there are no solution for Cr(VI)-induced lung tumors and we are still recur-
ring to the same therapeutic interventions used in the nineties, mainly based on 
the administration of ascorbate and soft metal chelating agents (Barceloux, 
1999). 
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Chapter 3  
Cancer Stem Cells and the Hierarchi-
cal Theory of Cancer 
With the accumulating knowledge on the diverse areas of cancer, the stochastic 
model started to be questioned. By assuming the tumor to be a mass of 
hyperproliferative cells equally provided with the ability to drive tumor’s growth, this 
model justifies cellular heterogeneity and malignant progression mainly by the action of 
adaptive selective pressures acting over new genetic mutations or environmental altera-
tions (Garvalov and Acker, 2011). However, evidence suggesting that tumor initiation 
and maintenance may only be ascribed to a limited population of cells within the tumor, 
along with the identification of cells with progressive degrees of differentiation shook 
the foundations of this theory and drove the edification of new ones. 
The hierarchical model of cancer emerged as an alternative theory trying to ex-
plain the presence of high degrees of cellular heterogeneity within the tumors. Accord-
ing to this model, tumors are hierarchically organized heterogeneous entities coordinat-
ed by a small subset of cells with self-renewal and multilineage differentiation abilities, 
named CSCs (Chen et al., 2010; Medema, 2013). These cells are more tumorigenic and 
capable of generating a serially transplantable phenocopy of the human tumor when 
xenotransplanted into immunocompromised mice (Garvalov and Acker, 2011). Also, 
much alike normal stem cells (SCs), they divide asymmetrically to provide tissues with 
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progenitor cells while keeping the pool of endogenous SCs (Padilla-Nash et al., 2012). 
Moreover, they inhabit discreet niches within the tumor, where a very complex network 
of communication with the tumor stroma exists (Vermeulen et al., 2012). As a conse-
quence of this intense crosstalk, CSCs become extremely plastic and they can differenti-
ate or not into progenitor and eventually terminally differentiated tumor cells depend-
ing on the signals released by the stromal cells (Vermeulen et al., 2012).  
An immediate corollary of the CSCs model is that, notwithstanding the fact that 
tumors are comprised of heterogeneous cell populations, only the small fraction of CSCs 
have the ability to self-renew and to produce phenotypically diverse populations and 
thus to metastasize (Garvalov and Acker, 2011). The link between CSCs and metastases 
has also been supported by several studies even though only a few of them have direct-
ly tested the metastatic capability of putative CSCs in vivo (Singh and Settleman, 2010). 
Nonetheless, the attained results showed that even though in vitro the CSCs phenotype 
alone may exhibit invasive properties, in vivo this phenotype may not be enough to de-
termine or predict metastases formation. In fact, albeit two distinct CD133+ pancreatic 
CSCs sub-populations with tumorigenic potential can be isolated, just the subpopulation 
concomitantly positive for CD133 and C-X-C chemokine receptor (CXCR) type 4 (CXCR4) 
caused liver metastases (Hermann et al., 2007). 
3.1 On the origin of CSCs: theories, myths and 
speculations 
Since the XIX century that it has been hypothesized that tumors are main-
tained by a discreet and eccentric population of cells that inhabit them (Trosko 
and Chang, 1989). These cells would portray stem properties and underline the 
malignant features of tumors (Wicha et al., 2006). However, the first time CSCs 
were isolated from tumor samples was in 1994 when Lapidot and coworkers 
identified a cell population able to initiate human acute myeloid leukemia follow-
ing transplantation into severe combined immunodeficient (SCID) mice (Lapidot 
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et al., 1994). From there on, CSCs have been identified and characterized in vir-
tually all human neoplasias (Vermeulen et al., 2012). 
It was initially proposed that CSCs originate following the mutational 
transformation of tissue-endogenous SCs, inducing dysregulated self-renewal 
properties in these cells and selectively driving tumor growth (Visvader, 2011). 
However, alternative evidence further suggested that CSCs may also arise from 
restricted progenitors likewise due to oncogenic mutations (Pardal et al., 2003). 
More recently, however, this mostly unidirectional view of CSCs formation was 
questioned and an active role was attributed to the microenvironment. The 
works of Takahashi and Yamanaka showing that cells portraying pluripotent 
properties can be attained by artificial inducing these properties in differentiated 
cells through genetic manipulation (Yamanaka and Blau, 2010), made the central 
dogma of stem cell biology to collapse. Consequently a big paradigm shift took 
place in what regards the understanding of the CSCs biology. For the first time it 
was hypothesized that in addition to the abovementioned pathways to originate 
CSCs, these cells may also be obtained through dedifferentiation of tumor differ-
entiated cells (Figure 3.1) (Vermeulen et al., 2012). 
Previous studies from the Weinberg’s group further supported the dedif-
ferentiation theory as they showed that CSCs’ features result from an epithelial 
to mesenchymal transition (EMT) happening in the tumor (Mani et al., 2008). In 
fact, authors showed that EMT induces deep phenotypic changes in cells, which 
are accompanied by the expression of CSCs markers and an increase in the self-
renewal and tumor formation abilities (Mani et al., 2008). Besides suggesting 
EMT as a possible intermediary step in the route to CSCs’ formation, these re-
sults also unveiled that that process may depend upon alterations in the 
expressome of cells (Medema, 2013). In agreement, Vermeulen and collabora-
tors showed that myofibroblasts-secreted hepatocyte growth factor (HGF) is a 
potent inducer of EMT, which acts through the activation of the EMT-promoting 
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factors SNAIL and TWIST, resulting in the induction of CSCs’ formation through 
dedifferentiation of tumor cells (Vermeulen et al., 2010; Wu and Yang, 2011). 
 
 
Figure 3.1 - Possible different origins of CSCs. CSCs can 
be attained from tissue-endogenous normal SCs through 
the accumulation of oncogenic mutations or, in a similar 
way, from restricted progenitor cells. More recently, it was 
proved that CSCs may also result from the stromal-
orchestrated dedifferentiation of differentiated tumor cells. 
Adapted with permission from Welte et al., 2010. 
 
Whether CSCs arise from pre-existing tissue SC, restricted progenitors or 
dedifferentiation of terminally differentiated cells is currently accepted to de-
pend on the context. In agreement, the accumulating knowledge on the field led 
the group of Medema to redesign the hierarchical model of cancer by introduc-
ing the microenvironment as a key player. According to their Emerging Dynamic 
CSCs Model, CSCs’ physiology depends mostly on stromal cells-released mole-
cules that strongly modulate their phenotype. Authors depict CSCs as very plastic 
entities that can be interconverted into any cell type of the tumor hierarchy. 
Heterogeneity is the result of CSCs’ asymmetric division that originates progeni-
  
 Chapter 3 
PhD in Biosciences – Specialization in Cellular and Molecular Biology 51 
tor cells, which ultimately will differentiate in a wide range of differentiated tu-
mor cells. Alternatively, the stromal cell population comprised of myofibroblasts, 
endothelial cells, stellate cells and monocytes may also induce stem cell symmet-
ric division and consequently enrich the CSCs pool of the tumor. As to the origins 
of CSCs, this model perfectly accommodates both the mutagenic and the dedif-
ferentiation hypothesis, but attributes a coordination role to the microenviron-
ment cells (Figure 3.2) (Borovski et al., 2011; Vermeulen et al., 2012). 
 
 
Figure 3.2 - The CSCs-based models for cancer formation. 
Recent evidence suggests that CSCs may form in response to 
microenvironmental clues released by stromal cells. Adapted from 
Vermeulen and Melo, 2012. 
3.2 CSCs’ biology and underlying cellular 
pathways 
CSCs’ undifferentiated status mainly relays on the integrity of their nich-
es. Recent evidence shows that this integrity is mainly sustained by the same 
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molecular pathways that govern normal SCs’ biology, thus supporting the theo-
ries of Weinberg and Medema on an overlapping gene expression signature be-
tween normal and CSCs (Garvalov and Acker, 2011; Mani et al., 2008; Seidel et 
al., 2010; Vermeulen et al., 2010). 
Wnt signaling cascade plays a central role in inducing and keeping CSCs 
populations. This highly conserved signaling pathway is essential during the early 
phases of embryonic development. It belongs to the family of morphogens, a 
group of molecules responsible for the attainment of the bodies’ shapes 
(Clevers, 2006). In adults, however, Wnt signals work on keeping tissues’ homeo-
stasis preferably acting over the endogenous SCs and controlling their division. 
For example, the weekly renewal of the intestinal epithelium is mainly regulated 
by the action of the Wnt signaling pathway over the intestinal SCs living in the 
bottom of the intestinal crypts (Medema and Vermeulen, 2011). 
The Wnt cascade can be subdivided into a canonical and a non-canonical 
signaling pathway, being the first more important regarding CSCs’ biology (De 
Sousa E Melo and Medema, 2012). The canonical Wnt signaling pathway is driv-
en by β-catenin, whose levels and cellular localization are extremely well regu-
lated as they strongly affect the activation of the signaling cascade. In fact, Wnt 
axis is generally turned off in a normal cell and, as a consequence, beyond the β-
catenin captive in the intercellular adhesion membrane complexes, all the re-
maining β-catenin molecules are targeted for proteasomal degradation by the 
adenomatous polyposis coli (APC) complex following phosphorylation at specific 
serine residues by the glycogen synthase kinase 3 beta (GSK3-β)/casein kinase 1 
(CK1) complex (MacDonald et al., 2009). In the presence of Wnt ligands, howev-
er, frizzled (Fzd) receptor is activated and the canonical pathway is turned on. As 
a consequence, the assembly of APC/GSK3-β/CK1 complex is blocked and β-
catenin is left free to migrate to the nucleus to work as a transcription factor 
(Figure 3.3) (MacDonald et al., 2009). The transcription activities of β-catenin are 
mediated by the T-cell factor (TCF)/ lymphoid enhancer factor (LEF) complex and 
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modulate the expression of genes involved in cellular proliferation and differen-
tiation, namely, MYC and cyclin D1 (CCND1) (MacDonald et al., 2009). Recent re-
ports in the literature unveiled the role of the wingless-type mouse mammary 
tumor virus integration site family (Wnt) axis in the development and mainte-
nance of tumor CSCs populations. For instance, Vermeulen and collaborators 
showed that the stemness of colon CSCs is regulated by microenvironment-
released Wnt signals while the Huelsken’s laboratory proved that skin CSCs’ 
maintenance is dependent on β-catenin signaling (Malanchi et al., 2008; 
Vermeulen et al., 2010). More recently, evidence came out implicating the in-
volvement of Wnt/β-catenin in brain (Gong and Huang, 2012), lung (Xu et al., 
2013) and breast (Cai et al., 2013) CSCs’ homeostasis as well as in mediating 
leukemias’ resistance to therapy (Yeung et al., 2010). 
 
 
Figure 3.3 - Wnt/β-catenin canonical signaling pathway. a) In the 
absence of WNT-frizzled ligands the excess of β-catenin in the cells is 
phosphorylated by the APC/GSK3/CK1 complex and subsequently tar-
geted for proteasomal degradation. b) In the presence of Wnt-frizzled 
ligands, however, β-catenin phosphorylation is prevented and the tran-
scription factor translocates to the nucleus where it activates the tran-
scription of targeted genes. Adapted with permission from Moon et al., 2004. 
  
    
54 Carlos F. D. Rodrigues │ University of Coimbra  
Another important signaling cascade activated by CSCs is the Notch 
pathway. Similarly to Wnt, this pathway is also very important during early em-
bryogenesis; however, differently, its activation is mediated by juxtacrine signal-
ization (Bolós et al., 2007). In adults, Notch signaling plays a crucial role in the 
preservation of adult SCs’ properties, as illustrated by the studies of van Es and 
colleagues showing that silencing of this cascade resulted in the lost of the stem 
potential of intestinal SCs and an increase in the pool of differentiated cells (van 
Es et al., 2005). Regarding CSCs, Notch signaling has also been said fundamental 
for their function. In agreement, Zhang and collaborators showed that the acti-
vation of the Notch signaling pathway drives hyperproliferation and the for-
mation of neural stem cell-like colonies in human glioma cells (Zhang et al., 
2008), while Hovinga and colleagues showed that its inhibition in glioblastoma 
targets CSCs (Hovinga et al., 2010). Moreover, experimental therapeutic ap-
proaches using inhibition of Notch signaling through the use of neutralizing anti-
bodies (ABs) against delta-like 4 ligand (DLL4) results in an accentuated decrease 
of CSC’s populations in human tumors (Hoey et al., 2009).  
Hedgehog signaling cascade is fundamental in determining dorsoventral 
body axis and in tissue repair during early embryonic phases. Conversely, in adult 
bodies the dysregulation of this pathway is a potent driver of tumorigenesis 
(Coni et al., 2013). This may happen due to the role of Hedgehog signaling in 
governing CSCs’ expressome with tremendous implications for their prolifera-
tion. In agreement, the laboratory of You showed that the downregulation of 
Hedgehog pathway in lung tumors induces a significant reduction in the CSCs 
population (Zhang et al., 2012). Also corroborating this observation are recent 
reports from Huang and Rodova showing that abrogation of Hedgehog signaling 
in pancreatic CSCs decreased the ability of this cell population to self-renewal 
(Huang et al., 2012; Rodova et al., 2012), and a study from the Eberhart labora-
tory revealing the dependency on the Hedgehog signaling for the maintenance of 
the CSCs population in gliomas (Bar et al., 2007).  
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CSCs not only relay on the activation of stem-associated cellular path-
ways, like the abovementioned, but they may also co-opt stromal cells to pro-
duce paracrine inducers of alternative signaling pathways. This is the case of 
Activin/Nodal signaling pathway, essential for the sustained growth of CSCs, 
which is activated by stellate cell-released factors following co-option by CSCs. 
Alternatively, Activin/Nodal may also be produced by CSCs and act over them-
selves in an autocrine loop (Lonardo et al., 2011).  
3.3 The search for a specific marker 
The implication of the aforementioned pathways in CSCs physiology 
strongly supported the search for specific markers of CSCs. The recognition of 
such markers would allow the understanding of CSCs biology and dynamics in 
the tumor, as they permit to specifically identify and isolate this population of 
cells. So far CSCs have been isolated based on some of their physiological proper-
ties. The classically used protocol is the selection and purification of CSCs based 
on their ability to form tridimensional spheres when cultured under low-
adherence conditions with appropriate mediums and supplements, the so-called 
sphere-forming assay (Eramo et al., 2008). Alternatively, CSCs can also be sepa-
rated by fluorescence associated cell sorting (FACS) based on their capacity to 
extrude Hoechst dyes through the ABC membrane pumps family (Goodell, 2005; 
Goodell et al., 1996). Although both methods exhibit advantages and weakness-
es, none of them is enough to identify CSCs per si and must be completed by the 
additional use of specific molecular markers.  
An ideal marker should only be expressed in a fully-stem CSCs and be lost 
as soon as differentiation begins (Medema, 2013). As a consequence, the mark-
ers proposed so far are typically intermediate molecules of the differentiation 
signaling pathways. The most renewed example is CD133 which is allegedly a 
marker of colorectal, lung, brain, pancreatic, breast and ovarian CSCs (reviewed 
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by Garvalov and Acker, 2011 and Medema, 2013). Corroborating CD133 utility as 
a CSCs marker are two studies from 2007 showing that only the CD133+ colorec-
tal cancer cells are able to initiate tumors  (O’Brien et al., 2007; Todaro et al., 
2007). In the next year, Medema’s group further showed that just one CD133+ 
cell is able to give rise to a sphere that induces a perfect phenocopy of the origi-
nal tumor following subcutaneous implantation in immunosuppressed mice 
(Vermeulen et al., 2008a). Nonetheless, the same group also alerted more re-
cently that it is possible to find CD133+ non-CSCs due to the fact that differentia-
tion from CD133+ CSCs is not accompanied by a downregulation of CD133 but 
from a change in the AC133 epitope, thus imposing prudence when using this 
protein as a marker (Kemper et al., 2010).  
More recently aldehyde dehydrogenase 1 (ALDH1) has also been pro-
posed as a marker for CSCs. Effectively, high levels of ALDH activity have been 
documented in CSCs isolated from diverse tumor samples, thus favoring the hy-
pothesis that this enzyme, or at least its antigen expression may be used as a tag 
for CSCs (Chen et al., 2009; Huang et al., 2009). Nonetheless, regardless of the 
use of ALDH1 as a marker of CSCs, the physiological meaning of its higher expres-
sion in CSCs is yet to be uncovered. 
3.4 Therapeutic implications of CSCs  
Therapy resistance has classically been ascribed to a small population of 
cells inhabiting the tumor that acquired an arsenal of pro-survival genetic muta-
tions. Following the destruction of the bulk of tumor cells, this population would 
clonally expand and recapitulate the tumor, usually with a more aggressive phe-
notype (Vermeulen et al., 2012). Studies corroborating this theory can be en-
countered throughout the literature in virtually all tumor types. The most exu-
berant example is the behavior of chronic lymphoid leukemia (CLL) following 
therapy. A recent paper from Ouillette and colleagues showed that the replace-
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ment of CLL TP53 mutation-harboring cells following therapy is dominated by  
the outgrowth of clones portraying very complex genetic alterations (Ouillette et 
al., 2013). But the advent of CSCs revolutionized the concept of tumor relapse by 
introducing the idea that CSCs may respond differently to therapy. In fact, many 
studies have shown that CSCs are substantially more resistant to therapeutical 
agents (either chemical or radiation) than the bulk of tumor cells, regardless of 
sharing the same genetic background (Al-Hajj et al., 2004). In agreement, an in 
vitro study from the group of Gomes recently showed that a CSCs population, 
isolated from an osteosarcoma cell line, has a relatively higher drug and radia-
tion resistance when compared to the progenitor cell line, as well as a higher 
tumorigenic ability (Martins-Neves et al., 2012). 
By accepting the hierarchical model of cancer, or more correctly, the dy-
namic CSCs model of cancer, researchers inherently assigned CSCs to the posi-
tion of survivors following therapy cycles and thus of drivers of tumors’ relapse. 
Experimental evidence strongly supported this suspicion by showing, for exam-
ple, that following the chemotherapeutical treatment of colorectal tumors there 
is an increment of the CSCs population (Wilson et al., 2011a). Similar observa-
tions were additionally found for lung (Huang et al., 2013), breast (Ithimakin et 
al., 2013; Lee et al., 2011), prostate (Wang et al., 2013) and pancreatic tumors 
(Izumiya et al., 2012) among others, leading the scientific community to under-
stand that current therapeutic approaches are actually the responsible for tumor 
relapses as they only target the bulk of tumor cells, leaving untouched the CSCs 
population and their arranged niches (Figure 3.4) (Garvalov and Acker, 2011; 
Vermeulen et al., 2012). 
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Figure 3.4 - The effect of conventional cancer therapies over CSCs. Con-
ventional therapies, either chemical- or radiation-based tend to target the bulk 
of tumor cells leaving untouched the CSC’s pool and their niches. Consequently, 
tumor relapse often occurs as CSCs may repopulate the tumor bed most of the 
times displaying even more aggressive properties. Adapted with permission from 
Garvalov and Acker, 2011. 
 
The understanding of the cellular basis of CSCs mediated tumor relapse 
prompted the search for therapeutic approaches that can effectively prevent 
tumor regrowth. Initially, it was believed that CSCs-targeted therapies would re-
solve the problem of tumor relapse and a plethora of new CSCs-targeted drugs 
have been developed. These drugs, much alike the CSCs’ markers, mainly target 
the signaling pathways involved in the homeostasis of the CSCs’ pool (Figure 3.5). 
For instance, blockage of the Hedgehog signaling pathway using cyclopamide, an 
antagonist of the Hedgehog co-receptor smoothened (SMO), results in the abro-
gation of the CSCs’ population in chronic myeloid leukemia (CML) (Zhao et al., 
2009). Alternative targets on CSCs were also surveyed, as reviewed by the groups 
of Frank and Acker (Frank et al., 2010; Garvalov and Acker, 2011). In agreement, 
Gupta and colleagues performed a high-throughput screening to identify selec-
tive inhibitors of CSCs from which they spot salinomycin as a potent reducer of 
the CSCs population, killing 100-fold more cells than common chemotherapeutic 
drugs (Gupta et al., 2009). Ongoing studies are dissecting the molecular targets 
of salinomycin and the signaling pathways it activates, prior to its test for intro-
duction in clinical practice (Arafat et al., 2013; Koo et al., 2013; Li et al., 2013). 
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Figure 3.5- Multi-ways of therapeutically targeting CSCs. 
Following the identification of CSCs as the drivers of tumor re-
lapse, many targeted therapies have been tried. So far the 
most effective relay on the interference with the signalling 
pathways underlying CSCs’ homeostasis. Adapted with permis-
sion from Frank et al., 2010. 
 
Most surprisingly, the results from the first CSCs-based therapy assays 
immediately revealed that solely by targeting CSCs tumors are not abrogated. In 
fact, due to the abovementioned ability of tumors to replenish their CSCs popu-
lation through dedifferentiation of differentiated tumor cells (Figure 3.6), CSCs-
targeted therapies were condemned at birth (Garvalov and Acker, 2011). A re-
cent study from Chaffer and colleagues provided the first experimental confirma-
tion that dedifferentiation takes place in human tumors, thus providing a route 
for therapy resistance following CSCs’ hit (Chaffer et al., 2011).   
 
 
Figure 3.6 - The effect of CSC-targeted therapies. Due to the ability of 
CSCs to be attained by dedifferentiation of differentiated tumor cell, CSCs-
targeted therapies fail to abrogate tumors as they replenish the population 
that sustains their growth. Adapted from Vermeulen and Melo, 2012. 
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Ongoing work now focuses on the development of combined therapies to 
target simultaneously the CSCs, their niches and the bulk of differentiated tumor 
cells (Figure 3.7). Successful studies both in vitro and in animal models have al-
ready been documented, as is the case of the use of salinomycin combined with 
gemcitabine to target pancreatic tumor cells (Zhang et al., 2011). In accordance 
to the dynamic cancer stem cell model, microenvironment-focused therapies 
have also been designed, particular those targeting the CSCs’ niches. For in-
stance, the perivascular sites are preferable niches for CSCs as they are enriched 
in both high levels of oxygen and high concentrations of nutrients. Moreover, an 
intricate paracrine signaling between endothelial cells and CSCs seems to be in-
volved in keeping CSCs’ undifferentiation properties and in potentiating their ro-
bustness, thus rendering cells more resistant to therapy  (Borovski et al., 2011). 
In light of these facts, anti-angiogenic therapies combined with cytotoxic drugs 
have been designed to eradicate tumors, and in the case of gliomas, they have 
been shown to render CSCs more susceptible to therapeutic agents (Folkins et 
al., 2007). However, contradictory results have been published regarding the im-
pact of anti-angiogenic therapies in tumors’ growth and progression and addi-
tional studies must be done to clarify their potentials (Pàez-Ribes et al., 2009). 
 
 
Figure 3.7 - The ideal CSCs-targeted therapeutic approaches. Tumor abro-
gation can only be attained through a combined therapy. One therapy may consist 
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of either target or induce differentiation of CSCs followed by hitting the bulk of 
tumor cells using a conventional cytotoxic drug. Alternatively, the CSCs’ niches 
may be disrupted by interfering with either environmental conditions or the con-
centration of paracrine molecules to target CSCs, followed again by a conventional 
cytotoxic drug to kill the bulk of the remaining tumor cells. Adapted with permission 
from Garvalov and Acker, 2011. 
3.5 Lung CSCs: the resident evil 
The first time cancer stem-like cells were identified in and isolated from 
LC samples was in 2008 by the group of de Maria (Eramo et al., 2008). Growing 
evidence on the potential existence of such cells drove the authors’ search and in 
agreement to the actual ideals, they managed to isolate a population of CD133+ 
cells that exhibit the capacity of growing indefinitely as tumor spheres in appro-
priately supplemented serum-free medium (Eramo et al., 2008). From there on, 
many other laboratories corroborated these findings, although debate persists 
over the molecular markers of lung CSCs. 
The normal lung parenchyma, like virtually any other human tissue, com-
prises a small population of undifferentiated cells. In the particular case of lung, 
which is an internal vital organ in intimate contact with the extracorporeal envi-
ronment, these cells are of extreme importance in restoring the respiratory epi-
thelium following environment-induced injuries (Rivera et al., 2011). In the prox-
imal bronchial airways, basal cells have been proposed to represent this popula-
tion of cells, as they have the potential to restore a fully differentiated epitheli-
um (Hong et al., 2004). These cells lay in the most internal layer of the 
pseudostratified respiratory epithelium and are the primary source of cells dur-
ing lung healing after injury (Musah et al., 2012). Nevertheless, as one approach-
es the respiratory sections of the lung, the pseudostratified epithelium progres-
sively turns to columnar and then cubic, and its cellular composition changes. In 
the more distal portions of the air conductive system, Clara cells become more 
abundant and inherit the responsibility of tissue repair. In agreement, these cells 
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have been proved to self-renew and generate ciliated cells in response to epithe-
lial injury (Rawlins et al., 2009). More internally, terminal bronchioles give rise to 
respiratory bronchioles lined by a very tiny epithelial layer comprised of a single 
sheet of cells. These cells can either be type I or type II pneumocytes (also 
known as alveolar cells), being the former more abundant and the latter the re-
sponsible for the surfactant production. Type II pneumocytes are also the undif-
ferentiated cells of the respiratory epithelium, with long confirmed ability to 
both self-renew and differentiate into type I pneumocytes (Adamson and 
Bowden, 1974). More distally, an additional population of relatively undifferenti-
ated variant Clara (ClaraV) cells lay near pulmonary neuroendocrine cells (PNEC), 
with which they establish an intimate communication to maintain epithelial di-
versity after injury (Giangreco et al., 2002). Finally, a subset of these ClaraV cells, 
independent of PNECs and displaying more undifferentiated properties, lay in 
the transition between the conductive and respiratory epithelium 
bronchioalveolar stem cells (BASC) and are considered the true stem cells of the 
bronchiole (Rivera et al., 2011). Figure 3.8 further provides a geographical idea of 
the distribution of the different cell population throughout the respiratory sys-
tem. 
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Figure 3.8 - The different cell types along the respiratory system. 
While penetrating into the lung, the pseudostratified respiratory epithelium 
changes towards a simple squamous epithelium. This structural modifica-
tion is accompanied by an alteration in the cellular constitution: basal cells 
disappear and their function is ensured by Clara cells; BASC establish at the 
transition between the conductive and respiratory epitheliums and finally, 
alveoli are lined by pneumocytes. Adapted from Eramo et al., 2010. 
 
The current literature on the origins of CSCs in lung tumors does not indi-
cate any particular source, but many. For instance, Kim and collaborators 
showed that BASCs are a potential source, as these cells are expanded in lung 
tumors sustaining their malignant proliferation (Kim et al., 2005). Moreover, the 
group of Crystal just showed that lung basal cells may be reprogrammed during 
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early phases of cigarette-induced LC in favor of the development of highly ag-
gressive lung tumors (Shaykhiev et al., 2013). Finally, dedifferentiation may also 
represent an alternative pathway for the development of LC CSCs, as cells similar 
to Clara, but with decreased secretory ability, have been isolated from lung pre-
neoplastic lesions and seem to sustain the subsequent malignant progression 
(Rivera et al., 2011). Nonetheless, regardless of their origins, lung CSCs have al-
ready a couple of well defined characteristics that may allow their identification. 
They can be isolated through the sphere-forming assay and are positive for the 
octamer-binding transcription factor 3 and 4 (OCT-3/4), the SRY-box containing 
gene 2 (SOX2) and the NANOG (Kitamura et al., 2009; Rivera et al., 2011). Addi-
tionally, the majority of the papers in the literature describe lung CSCs as being 
CD133+ (Kitamura et al., 2009; Medema, 2013; Rivera et al., 2011). However, this 
positivity is still arguable as independent studies have shown that CD133- 
glioblastoma cells have equivalent tumor initiation ability in mice to CD133+ cells 
(Beier et al., 2007; Joo et al., 2008). Finally, lung CSCs also express ALDH, and the 
isoforms 1A1 and 3A1 seem to be specific of NSCLC (Patel et al., 2008). 
Similarly to the populations of CSCs identified in other tumors, lung CSCs 
are more resistance to conventional therapies than the bulk of differentiated 
tumor cells. In agreement, Barr and colleagues showed that the treatment of 
these cells with therapeutic doses of cisplatin, a common cytotoxic drug used in 
the chemotherapy of NSCLC, targets the bulk of cells but leaves untouched the 
CSCs’ population (Barr et al., 2013). Moreover, combined therapeutic strategies 
have also been designed for LC with very promising results. For instance, the 
group of Gorelik recently showed that the combination of the cisplatin treatment 
with an inhibitor of the c-Kit receptor make the lung tumor cells more sensitive 
to therapy, thus favoring tumor eradication (Levina et al., 2010). 
Coming years will be crucial in defining an effective therapeutic approach 
for LC. The wide arsenal of arrays, along with genome wide association studies 
(GWAS), and the improvement and continuous development of new molecules 
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to be used as therapeutic agents are providing knowledge at such a high rate 
that it is expectable that very soon the complete picture of CSCs, their role in 
cancer and the different efficient ways to target them is completed. Never like 
now men was so eager and so able to go deep into the cell and dissect its intrica-
cies. This can only result in a positive outcome, translated in effective therapeu-
tic approaches and improvement of the quality of life of oncologic patients. 
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Chapter 4  
Hypothesis and Goals 
Regardless of the efforts to unravel the cellular and molecular mechanisms un-
derlying Cr(VI)-induced LC, much is yet to be undisclosed. The main obstacle seems to 
be the absence of uniformity among the experimental designs used in different labora-
tories, as well as the use of inadequate cellular systems and exposure regimens. 
Aiming to outline the abovementioned lacuna, the first goal of this project was to 
establish an adequate cellular system for the study of Cr(VI) carcinogenesis that ade-
quately mimics both the physiological and the epidemiological aspects of the process.  
Chapter 6 describes the developed strategy to attain such a system departing 
from a normal human bronchial epithelial cell line, and exposing it to a epidemiologically 
relevant concentration of Cr(VI).  
A second major aim of this project was to exhaustively characterize the different 
aspects of the malignization process, hoping to identify the drivers of the transfor-
mation, which could become potential therapeutical targets. 
In agreement, Chapter 7 presents the rational used to increase the malignant po-
tential of the Cr(VI)-derived malignant system aiming to exacerbate the Cr(VI)-induced 
features. Moreover, the different approaches used to dissect the malignant progression 
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are also presented, with particular reference to the metabolic and gene expression pro-
files. 
Driven by the results attained during the characterization of the Cr(VI)-induced 
malignant cellular systems, the last hypothesis proposed was that CSCs may have been 
involved in the transformation process mobilized by Cr(VI). To test this hypothesis a bat-
tery of assays were performed. 
Chapter 8 groups the results attained during the search for a CSC population 
within the malignant systems. A comparative analysis is also presented in order to pro-
vide an integrative picture of the malignization process and of the Cr(VI) effects over the 
lung epithelial cells. 
The ultimate aim of the work depicted in this thesis is to clarify the cellular and molecu-
lar mechanisms underlying the carcinogenesis of Cr(VI), giving particular emphasis to the 
role played by the stroma and the CSCs in that process. Ultimately, the attained results 
are believed to provide a better understanding on the different stages of Cr(VI)-induced 
lung carcinogenesis: onset, progression and metastases formation. As a consequence, 
they will represent a step-forward not only in chromium carcinogenesis but also in the 
understanding of the overall cancer biology. 
 
  
 
 
 
 
PART II 
Laboratory Procedures 
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Chapter 5  
Material and Methods 
5.1 Reagents, Solutions & Mediums  
The reagents used in the various experiments throughout this work were 
either of analytical grade or cell culture recommended and were acquired from 
Sigma-Aldrich (Sintra, Portugal) unless specifically stated. Conversely, all cell cul-
ture media and supplements were from Gibco® (Life Technologies, Carlsbad, CA, 
USA) unless the contrary is referred. Ultrapure water (milli-Q) was used anytime 
water was needed, in particular for the preparation of aqueous solutions. Plastics 
used for cell culture were attained from either Corning (Lowell, MA, USA) or SPL 
Life Sciences (Eumhyeon-ri, Korea). The protocols for the preparation of stock and 
secondary solutions are collectively grouped in the Appendix A of this thesis.  
5.1.1 Potassium Dichromate Aqueous Solution for 
Culture 
For the culture of cells in the presence of Cr(VI), the oxyanion was 
added as a 50 µM potassium dichromate (K2Cr2O7) aqueous solution, pre-
pared from dilution from a 2.5 mM stock solution. The solution was filtered 
prior to use to ensure sterilization. 
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5.1.2 Gelatin Coating Solution  
According to manufacturer’s instructions, BEAS-2B should be cul-
tured on the top a type-B gelatin from bovine skin solution. This solution 
was prepared by diluting the commercialized 2 % gelatin solution in 25 % of 
1x-phosphate-buffered saline (PBS) and 5 % of 2 % bovine serum albumin 
(BSA) solution. 
5.1.3 F12 Supplemented Growth Medium 
To prepare 500 mL of this cell culture medium, 5 mL of penicillin 
(5000 U/mL)-streptomycin (5000 µg/mL), 1 mL Ultroser G (Pall Corpora-
tion, Port Washington, NY, USA), 100 µl of amphotericin B and 97,9 mL of 
Ham’s F12 medium. 
5.1.4 CSCs’ Isolation Medium 
The liquid matrix of this medium was prepared by mixing 250 mL of 
DMEM:F12 (1:1) cell culture medium, with 5 mL of penicillin (5000 U/mL)-
streptomycin (5000 µg/mL), 10 µl of 1mM progesterone solution (Sigma-
Aldrich) and 5 mL of the commercialized insulin, transferrin, selenium (ITS) 
sodium pyruvate solution. Subsequently, 0.6 g of sodium bicarbonate   
(NaHCO3) was dissolved in the liquid phase, along with 0.08 g of putrescine. 
2 % methylcellulose solution was then used to perform the final volume of 
500 mL. 
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5.1.5 Preparation of Low Adherence 6-well Plates for 
CSCs’ Isolation 
Low adherence conditions are mandatory for the isolation of CSCs. 
To attain them, one can either buy commercially available low-adherence 
supports or prepare them in the laboratory. For our experiments we 
choose to prepare ourselves the 6-well plates by coating them with a 2 % 
poli-(2-hydroxyethyl methacrylate) (poli-HEMA) solution. 
To prepare 100 mL of a 2 mg/mL coating solution, 2 g of poli-HEMA 
were added to 100 mL of 95 % ethanol in a glass flask, and allowed to dis-
solve over a stirring plate with mild agitation for circa 8 h at room tempera-
ture (RT). After complete dissolution, 6-well plates were coated with        
0.4 mL/well of this solution and allowed to dry at room temperature, in a 
sterile atmosphere over a stable bench. Following drying, plates were fur-
ther sterilized by exposing them to UV light for 20 min. Whenever plates 
were not immediately necessary, they were sealed with Parafilm® and 
stored at 4 ºC.  
5.1.6 N2 Medium for CSCs’ Growth 
500 mL of the N2 medium were prepared by mixing 5 mL of penicil-
lin (5000 U/mL)-streptomycin (5000 µg/mL) with 5 mL of the ITS solution, 
100 µl of amphotericin B and 10 µl of the 1mM progesterone solution. Sub-
sequently, 0.6 g of NaHCO3 and 0.08 g of putrescine were dissolved in the 
medium. Sterility was ensured by filtration. 
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5.1.7 DMEM Cell Culture Medium Supplemented with 
10 % FBS 
500 mL of this medium were prepared by mixing 444.9 mL of 
DMEM cell culture medium with 50 mL of fetal bovine serum (FBS), 5 mL of 
penicillin (5000 U/mL)-streptomycin (5000 µg/mL) and 100 µl of amphoter-
icin B. 
5.1.8 Freezing Solution 
The solution used to freeze cells was prepared by mixing cell culture 
medium:FBS:dimethyl sulfoxide (DMSO) at the proportion of 7:2:1.  
5.2 Cells and Cell Culture Procedures 
From the nine different cellular systems used in this work, only BEAS-2B 
was attained from a commercial source. The remaining eight cell lines were pro-
duced under the scope of this project using original protocols. Minor description 
will be provided in this section regarding the novel cell lines, as it is an integrant 
part of both the results and discussion of Part III.  
5.2.1 Bronchial Epithelial Airway System-2B (BEAS-2B)  
BEAS-2B cells were obtained from the European Collection of Cell 
Cultures (ECCAC, Salisbury, UK; ECCAC no. 95102433). This system has been 
produced in 1988 by the group of Curtis Harris through the use of an ade-
novirus 12 (AD12)-simian virus 40 (SV40) hybrid virus. The resultant immor-
talized human bronchial epithelial cells were proved to retain the ability to 
form an epithelium in deepithelialized rat tracheas, as well as to produce 
mucin when inoculated onto a collagen matrix (Reddel et al., 1988).  
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Cells grown as adherent monolayers were maintained in either 
CloneticsTM BEGM medium (Lonza, Basel, Switzerland) supplemented with 
bovine insulin, bovine pituitary extract, epinephrine, human epidermal 
growth factor, hydrocortisone, retinoic acid, triiodothyronine, transferrin 
and the antibiotics amphotericin-B sulphate and gentamicin (Lonza) or 
LHC-9 medium, a recently produced equivalent from Gibco. Cells were kept 
at 37 ºC in a 95 % air/5 % CO2 incubator. Vented culture flasks were coated 
with gelatin solution  2 h before use, and except otherwise stated cells 
were seeded at a the recommended initial density of 4x103 cells/cm2. Sub-
culture was performed using a 0.25 % trypsin-1 mM EDTA solution 
(Biochrom, Cambridge, UK) whenever cultures reached 80 % confluence. 
Continuous culture in the presence of 1.0 μM Cr(VI) described in 
Chapter 6 started at passage (#) 4. Control cultures, grown in the absence 
of Cr(VI), were always maintained in parallel. 
5.2.2 RenG2, Cont1, DRenG2, DDRenG2, SC-DRenG2, 
SC-DDRenG2 and iRenG2 Cellular Systems 
The attention of the RenG2 following a low density culture of the 
BEAS-2B cells in the presence of 1.0 μM of Cr(VI) is of part of the novelty of 
this work and will be explored in the Part III of this manuscript. Suffice to 
say now that these cells, along with their non-malignant controls, the 
Cont1 system (BEAS-2B cells cultured at low density but in the absence of 
Cr(VI) oxyanions), were cultured in the same conditions and manipulated 
using the same protocols established for BEAS-2B cells. 
All the remaining cell lines were attained following manipulation of 
the RenG2 system. They are all malignant and some of them portray   
stem-like properties. The derivative systems (DRenG2 and DDRenG2) were 
produced by direct in vivo isolation of RenG2- and DRenG2-xenograft-
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derived cells, and following their establishment were cultured using the 
same protocol as their progenitors, but in F12 supplemented growth medi-
um. Conversely, due to their similarities with RenG2, iRenG2 were cultured 
in LHC-9 cell culture medium. 
5.2.3 Mouse Fibroblasts (FR) Primary Cell Line 
For the co-culture studies, a primary mouse stromal cell line was 
needed. To attain it, a mouse from the same colony as the ones used for 
the production of the derivative cellular systems was anesthetized using a 
77 % ketamine (Ketalar®, Pfizer, New York City, NY, USA), 23 % chlorproma-
zine (Largactil®, Laboratórios Vitória, Amadora, Portugal) solution, and cells 
from the thoracolumbar aponeurosis were surgically isolated. Tissue frag-
ments’ were then washed several times with PBS and divided into smaller 
pieces which were distributed throughout the basis of a T25 cell culture 
flask. A small drop of FBS was next added to each of the fragments to help 
them attach to the plastic surface of the flask and to provide them with nu-
trients. Finally, the flask was turned upside-down and 5 mL of DMEM cell 
culture medium supplemented with 10 % FBS were added to the top sur-
face of the flask. Fragments were allowed to attach upside-down for 24 h 
in the incubator and after that period the flask was gently turned to the up-
right position allowing cells to contact with the cell culture medium. In the 
subsequent days cells slowly started to detach from the fragments and to 
form a monolayer of cells that ended up covering almost all the bottom 
surface of the flask. Following trypsinization cells were sub-cultured and 
amplified and various aliquots criopreserved for subsequent use. 
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5.3 Clonogenic Assays  
This cell biology technique evaluates the ability of a single cell to grow at 
unfavorable low densities in the form of a colony. It allows to compare different 
cell populations, malignant vs. non-malignant or cells derived from different 
treatment regimens (Franken et al., 2006). Moreover, increased clonogenic ability 
is frequently associated with a malignant phenotype (Barr et al., 2013).  
The optimized clonogenic assay used encompassed the plating of 13 
cells/cm2 onto 100 mm Petri dishes. Cells were allowed to grow for 15 days and 
then fixed and stained with crystal violet according to the protocol established by 
the group of van Bree (Franken et al., 2006). Surviving colonies (containing more 
than 10 cells) were scored to assess cloning efficiency and the complete protocol 
was repeated at least three times. 
Plating efficiency (PE) was calculated according to Equation 1 and the re-
sults were presented as a mean of three independent assays. 
 
   
                     
                 
          Equation 1 
5.4 Generation of the Subclonal Cell Lines: 
RenG2 and Cont1 
The low density culture in the presence of Cr(VI) resulted in the formation 
of numerous dense clumps with deeply altered morphology. For the generation of 
subclonal cell lines, several of these clumps were isolated using glass cloning rings 
(Figure 5.1) and then reseeded onto 150 mm Petri dishes to be cultured again in 
the presence of 1 µM Cr(VI). 10 days later, three morphologically altered colonies 
were isolated and transferred into 3 different wells of a 6-well plate. When cul-
tures reached near 80% confluence, cells were trypsinized and reseeded onto T25 
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flasks, again in the presence of 1 µM Cr(VI). In the case of BEAS-2B control cultures 
the cloning rings were used to isolate randomly chosen colonies, as none dis-
played particular morphological features. The cells thus isolated were subjected to 
the same treatment as the Cr(VI)-treated cells.  
 
 
Figure 5.1 - Colony isolation using cloning 
rings. Cloning rings are small glass rings that can be 
placed around cellular colonies in order to isolate 
them. The protocol of isolation encompassed a 
normal tripsinization followed by cells’ collection 
using PBS. This proceeding was cautiously done in-
side the ring.  
  
Following expansion of the isolated colonies in the 6-well plate, three 
subclonal cell lines were established for either Cr(VI)-exposed and control cells. 
Karyotype and gene expression profiles were equivalent among the colonies, so 
we randomly choose one of each condition to continue the studies. From Cr(VI)-
exposed isolated colonies, RenG2 cellular system was produced; the system ob-
tained from the control low-density colonies was named Cont1. 
5.5 Cytogenetic Analys1s 
For cytogenetic analysis cells were cultured in 75 cm2 flasks and allowed to 
reach approximately 75 % confluence. The preparation of metaphase chromo-
somes was carried out according to standard procedures optimized to our cul-
  
 Chapter 5 
PhD in Biosciences – Specialization in Cellular and Molecular Biology 79 
tures. Briefly, cells’ cycle was stopped in pro-metaphase by the addition of 200 µl 
of colcemid to the cell culture flask followed by a 25 min incubation period at      
37 ºC/95 % air/5 % CO2. After this period, the cell culture medium was discarded 
and cells were washed using PBS. Cells were then dethatched by tripsinization and 
collected using PBS to a 10 mL centrifuge tube. 
To get rid of remaining cellular debris or trypsin, tubes were centrifuged for 
5 min at 1000 revolutions per minute (rpm) and the supernatants were discarded. 
Cells were then resuspended in 1 mL of FBS, to inactivate any remaining trypsin, 
plus 9 mL of a 5 mM potassium chloride (KCl) hypotonic solution. Cells and their 
elements were allowed to swell for 17 min at 37 ºC. 
After swelling, fixation was initiated by the addition of 1 mL of an ice-cold 
methanol:acetic acid (3:1) fixation solution to the tube containing the hypotonic 
solution. This step was of extreme importance to prepare and preserve the struc-
ture of the chromosomes for the next fixation steps. The hypotonic solution was 
then removed by centrifugation, 5 min at 1000 rpm, and 10 mL of the fixation so-
lution were used to ressuspend the pellet. Fixation was promoted by placing the 
tubes at 4 ºC for  1 h. Passed that time, tubes were again centrifuged 5 min at 
1000 rpm and the pellets resuspended in 10 mL of the fixation solution. Tubes 
were kept at 4 ºC until the preparation of the metaphase spreads. 
Metaphase spreads were prepared by dropping small volumes of the re-
suspended fixed cells into microscope slides. This process induced the mechanic 
rupture of the cells’ membrane, thus allowing the spread of the chromosomes 
(Figure 5.2). 
Chromosomes were giemsa-banded (GTG-banding) in order to organize 
them into karyotypes. The initial banding protocol step relays on the action of 
trypsin over the different types of chromatin. Therefore, microscope slides were 
immersed in a   0.4 % trypsin solution for a period of time optimized for each cell 
line everytime time the protocol was performed. Trypsin only digested the more 
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decondensed chromatin (the euchromatin), leaving untouched the heterochroma-
tin. Subsequently, slides were washed and the striped chromosomes were labeled 
with giemsa by immersing the slides into the dye for as much time as the estimat-
ed in the optimization steps. 
 
 
Figure 5.2 - Preparation of metaphase spreads. Following cells’ 
fixation, metaphase spreads were prepared by dipping a small drop 
of the fixed cellular suspension over the microscope slides.  
 
For each passage or cell line studied at least 50 metaphase spreads were 
analyzed and 20 karyotypes constructed using a Nikon microscope (Nikon Portu-
gal, Lisbon, Portugal) coupled with Applied Imaging® CytoVision® software 
(Genetix, New Milton, UK). 
5.6 Gene Expression Analysis by Reverse   
Transcriptase-quantitative Polymerase Chain 
Reaction (RT-qPCR) 
A very accurate and reliable way to monitorize malignant transformation-
associated changes is to evaluate the expression of some genes involved in the 
underlying processes. That can be attained by isolating the messenger ribonucleic 
acid (mRNA) from cells and subsequently analyze its contents, which would repre-
sent the cells’ expressome at a certain time point.  
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For mRNA isolation, 1x106 cells were initially collected in RNAlater® RNA 
stabilization reagent (Bioportugal, Porto, Portugal) and stored at -20 ºC. For total 
RNA isolation, the RNAeasy® Mini Kit (Qiagen, Venlo, Netherlands) was used. To 
quantify the RNA extracted and verify its integrity, samples were analyzed using 
the RNA 6000 Nano Chip® Kit (Agilent Technologies, Santa Clara, CA, USA) in an 
Agilent 2100 Bioanalyzer with the 2100 Expert Software (Agilent Technologies), 
according to the manufacturer’s instructions. 
1 µg of total RNA was reverse transcribed using the SuperScript™ III First-
Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA). The reactions 
were carried out in a GeneAmp PCR System 9600 Thermal Cycler (Perkin Elmer, 
Waltham, MA, USA). Reaction products were digested with 1 μL RNase A 
(Amresco, Solon, OH, USA).  
Relative quantification of gene expression by qPCR was performed in a 
7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). 
For normalization purposes, optimal housekeeping genes for this study were se-
lected using the geNorm™ Housekeeping Gene Selection Kit (PrimerDesign, South-
ampton, UK) and the geNorm™ software (Ghent University Hospital, Ghent, Bel-
gium). Real-time PCR reactions used QuantiTect® Primer Assays (Qiagen) for each 
of the different genes. PCR reactions were carried using 100 ng of cDNA sample, 
1× QuantiTect® Primer Assay and 1× iTaq™ Universal SYBR® Green Supermix 
(BioRad, Hercules, CA, USA), in a total volume of 10 μL, using the following thermal 
profile: 15 min at 95 ºC (PCR initial activation step) and 40 cycles of 15 s at 95 ºC, 
30 s at 60 ºC and 30 s at 72 ºC. RT-qPCR results were analyzed using RQ Manager 
1.2.1 software (Applied Biosystems) and the 2-ΔΔCt method (Livak and Schmittgen, 
2001).  
The primers used in this study were GAPDH_2_SG, TOP1_1_SG, 
CCNB1_1_SG, LDHA_1_SG, HIF1α_1_SG, SLC2A1_1_SG, MYC_1_SG, SPARC_1_SG, 
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EGFR_1_SG, MAPK14_1_SG, MAP2K4_1_SG, MAPK1_1_SG, XRCC1_1_SG, 
XRCC3_1_SG, XRCC5_1_SG, RAD51_1_SG, MSH2_1_SG, CAV1_1_SG, 
DNMT1_1_SG, MLH1_1_SG. They have all been acquired from Qiagen and their 
sequence is depicted in Table III of Appendix A.   
5.7 Microsatellite (MSI) Analysis 
The pentaplex PCR of five mononucleotide repeats (NR-21, NR-24, NR-27, 
BAT-25 and BAT-26) is commonly used to establish the MSI status of human cells, 
being  100 % sensitive and specific (Buhard et al., 2004). In our samples, these 
mononucleotide repeats were amplified in a pentaplex PCR reaction using a T3 
Thermocycler (Biometra, Göttingen, Germany). Primer sequences were as previ-
ously described (Buhard et al., 2004). All the reverse primers (Thermo Scientific, 
Waltham, MA, USA) were 5’-labelled with a fluorescent tag (HEX for markers NR-
24, NR-27 and BAT-26, and 6-FAM for NR-21 and BAT-25) to allow for microsatel-
lite detection using an Applied Biosystems 3730XL DNA Analyzer (Applied 
Biosystems). The PCR reaction was carried out in a total volume of 25 µl that con-
tained 1× GoTaq® Flexi Buffer (Promega, Madison, WI, USA), 0.2 mM dNTPs,       
2.5 mM magnesium dichloride (MgCl2), 8 pmol of primers NR-21, NR-24 and      
NR-27, 10 pmol of primer BAT-25, 12 pmol of primer BAT-26, 0.75 U of GoTaq® 
Flexi A DNA Polymerase (Promega) and 5 µl of genomic DNA.  
Genomic DNA was extracted from the cells with the Puregene® DNA Isola-
tion Kit (Qiagen), according to the manufacturer’s instructions. After an initial de-
naturation at 95 ºC for 5 min, PCR steps were as follows: 35 cycles of denaturation 
at 94 ºC for 30 s, annealing at 54 ºC for 45 s and extension at 72 ºC for 30 s. Final 
extension was carried out at 72 ºC for 10 min. Successful amplification was con-
firmed by electrophoresis on a 3.5 % agarose gel and PCR products were sent to 
Macrogen Inc. (Seoul, Korea) (http://www.macrogen.com) for fragment analysis. 
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Allelic sizes estimation and MSI analysis were made using the GeneMarker® soft-
ware (SoftGenetics, State College, PA, USA). The Cr(VI)-exposed cell line would be 
considered MSI positive if, at least, 2 out of 5 markers showed band shifting, when 
compared to the control, non-exposed one. 
5.8 In vivo Studies 
Animal studies were mentored by category C researchers credited by the 
Federation for Laboratory Animal Science Associations (FELASA). All the proce-
dures were in agreement with the European Convention for the Protection of Ver-
tebrate Animals used for Experimental and Other Scientific Purposes (CETS no. 
123), as well as the Portuguese rules (DL 129/92). 
Two types of animals have been used in this project. For the evaluation of 
the RenG2’s malignant potential, 107 cells suspended in 100 µl of PBS were subcu-
taneously injected into four 6-week-old BALB/c-nu/nu mice. 3 control mice inject-
ed with 100 µl of PBS were kept in parallel. Animals were maintained in 
eurostandard type III-H cages (Tecniplast, Buguggiate, Italy) coupled to a 1291H 
support and ventilation system (Tecniplast)  to ensure appropriate conditions. An-
imals were weekly screened for tumors by observation, palpation, and indirectly 
by weight measurement. Two months after the injection tumors were resected 
and fixed in formalin. 
The derivative systems were also attained using BALB/c-nu/nu mice. To this 
end, one of the tumors formed during the evaluation of RenG2’s malignant poten-
tial was divided into 2 parts: half of it was used to identify the histological type of 
the tumor, and the other half was divided into small fragments and used to estab-
lish a primary culture out of it. The protocol used was equal to that used for the 
establishment of the FR primary cell line, exception made to the cell culture medi-
um, which here was the F12 supplemented growth medium. The attained culture 
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turned out to be immortal and was baptized as DRenG2 (first derivative cell line). 
The second derivative system, the DDRenG2 cell line, was similarly produced by 
subcutaneously injection of 107 DRenG2 cells into BALB/c-nu/nu mice and estab-
lishment of a primary culture out of fragments collected from the induced tumors. 
5.9 Histopathological Analysis 
Whenever tumors developed in mice, they were resected and sent for 
pathological analysis. An experienced pathologist performed current 
histopathological examination on the collected samples. For that end, formalin 
fixed tumors were embedded in paraffin and thinly sliced using a RM2135 Minot 
microtome (Leica, Solms, Germany). Tumor slices were then stained with 
hematoxylin and eosin for microscopic evaluation of their major morphological 
features. Immunohistochemistry was subsequently performed in order to attain 
the histological type of the developed tumor. The markers used were LCA (lym-
phoma marker; clone 2B11 + PD7/26), HMB-45 (melanosome marker), MNF116 
(cytokeratin AB marker for carcinomas; clone MNF116), and Vimentin 
(mesenchymal marker; clone Vim 3B4), all of them obtained from Dako Corpora-
tion (Carpinteria, CA, USA). 
5.10 Metabolic Studies: 18FDG uptake  
The metabolic status of each cellular system was accessed using            
[18F]-fluoro-2-deoxyglucose (18FDG), a radiopharmaceutical glucose analogue de-
signed for positron emission tomography (PET), routinely used in clinical PET imag-
ing studies. 
1.5 mL of single-cell suspensions containing 2x106 cells/mL were prepared 
in each cell’s culture medium, from either adherent-growing cell lines or tridimen-
sional spheres. The suspensions were placed in 10 mL centrifuge tubes and left for 
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recovery for 60 min at 37°C. Subsequently, a calculated volume of 37 ºC-heated 
18FDG was added to each tube in order to attain a final concentration of             
0.75 MBq/m. Tubes were gently homogenized and then conserved at 37 ºC under 
a heat plate (FALC, Treviglio, Italy). After 60 min of incubation, samples of 200 μL 
were collected to 1.5 mL microcentrifuge tubes containing 500 μL of ice-cold PBS. 
Tubes were then centrifuged 1 min at 10000 rpm in an Eppendorf miniSpin Centri-
fuge (Eppendorf, Hamburg, Germany) and the supernatants were collected into 
glass tubes. 500 μL of ice-cold PBS were added to the pellets to wash any remain-
ing radioactive medium and tubes were again centrifuged for 1 min at 10000 rpm. 
Supernatants were collected to the same glass tube as previous and cell pellets 
were preserved. Finally, both the supernatants and the pellets were assayed for 
radioactivity using a Radioisotope Calibrator Well Counter (CRC-15W Capintec, Sa-
vannah, GA, USA) narrowed to the 18F sensitivity energy window (400-600 keV). All 
cell populations were studied in triplicate in at least three sets of independent ex-
periments. The attained results represent the percentage of cells’ radioactivity 
relatively to the total radioactivity added, normalized per million of cells.  
5.11 Flow Cytometry-based Cellular Characteri-
zation  
A molecular signature for each cell line was searched for using basic flow 
cytometry assays. To this end, 300 µL of single-cell suspensions containing      
1x105 cells were prepared. Four different cytometry tubes were prepared per cel-
lular system, two tubes destined to be the blank controls and the other two to be 
incubated with the selected panel of fluorescence-labeled monoclonal antibodies 
(mABs) as schematized in Table I. The mABs used were CD31 (WM59, BD Biosci-
ences, San Jose, CA, USA), NGFR (C40-1457, BD Biosciences), CD14 (M5E2, BD Bio-
sciences), CD13 (Immu103.44, Beckman Coulter, Pasadena, CA, USA), CD133 
(293C3, Miltenyi Biotec, Bergisch Gladbach, Germany), CD11b (ICRF44, BD Biosci-
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ences), CD45 (HI30, Invitrogen), CD106 (51-10C9, BD Biosciences), CD105 (1G2, 
Beckman Coulter) and HLA A, B, C (G46-2.6, BD Biosciences). The volumes of each 
mAB were selected according to manufacturer’s recommendations and are listed 
in Table I. 
 
Table I - Markers and fluorophore used in the 
flow cytometry-based cellular characterization 
studies. 
 Tube 1 Tube 2 
FITC CD31 10 µL CD106 10 µL 
PE NGFR 10 µL CD30 10 µL 
PerCP5.5 CD14 2.5 µL - - 
PeCy7 CD13 2.5 µL CD13 2.5 µL 
APC CD133 10 µL HLA-A,B,C 10 µL 
PB CD11b 2.5 µL CD11 2.5 µL 
PO CD45 2.5 µL CD45 2.5 µL 
FITC – Fluorescein isothiocyanate; PE – Phycoerythrin; PerCP – Perid-
inin-cholophyll-protein complex; PeCy7 – Phycoerythrin Cy7-
conjugated; APC – Allophycocyanin; PB – Pacific blue; PO – Pacific or-
ange. 
 
Following the addition of the mABs, tubes were incubated for 15 min in the 
dark at RT. 2 mL of PBS were then added to each tube to help removing the excess 
of fluorophore, and the tubes were centrifuged for 5 min at 1500 rpm. After cen-
trifugation, pellets were resuspended in circa 200 µL of the supernatant. Control 
tubes were also centrifuged and resuspended, albeit the washing step with PBS 
was avoided. Sample readings were carried out in a FACS Canto II Flow Cytometer 
(BD Biosciences) and the attained results were analyzed using the CellQuest soft-
ware (BD Biosciences). 
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5.12 Immunocytochemistry 
AB-based assays are very powerful techniques in the dissection of cellular 
constituents. In this project, immunocytochemistry was mostly used to highlight 
cell lines’ specific features that may be responsible for the observed physiological 
differences, and consequently, may had driven Cr(VI)-induced BEAS-2B malignant 
transformation and the formation of a CSC population within the derivative sys-
tems.  
4x103 cells/cm2 were seeded on the top of 2 % gelatin-coated microscope 
slides placed inside a 100 mm cell culture dish and cells were allowed to grow until 
the cultures reach approximately 80 % confluence. By then, the medium was as-
pired and the slides were rinsed twice with PBS and collected into centrifuge tubes 
containing 50 mL of 95% ethanol. Tubes were stored at 4 ºC until slides were pro-
cessed. 
To quench the endogenous peroxidase activity slides were incubated for  
15 min in a 3 % hydrogen peroxide (H2O2) solution. Subsequently, blockage was 
promoted by allowing the cells to contact for 5 min with the Ultra V Block solution 
(Ultra Vision Kit, Thermo Scientific). Staining encompassed incubating the slides 
with an optimized primary AB solution for 1 h at RT. Slides were then washed with 
PBS and incubated with the biotin-labeled secondary AB (Ultra Vision Kit, Thermo 
Scientific) for 15 min at RT. Revelation was made by adding the peroxidase-
conjugated streptavidin (Ultra Vision Kit, Thermo Scientific) along with the 
chromogen diaminobenzidine tetrahydrochloride (DAB), and counterstaining was 
promoted by incubating slides with hematoxylin. Finally, slides were dehydrated 
and mounted using the Tissue-Tek Glas Mounting Medium (1408, Sakura, Tor-
rance, CA, USA). 
The primary ABs used to stain all the cell lines were Vimentin (Vim3B4, 
Dako Corporation, Carpinteria, CA, USA) and α-Smooth muscle actin (αSM-1, 
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Leica). Cells’ were observed in a Nikon Eclipse 80i microscope and photographs 
were taken using a Nikon Digital DXM1200F coupled camera. 
5.13 Scratch Assay 
The scratch assays are widely used to infer on the ability of cells to migrate. 
Liang and collaborators provided the first protocol for the technique and high-
lighted the inexpensiveness and easiness with which it can be accomplished (Liang 
et al., 2007). Even though it encompasses some limitations, when carefully inter-
preted in the context of other results, it often provides valuable information. 
To perform the scratch assay, 4x103 cells/cm2 were added to previously 2 % 
gelatin-coated 60 mm cell culture dishes and cells were allowed to growth until 
forming a complete monolayer. Subsequently, a linear scratch was made in the 
monolayer using a p200 pipet tip. Cultures were then rinsed with PBS to remove 
any cellular debris and the medium was replaced. Marks were done in the dishes 
to ensure the photos were taken in approximately the same site over time. Cells 
were allowed to grow, and photographs were taken at 0 h, 12 h, 19 h, 24 h, 27 h, 
37 h, 49 h, 60 h, 73 h, 82 h, 93 h, 176 h and 200 h using a Moticam 2300 3.0 M Pix-
el USB 2.0 camera (Motic, Xiamen, China) coupled to a AE31 microscope (Motic). 
5.14 Drug Resistance Studies 
Resistance to both chemo- and radiotherapy is a particular feature com-
monly attributed to CSCs. To test the differential chemoresistance of the isolated 
CSCs, proliferating spherical clones were dissociated into a single-cell suspension 
and plated into a 24-well plate in N2 cell culture medium. Concomitantly, all the 
five cell lines previously amplified in T75 flasks were also platted in 24-well plates. 
The optimized initial cellular density for all cell lines was 8x103 cells/cm2. 24 hours 
after seeding the cells, 10 µL of each drug solution [cisplatin (Cis, CG6413, Gene-
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ris®, Amadora, Portugal), methotrexate (MTX, Teva Pharmaceutical Industries) and 
gemcitabine (Gem, Gemzar®, Lilly, Indianapolis, IN, USA)] were administered to at-
tain the desired final concentration (0.0 µM, 0.1 µM, 10 µM and 50 µM). For each 
condition, including the controls, three independent assays were carried in tripli-
cate.  Cells’ viability was assessed every 24 h, during 3 days using the 3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) reduction assay 
(Figure 5.3). 
 
 
Figure 5.3 - Experimental design of the drug resistance studies. Cells 
were seeded at the optimized density 24 h prior to the beginning of the study. 
At 0 h, equal volume of either the drug solutions or the drug vehicle was added 
to each well. Viability was assessed 24 h, 48 h and 72 h after the beginning of 
the incubation period. 
 
The ability of cells to reduce MTT is fundamentally based on the integrity of 
their mitochondria. Consequently, any harm directed towards these organelles or 
anything that compromises cells’ viability is translated into a diminished ability of 
cells to reduce MTT (van Meerloo et al., 2011). The calculation of cells’ viability 
relatively to the controls was made according to Equation 2, where the Abs Sam-
ple means the absorbance (Abs) of the solution collected from treated cells minus 
the absorbance of the dissolution vehicle and the Abs Control means the same 
from the control, untreated cells.  
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         Equation 2 
 
In order to circumvent bias resultant from differences in mitochondria 
number between cell lines, which would provide false positive viability values, di-
rect cell counting using trypan blue was used. To this end, samples of cellular sus-
pensions were collected and diluted in appropriate volumes of trypan blue stain-
ing. Cells were counted under a microscope in a Neubauer’s chamber. 
5.15 Cellular Doubling Times  
The doubling time (DT) of a culture intends to mirror the time individual 
cells need to travel their cycle one complete turn. There are various ways to assess 
cells’ viability, but the colorimetric assay based on MTT’s reduction is still the one 
of the most used, as it represents a very easy and inexpensive technique. 
For the MTT assay, cells were seeded into 24-well plates at an optimized in-
itial cellular density of 8x103 cells/cm2. At the desired time points (Figure 5.4) cell 
culture medium was discarded and the wells were rinsed with 200 µL PBS. 500 µL 
of  0.5 mg/mL MTT were then added to each well and cells were left in the incuba-
tor for 4 h. Subsequently, the MTT solution was cautiously removed, leaving un-
touched the violet formazan crystals to be dissolved in 500 µL of acid isopropanol. 
The samples’ absorbance was measured at 570 nm in a multiplate reader accord-
ing to manufacturer’s instructions. 
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Figure 5.4 - Experimental design of the cellular duplication time study. 
Cells were seeded at the optimized density 24 h prior to the beginning of the 
study. At 0 h, 24 h, 48 h, 60 h and 72 h cells viability was assessed. The time 
needed to duplicate the viability reflects cell’s DT. 
 
Each cell line DT was attained using the Equation 3, where t means time, 
N(0) means cells’ viability at 0 h and k represents the growth rate (number of dou-
blings that occur per unit of time). Calculations were made using the Doubling 
Time software at Doubling Time webpage (V. 2006). 
 
         
    Equation 3 
 
Similarly to what has been described for drug resistance studies, cellular 
proliferation was monitorized by trypan blue direct cell counting in a Neubauer’s 
chamber. 
5.16 Sphere-forming Assay and the SC-DRenG2 
and SC-DDRenG2 Cell Lines 
In light of the results attained during the characterization of the malignant 
cellular systems, it seemed logical that an eventual stem-like population living in-
side the BEAS-2B cellular system may have responded to Cr(VI) by amplifying itself 
and giving birth to a CSCs pool in the malignant systems. To test this hypothesis, 
the sphere-forming assay was used. This assay takes advantage of an intrinsic 
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property of CSCs, i.e., their ability to form tridimensional spheres when cultured 
under low-adherence conditions with appropriate mediums and supplements, to 
efficiently isolate that individual cell population. The use of the sphere-forming as-
says meets consensus throughout the scientific community as it has been widely 
used to isolate CSCs from different tumor types. 
Except for FR mice cells, all the cell lines under study were scrutinized for 
the presence of CSCs. Low adherence 6-well plates were prepared according to 
the previously described protocol (section 5.1.5) as was the isolation medium (sec-
tion 5.1.4). For the isolation, a cellular suspension containing 3x104 cells/mL was 
prepared in CSCs’ isolation medium and 2 mL of this suspension were added to 
each well of the plate. Isolation medium was supplemented with 10 ng/mL of both 
human EGF (E9644, Sigma-Aldrich) and bFGF (100-18B, PeproTech, London) and 
cells were allowed to grow under normal conditions. Supplements’ concentration 
was replaced twice a week. 
Whenever sphere formation was observed, and when spheres reached a 
satisfactory volume (which normally happens circa 15 day after platting), they 
were collected, washed with PBS, and plated in a T25 cell culture flasks provided 
with 5 mL of  N2 medium. Cells were allowed to attach and expand, and when 
they attained nearly 80 % confluence, the protocol of isolation was repeated. The 
procedure was repeated until third generation spheres were attained, as these 
cells are considered a pure clonal-derived CSCs population. 
The spheres isolated from DRenG2 and DDRenG2 cellular systems gave rise 
to the SC-DRenG2 and SC-DDRenG2 cell lines, respectively.  
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5.17 Comparative Genome Hybridization Array 
(aCGH) 
aCGH is a molecular cytogenetic tool that identifies unbalanced chromo-
somal rearrangements with a resolution in the range of Kb (Darai-Ramqvist et al., 
2006). The use of aCGH for analysis of solid tumors has revealed a number of re-
current chromosomal copy number aberrations including micro-deletions and mi-
cro-amplifications that had not been previously detected by any existing conven-
tional cytogenetic technique. 
This method provides a comparative genomic analysis between two DNA 
samples. Most often, one compares normal and tumor cells-derived DNAs; how-
ever, in this work, BEAS-2B were initially compared with a normal standard mascu-
line control (DD7101, Promega) and the remaining six cell lines (Cont1, RenG2, 
DRenG2, DDRenG2, SC-DRenG2 and SC-DDRenG2) were conversely compared with 
BEAS-2B cells. 
For the aCGH analysis of our systems, DNA was extracted using the High 
Pure PCR Template Preparation Kit (11796828001, Roche Applied Science, Basel, 
Switzerland), according to manufacturer’s instructions. Then BEAS-2B-extracted 
DNA was labeled with the cyanin (Cy) 3 (Cy3) fluorophore, while DNA derived from 
the remaining systems was labeled with Cy5. The labeling step was attained using 
the SureTag Complete DNA Labeling Kit (5190-4240, Agilent Technologies). DNA 
samples were subsequently fragmented and mixed with unlabeled human COT-1 
DNA (EA-020, Kreatech Diagnostics, Amsterdam, Netherlands) to suppress repeti-
tive DNA sequences. Finally, the DNA mixture was hybridized to a SurePrint G3 
Human CGH Microarray   180 K (G4449A, Agilent Technologies) containing hun-
dreds or thousands of printed defined DNA probes. The fluorescence ratio along 
the chromosomes was measured in a DNA microarray scanner C (Agilent Technol-
ogies). DNA regions containing fluorescence unbalances were spotted for further 
analysis, as they represent regions of gains or losses of genetic material, compared 
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to the reference sample. Data was processed using the Feature Extraction Soft-
ware version 10.7 (Agilent Technologies) and results were analyzed using the Ag-
ilent Genomic Workbench life edition 6.0 aCGH data analyzing software (Agilent 
Technologies). 
5.18 Co-culture of RenG2 and FR: The Attain-
ment of the iRenG2 System. 
As it was only possible to isolate spheres out of DRenG2 and DDRenG2 cell 
lines, we hypothesized that the cells in the mice lumbar subcutaneous compart-
ment may have driven RenG2 cells’ dedifferentiation. To assess this hypothesis FR 
cells were cultured in a 6 well plate equipped with 4.5 cm2 Transwell® insert 
(CLS3450, Corning) containing RenG2 cells, as illustrated in Figure 5.5. The ulti-
mate goal of this co-culture was to mimic as much as possible the conditions that 
RenG2 cells faced in mice lumbar subcutaneous compartment, when these cells 
were injected to attain the derivative systems. As so, co-cultures were kept in the 
incubator for two months and mediums were changed every 15 days. The condi-
tioned mediums of both compartments were preserved and stored at 4 ºC until 
further analysis.  
 
 
Figure 5.5 - Co-culture experimental design. Using a 6-
well plated adapted transwell system, RenG2 and FR cells 
were co-cultured for 2 months. FR cells were cultured in 
DMEM in the lower compartment, while RenG2 cells were 
housed in the upper compartment in LHC-9. 
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After 2 months in co-culture, RenG2 cells were isolated and re-baptized 
iRenG2. Their ability to for spheres was assessed as described in section 5.16 and 
their molecular signature was also searched for as in sections 5.6 and 5.11. 
5.19 Multiplex Cytokine Array: The Search for 
the Guilty! 
To further test the hypothesis of a stromal-driven crosstalk and to search 
for its potential orchestrators, the BioPlex® multiplex cytokine array (BioRad) was 
performed in the conditioned media of the co-cultured cells. Our results were fur-
ther validated by simultaneously analyzing conditioned media collected from oth-
er control standard cultures and co-cultures. The complete experiment layout is 
depicted in Figure 5.6.  
 
 
Figure 5.6 - Experimental layout to attain the different conditioned me-
dia. A) Co-culture of RenG2 with FR cells to test the hypothesis of stromal-
induced dedifferentiation. B) Standard control cultures of both FR and RenG2 
cells. C) Control co-cultures of RenG2 cells with FR cell culture media, of FR cells 
with LHC-9 media and of both media, without cells. All cultures were left for 2 
months and media were changed every 15 days. 
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FR cells-derived cytokines were searched for using the Bio-Plex Pro™ 
Mouse Cytokine 23-plex Assay Kit (#M60-009RDPD, BioRad), which contains beads 
to detect eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte mac-
rophage colony-stimulating factor (GM-CSF), interferon gamma (INF-γ), IL-1α, IL-
1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17A, KC (also 
known as CXCL1), monocyte chemotactic protein-1 (MCP-1, also known as 
chemokine (C-C motif) ligand (CCL) 2, CCL2), macrophage inflammatory protein 
(MIP) 1α (MIP-1α), MIP-1β, regulated on activation, normal T cell expressed and 
secreted (RANTES, also known as CCL5) and tumor necrosis factor α (TNF-α). 
Samples were studied in triplicate in a Bio-Plex® 200 System (BioRad) ac-
cording to manufacturer’s instructions, and the attained results were analyzed us-
ing the Bio-Plex Manager™ Software, Standard Edition (BioRad). 
5.20 Enzyme-linked immunosorbent assay 
(ELISA)  
Considering that BioRad did not have commercially available multiplex 
beads for activin-A analysis, we assayed the levels of this cytokine in our condi-
tioned media by ELISA. To this end, the Human/Mouse/Rat Activin-A Quantikine 
ELISA Kit (#DAC00B, R&D Systems, Minneapolis, MN, USA) was acquired and our 
samples were processed according to manufacturer’s instructions. 
5.21 Data Processing and Statistics 
Unless stated otherwise, data here presented result from at least three in-
dependent experiments carried out in triplicate, and the results’ statistical analysis 
was carried out using the Graph Pad Prism software version 5 (GraphPad Inc., San 
Diego, CA, USA). 
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Whenever possible, data normality was tested using the Kolmogorov-
Smirnov test with Dallal-Wilkinson-Lillefor correction. To assess statistical signifi-
cance between means of the cell lines under study a one-way ANOVA was used 
followed by correction for multiple comparisons. Thus, Bonferroni’s pos-hoc test 
was applied for comparisons between all cell lines while Dunnett’s test was used 
to compare cell lines to BEAS-2B in the clonogenic assay. A two-way ANOVA fol-
lowed by a Bonferroni pos-hoc test was specifically used in the analysis of the re-
sults from the gene expression study as both the gene and the cell line variations 
were to be considered simultaneously. A 5 % level was defined as the threshold of 
significance for the differences and the P value was categorized according to their 
interval of confidence. 
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Chapter 6  
Attainment of a Reliable Cellular  
System 
6.1 Introduction 
In the last half century many studies were conducted on Cr(VI)-induced 
lung carcinogenesis. Different experimental designs and systems (both in vitro and 
in vivo) have been developed, as well as different exposure regimens to the oxyan-
ion. However, and as previously dissected in Chapter 2, regardless of the ad-
vantages and disadvantages of each system and the valuable information provid-
ed, the molecular mechanisms underlying Cr(VI)-induced LC are still undisclosed. 
Chemical and biochemical processing of Cr(VI) have been exhaustively 
studied in vitro. However, significant divergence is observed among the results at-
tained in different laboratories or study designs. The main reason underlying this 
divergence may relay on the fact that very few studies utilized epithelial lung cells 
and most of them used excessive concentrations of Cr(VI). In agreement, the ma-
jority of Cr(VI)-based studies employed lung malignant cell lines, whose physiology 
is already deeply altered by the transformation process. Additionally, some labora-
tories also used cell lines from other regions of the respiratory system, which may 
also differ greatly from epithelial cells in what concerns Cr(VI)-uptake and intracel-
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lular actions. Finally, Cr(VI) concentration is also of great importance, as cellular ef-
fects of low and high Cr(VI) levels greatly differ and evoke dramatically different 
cellular responses (Nickens et al., 2010). 
Based on the epidemiological studies available, as well as on previous re-
sults attained in our laboratory (Costa et al., 2010), we set the concentration of 
Cr(VI) in 1.0 µM. This concentration appropriately mimics an occupational expo-
sure to low concentrations of atmospheric Cr(VI). Furthermore, we choose a non-
malignant immortalized human bronchial epithelial cell line (BEAS-2B), cultured in 
a cell culture media that avoids Cr(VI) reduction in the extracellular space (Borthiry 
et al., 2008).   
The main goal of this study was to develop an adequate and reliable sys-
tem for the study of Cr(VI) carcinogenesis. Our driving hypothesis was that by 
promoting a chronic exposure of BEAS-2B cells to 1.0 µM of Cr(VI) and monitoring 
our cultures for morphological, karyotypic and gene expression changes we would 
be able to reach our goal.  
6.2 Results 
6.2.1 Characterization of BEAS-2B cells 
The karyotypic study of BEAS-2B cells along time in culture was 
mostly prompted by the lack of detailed information on their cytogenetic 
constitution and the first karyotypes immediately showed a group of con-
stant chromosomal alterations. In fact, all low-passage BEAS-2B cells pre-
sented an isochromosome of the long arm of chromosome 5 [i(5)(q10)], a 
terminal deletion of the short arm of chromosome X (Xp-) and additional 
material on the short arm of chromosomes 15 (15p+), 16 (16p+) and 22 
(22p+) (Figure 6.1). Additionally, chromosomal alterations presented as 
mosaics were documented. For instance, chromosome 20 trisomy 
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[tris(20)], found in 80 % of the analyzed metaphases, and a chromosome 
14 with additional material in its short arm (14p+) in 70 %. Finally, structur-
al alterations of the banding pattern of the long arm of chromosome 2 
[der(2)] were documented in 20 % of the metaphases studied. 
 
 
Figure 6.1 - Representative karyotype of BEAS-2B cell line at #15. At this 
passage, i(5)(q10)del(qter) was already present along with all the other 
chromosomal alterations. At least 20 karyotypes were constructed for each cell pas-
sage analyzed.  
 
The mosaicism observed for both the tris(20) and the 14p+ tended 
to decrease along the time in culture, being completely eliminated be-
tween #25 and #41. The opposite was observed for the der(2), which 
reached 100 % prevalence at #25. Finally, a terminal deletion on i(5)(q10) 
[i(5)(q10)del(qter)], probably resulting from the culture protocol, arises be-
tween #12 and #25 and at #41 was definitely established in all cells. Figure 
6.2 illustrates the proportional variation of these alterations along       
BEAS-2B’s time in culture. 
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Figure 6.2 - Structural chromosomal changes of BEAS-2B cells 
along time in culture. While the population of cells portraying the 
i(5)(q10)del(qter) and the der(2) tend to be amplified along time, 14p+- 
and tris(20)-carrying cells tend to disappear. The results are expressed in 
percentage in relation to a normal diploid cell line and were obtained from at 
least 20 karyotypes constructed per #. 
 
Cells’ ploidy stability was also analyzed to validate the results at-
tained by Reddel and collaborators, according to which 72 % of the      
BEAS-2B cells remain near diploid until #29 (Reddel et al., 1988). Giemsa-
colored counts of at least 50 metaphase spreads further confirmed those 
results, as depicted in Figure 6.3. Initial passages of BEAS-2B cells still re-
tained tris(20), which was translated into a higher proportion of 
hyperdiploid cells. However, as previously mentioned, this mosaic cellular 
population tended to be eliminated and the percentage of hyperdiploid 
cells concomitantly diminished. The fraction of hyperdiploid and 
hypodiploid cells that was observed in latter passages potentially repre-
sents culture-induced chromosomal unbalances. 
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Figure 6.3 - Ploidy analysis of control BEAS-2B cells over time. 
In agreement with previous observations, BEAS-2B cells re-
mained mostly diploid throughout the time in culture. Yet, an 
initial increased percentage of hyperdiploid cells potentially 
represented the mosaic tris(20) population identified in karyo-
typic studies. For this study at least 50 giemsa-stained metaphase spreads were 
counted for each cell passage. 
 
In order to attain their better characterization, the gene panel 
whose expression was later used to monitor Cr(VI)-induced malignant 
transformation was also applied to BEAS-2B cells. The gene expression pro-
file at different passages of BEAS-2B cells was compared with BEAS-2B #5 
cells’ profile using the 2-ΔΔCt method. The attained results are depicted in 
Figure 6.4.  
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Figure 6.4 - Relative gene expression quantification of BEAS-2B cells’ pas-
sages to BEAS-2B #5. The majority of the analyzed genes tended to be down-
regulated, thus corroborating the non-malignant signature of BEAS-2B cells. MMR 
system revealed to be functional, even though with no consistent pattern of acti-
vation. Bars represent means. Bars represent means (N=1). 
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Despite some negligible exceptions at isolated passages, the expres-
sion of the selected genes was globally downregulated thus confirming the 
non-malignant nature of BEAS-2B. Moreover, the fluctuations of the ex-
pression of MLH1 gene unveiled a functional MMR System. 
6.2.2 Exposure of BEAS-2B to 1.0 µM Cr(VI)  
Aiming to malignantly transform BEAS-2B cells by the action of 
Cr(VI), a concentration of 1.0 µM was endorsed. Our choice was sustained 
by both epidemiologic studies (Davies, 1984; Langård, 1990) and the ob-
servation that this concentration is only slightly cytotoxic (Costa et al., 
2010). Control cultures of BEAS-2B cells were kept in parallel to monitor 
eventual changes occurred in the absence of Cr(VI). 
After the first 10 passages in culture, both control and Cr(VI)-
treated BEAS-2B cells, seeded at the regular cellular density                  
(4x103 cells/cm2), displayed similar morphologies, although the former cul-
tures tended to became increasingly less resistant to trypsinization. Follow-
ing 12 passages in the presence of Cr(VI), BEAS-2B cultures became non-
homogeneous (Figure 6.5, right), with discrete collections of cells display-
ing a growth pattern and/or distinct morphologic appearance from those 
of the normal diamond-shaped epithelial cells. As illustrated in Figure 6.5 
(left), control cultures retained cells’ normal morphology. 
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Figure 6.5 - Effect of Cr(VI) on the morphology and growth pattern of 
BEAS-2B cells. BEAS-2B cells grown in the absence of Cr(VI) (left) displayed 
an organized growth pattern with cells portraying a diamond-shaped mor-
phology. Cr(VI) (right) induces cellular disorganization and deep morpho-
logical changes, with spindle-like shaped cells being particularly abundant. 
A magnification of 100x was used in both panels. 
 
Nevertheless, besides the morphologic alterations, no additional 
karyotypic changes where induced by the exposure of BEAS-2B cells to    
1.0 µM of Cr(VI) when cells were cultured at the recommended cellular 
density (Figure 6.6). Moreover, no major alterations were observed in the 
behavior of these structural chromosomal alterations along the time in cul-
ture of Cr(VI)-exposed BEAS-2B (Figure 6.7). Conversely, Cr(VI) did seemed 
to affect cells’ ploidy as Cr(VI)-exposed cells showed an increase in the per-
centage of hyperdiploid cells in the early passages (#7 and #12) and an in-
crease in the fraction of hypodiploid cells after more prolonged culture 
(>#25) (Figure 6.8). These results were in agreement with previous similar 
studies attained using human bronchial fibroblasts exposed to Cr(VI) 
(Holmes et al., 2006). 
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Figure 6.6 - Representative karyotype of Cr(VI)-exposed BEAS-2B cell 
line at #17. The analysis of the karyotype showed that no additional alterations 
were induced in BEAS-2B cells by the presence of 1.0 µM Cr(VI), when the cells 
were cultured at the normal cellular density. At least 20 karyotypes were con-
structed for each cell passage analyzed. 
 
 
Figure 6.7 - Behaviour of structural chromosomal changes along 
time in Cr(VI)-exposed BEAS-2B cells. While the population of cells 
portraying the i(5)(q10)del(qter) and the der(2) tend to be amplified 
along time, 14p+- and tris (20)-carrying cells tend to disappear. The results 
are expressed in percentage in relation to a normal diploid cell line and were 
obtained from at least 20 karyotypes constructed per #.  
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Figure 6.8 - Ploidy analysis of Cr(VI)-exposed BEAS-2B cells over 
time. The observed increase in hyperdiploid cells during the early pas-
sages of BEAS-2B cells resulted from Cr(VI)-induced genetic damage. 
Also observable was an increase in the percentage of hypodiploid cells in 
latter passages, what may also be attributed to Cr(VI), as it has been 
previously observed in human bronchial fibroblasts. For this study at least 
50 giemsa-stained metaphase spreads were counted for each cell passage. 
 
Gene expression analysis of the Cr(VI)-exposed cells revealed a pat-
tern that although slightly different from that of control BEAS-2B cells, did 
not patronize a malignant phenotype (Figure 6.9). Again, an exception 
should be emphasized, now for the genes involved in the DNA repair sys-
tems who were shown to be upregulated, most probably as a consequence 
of Cr(VI)-mediated genotoxic effects. Taken together these observations 
further corroborated the failure of the employed strategy to malignantly 
transform BEAS-2B cells. 
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Figure 6.9 - Relative gene expression quantification of Cr(VI)-exposed  
BEAS-2B cells to BEAS-2B cells at the same passage. Overall there is no con-
sistent pattern of expression among the analyzed genes. Genes associated to ma-
lignant transformation tended to be downregulated and the MMR system follows 
the random tendency of the remaining genes. Bars represent means (N=1). 
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6.2.3 Low density cultures in the presence of Cr(VI) 
and establishment of the subclonal cell lines 
Once the adopted strategy did not succeed on malignantly trans-
form BEAS-2B cells, alternative approaches were investigated. Following an 
exhaustive review of the pathophysiology dynamics of Cr(VI)-induced lung 
tumors, we realized that notwithstanding the fact that the overall concen-
tration of Cr(VI) in the entire lung is very low, that same concentration at 
bronchial bifurcations is incredibly high. This means that the availability of 
Cr(VI) oxyanions per cell is greatly increased at these sites in comparison 
with the rest of the lung parenchyma. It was hypothesized that by increas-
ing each cell surface area to Cr(VI) we would be able to increase the availa-
bility of Cr(VI) per cell, thus better mimicking the reality of Cr(VI)-exposed 
individuals. 
To attain our goal we decided to culture Cr(VI)-exposed BEAS-2B 
cells at a very low density (13 cells/cm2), in the presence of 1.0 µM of 
Cr(VI). As expected, the increased availability of Cr(VI) per cell deeply ac-
centuated its effects, as profoundly morphologically altered cells, with an 
abnormal growth pattern, were visible in many areas of the culture. Sever-
al dense clumps containing cells with clearly altered morphologies were al-
so documented (Figure 6.10, right). Conversely, control BEAS-2B cells cul-
tured at the same cellular density showed no changes on their morphology 
and growth pattern (Figure 6.10, left).  
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Figure 6.10 - The effects of Cr(VI) on the culture of both control and 
Cr(VI)-exposed BEAS-2B cells at low cellular density. When cultured at very 
low density, control BEAS-2B cells (left) formed colonies that retained the appear-
ance of a normal epithelium. In contrast, Cr(VI)-exposed cells (right) tended to 
form dense cellular aggregates of approximately spherical shape. A magnification of 
100x was used in both panels.  
 
The deep contrast observed between the morphology of control 
and Cr(VI)-exposed colonies revealed that the employed strategy succeed-
ed in transforming BEAS-2B cells. 
6.2.4 Characterization of the Cont1 and RenG2 
subclonal systems  
To verify our hypothesis, three dense clumps from low density cul-
tured Cr(VI)-exposed BEAS-2B cells, as well as 3 BEAS-2B control colonies 
were ring-cloned. Following isolation, Cr(VI)-treated cells were expanded 
and the resulting cell lines named RenG1, RenG2 and CrossG1. Similarly, 
the isolated control colonies were given the names Cont1, Cont2 and 
Cont3. 
Initial characterization studies based on morphologic and karyotypic 
analysis of the expanded colonies revealed that, even though isolated from 
different foci, the RenG1, RenG2 and CrossG1 systems portrayed very simi-
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lar features. Likewise, Cont1, Cont2 and Cont3 were equivalent. These ob-
servations lead us to randomly choose the RenG2 and Cont1 cell lines to 
continue our studies. 
The cytogenetic analysis of the Cont1 cell line revealed a karyotype 
rather similar to that of the BEAS-2B cells. In fact, the same karyotypic al-
terations could be found in the subclonal systems, excepting the tris(20). 
RenG2 cells, on contrary, showed a marked karyotypic alteration (Figure 
6.11) with cells carrying circa 82 chromosomes, the majority in tetrasomy.  
 
 
Figure 6.11 - Representative karyotype of RenG2 cells at #4. Most of the 
chromosomes showed four copies. The alterations observed in the parental cell 
line, e.g., the i(5)(q1.0)del(qter), allowed to hypothesize that an intermediate 
tetraploid may have been generated during the malignization of Cr(VI)-exposed 
BEAS-2B cells. At least 20 karyotypes were constructed for each # analyzed. 
 
As to the gene expression profile, it revealed that Cont1 cells’ ex-
pression pattern overlapped with that of BEAS-2B cells. In contrast, RenG2 
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cells presented almost all the analyzed genes overexpressed in comparison 
to Cont1 cells (Figure 6.12). 
 
Figure 6.12 - Relative gene expression quantification of RenG2 cells to 
Cont1 #4. The gene expression profile of RenG2 cells corroborated the karyotype 
analysis, thus supporting a malignant nature for this cell line. Regardless minor 
exceptions, all genes grouped as malignant transformation-related genes were 
overexpressed. DNA repair genes were constitutively upregulated probably as a 
result of both Cr(VI) presence and GI. Bars represent means (N=1). 
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The evident overexpression of the MYC gene along with the 
karyotypic drift observed in RenG2 cells strongly suggested the success of 
the implemented strategy on malignantly transforming BEAS-2B cells. 
Moreover, the overall activation of the MAP kinases’ pathways suggested 
their recruitment during the transformation process, corroborating the 
findings of Chuang and Yang (Chuang and Yang, 2001). Finally, EGFR activa-
tion also seemed to have played a pivotal role in the malignization process, 
further substantiating the observations of Lonardo and colleagues (Lonardo 
et al., 1999). 
6.2.5 MMR activation status and MSI Analysis of 
RenG2 cells 
As previously mentioned, Cr(VI) may lead to MMR system inactiva-
tion, consequently driving MSI development in chromate tumors 
(Takahashi et al., 2005). To assess whether Cr(VI)-driven BEAS-2B cells’ ma-
lignant transformation involved MSI formation pentaplex PCR analysis of 
the MSI-associated repeats was carried out in RenG2 cells.  
Figure 6.13 depicts the chromatograms attained from the MSI 
screening of RenG2 cells. As only the NR-24 repeat showed a significant 
shift banding from the control, according to the established criteria, no MSI 
was present in the RenG2 system. 
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Figure 6.13 - MSI analysis of RenG2 cell line. The chromatograms showed 
a comparison between BEAS-2B control cell lines (red) and RenG2 cells (green 
or blue). Only for the NR-24 repeat a significant drift was observed relative to 
BEAS-2B cells, meaning that no MSI was present in the genome of RenG2 cells. 
Red line represent the control and Green/Blue lines represent the samples. 
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In agreement with a fully functional MMR system, RT-qPCR analysis 
of MLH1 in RenG2 cells revealed its upregulation in comparison to BEAS-2B 
cells (Figure 6.14). However, because the action of demethylase 1 may also 
drive MMR inactivation through epigenetic silencing of MMR-related 
genes, the expression level of DNMT1 was simultaneously assessed (Figure 
6.14).  
 
 
Figure 6.14 - Relative gene expression analysis of DNMT1 and 
MLH1 genes. In agreement with the absence of MSI, both MLH1 and 
DNMT1 proteins were being actively transcribed in RenG2 cells, indicat-
ing an active MMR system. Bars represent means (N=1). 
 
Taken together, our results showed that in spite of the slight 
DNMT1 overexpression, MLH1 was not silenced and thus no MSI was de-
veloped in RenG2 cells.  
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6.2.6 Tumorigenic potential of RenG2 cells 
In vivo tumorigenicity assays are the gold standard for the evalua-
tion of cells’ tumorigenic potential. Therefore, BALB/c-nu/nu mice were 
used to confirm RenG2 cells’ malignant potential. 
None of the three male mice subcutaneously injected in the lumbar 
region with control BEAS-2B cells developed tumors, thus highlighting the 
non-tumorigenic nature of these cells and further confirming Reddel’s ob-
servations (Reddel et al., 1988). RenG2 cells, however, succeeded at induc-
ing tumors in three out of the four injected mice. 
Histopathological analysis of the tumors revealed negative staining 
for LCA and HMB45, and positive staining for MNF116 (Figure 6.15). The 
positivity of MNF116, an epithelial pan-cytokeratin marker, along with the 
slight and ubiquous expression of the mesenchymal marker vimentin, re-
veals the epithelial nature of the attained tumors. 
 
 
Figure 6.15 - Histopathological analysis of the RenG2-induced 
tumors. The positivity of MNF116 (bottom left), the slight ubiquous 
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positivity of vimentin (bottom right) and the negativity of both LCA (top 
left) and HMB45 (top right) identified the epithelial nature of the RenG2 
induced tumors. A magnification of 400x was used in all panels. 
6.3 Discussion 
Most frequently the studies on carcinogenesis begin with the selection of a 
malignant cellular system, whose intricacies are then exhaustively dissected while 
searching for the pathways underlying its sustained malignant potential. Eventual-
ly, therapeutic strategies are designed and tested, and the recovery of the system 
is attempted. Despite the fact that much of what is actually known on tumor biol-
ogy was attained by the employment of similar strategies, potentially precious in-
formation may actually be lost when the malignization process is bypassed.  
Due to the lack of an adequate system, and to prevent losing any important 
clue, it was decided to initiate the studies by transforming a non-malignant im-
mortalized human bronchial epithelial cell line. Moreover, primary cultures were 
not compatible with the intended prolonged exposures to sub-lethal concentra-
tions of Cr(VI) as they have short lifespans. BEAS-2B cells were chosen as they rep-
resented the commercially available system that better mimic normal human lung 
epithelium. However, regardless of all the advantages BEAS-2B cells may have, at-
tention should be given to the fact that they were obtained following a SV40-
based immortalization protocol whose success relays on the sequestration of the 
P53 protein, the so-called guardian of the genome. The involvement of P53 in hu-
man cancers is amply accepted, so it could be thought that the immortalization by 
SV40 might per si drive the malignant transformation of BEAS-2B cells. Yet, this 
and other studies revealed that P53 sequestration alone is not sufficient for the 
neoplastic transformation of BEAS-2B cells, as non-treated BEAS-2B cells were nei-
ther malignant nor tumorigenic (Reddel et al., 1988). 
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As the induction of aneuploidy and the morphological transformation ob-
served in this study parallels the results obtained with other human and rodent 
SV40-immortalized cells (Li et al., 1997; Zhu and Gooderham, 2002), and with a 
SV40-transgenic mouse model (Ornitz et al., 1987), following exposure to chemical 
carcinogens, we cannot exclude that P53 deficiency may had pre-disposed RenG2 
Cr(VI)-damaged cells to aneuploidy. In fact, loss of P53, either by gene disruption 
or small interfering RNA-mediated depletion, is known to sensitize cells to aurora 
kinase B (AURKB) inhibition, promoting mitotic slippage (Marxer et al., 2013). Ad-
ditionally, as the P53-dependent post-mitotic checkpoint is also important for pre-
venting genome reduplication after mitotic slippage (Marxer et al., 2013), cells 
with DNA damage may have continued to divide, being subjected to asymmetric 
chromosome segregation. Aneuploid genomes similar to that of RenG2 cells have 
been found in a wide range of tumor cells and their development was hypothe-
sized to underline malignant transformation (reviewed by Potapova et al., 2013). 
Even though the mutagenic effect of carcinogens is generally accepted as 
the driving force of malignant transformation, changes in ploidy and the conse-
quent imbalance in gene expression also seem to play an important role (Nguyen 
and Ravid, 2006). The group of David Pellman has been successfully dissecting the 
theory of a tetraploid intermediate during the route for malignancy (Ganem et al., 
2007). Based on Shi and King, who observed that cell lines with relatively high 
spontaneous rates of chromosome non-disjunction in late mitosis tend to give rise 
to tetraploid cells, Pellman’s laboratory further discovered that these tetraploid 
cells may be the source of the full malignant aneuploid tumor cells (Shi and King, 
2005). They realized that problems during cell division, for instance induced by a 
carcinogenic agent, may result in karyo- and/or cytokinesis abrogation. Conse-
quently, if the cells had already duplicated their DNA content, tetraploid cells 
would be formed. These cells were shown to have increased resistance to the mi-
croenvironment stresses (Castedo et al., 2006) and, most frequently, to be provid-
ed with an additional set of centrosomes (Ganem et al., 2007). The presence of 
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twice the number of centrosomes may be responsible, in a subsequent cellular di-
vision, for the development of a catastrophic mitosis resultant from a multipolar 
spindle establishment (Ganem et al., 2007). Cells that successfully escape these 
mitotic catastrophes may enter in asymmetrical cell division, thus driving the for-
mation of an aneuploid progeny vested with high malignant potential (Ganem et 
al., 2007, 2009; Godinho et al., 2009). 
Considering the abovementioned observations it became clear that cancer 
development may not necessarily require mutations in cancer related genes, but 
an imbalance in the dosage of thousands of normal genes, caused by random 
aneuploidization and consequent GI development (Duesberg and Li, 2003; Nguyen 
and Ravid, 2006). In other words, such observations state that cells may become 
transformed in the absence of mutations on tumor suppressor genes and/or on-
cogenes. 
Wise’s laboratory have long been working on a link between Cr(VI)-
exposure and aneuploidy development. Using a clonal cell line derived from nor-
mal human bronchial fibroblasts exposed to different concentrations of lead 
chromate, Holmes and colleagues showed for the first time that particulate chro-
mate induces aneuploidy (Holmes et al., 2006). Moreover, authors also showed 
that the aneuploid cells resulted from multipolar mitosis established following 
centrosome amplification (Holmes et al., 2006). It thus seemed reasonable that 
the karyotypic drift observed in RenG2 cells, that showed many chromosomes in 
tetrasomy, may have resulted from an abrogated cell division that lead to the for-
mation of tetraploid cells harboring extra centrosomes. The subsequent division of 
these tetraploids may then have occurred through a multipolar mitosis favoring 
the formation of the aneuploid malignant RenG2 cells (Figure 6.16). Additional 
studies should be done to further confirm this hypothesis. 
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Figure 6.16 - Proposed model for the development of RenG2's aneuploid 
genome. Following culture at very low density in the presence of Cr(VI), BEAS-2B 
may have abrogated their cellular division ending up forming tetraploid cells. The 
development of a tetraploid genome eventually boosted cells’ survival under 
Cr(VI)-sustained adverse conditions, but when these cells attempted to divide, 
multipolar mitoses may have occurred as a consequence of the increased number 
of centrosomes. The cells that survived aberrant mitosis portrayed an aneuploid 
genome and the morphological features of malignant cells. These cells were 
named RenG2 cells. 
 
However, the malignant transformation of BEAS-2B cells following low 
density culture and prolonged exposure to Cr(VI) cannot be ascribed solely to 
Cr(VI) effects on chromosome segregation and GI. In fact, the upregulation of the 
genes associated to the most important DNA repair systems (BER, HR and NHEJ) 
observed in the RenG2 system indicated that DNA damage played an important 
role in the overall process of transformation. Contradicting the assertion that GI 
only develops in cells whose DNA repair pathways are seriously compromised 
(Grlickova-Duzevik et al., 2006; Stackpole et al., 2007; Vilcheck et al., 2002), our 
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hypothesis was further reinforced by other unpublished observations showing that 
BEAS-2B cells exposed for only five passages to Cr(VI) preserved a normal pheno-
type, even when cultured at very low cell density. Moreover, the fact that chronic 
exposure of BEAS-2B cells to Cr(VI) increased their duplication time most probably 
reflects the action of DNA repair systems in attempting to repair Cr(VI)-induced 
DNA damage (Costa et al., 2010). 
Studies on diverse human cellular systems showed that MMR is fundamen-
tal on mediating cellular responses to Cr(VI), and that chronic exposures to toxic 
doses of the oxyanion may result in the selective outgrowth of MMR-deficient 
cells (Peterson-Roth et al., 2005; Reynolds and Zhitkovich, 2007; Reynolds et al., 
2007, 2009; Zecevic et al., 2009). Moreover, this deficiency has been associated 
with high spontaneous mutagenesis rates, as well as with a high incidence of MSI 
among chromate cancers (Hirose et al., 2002; Kondo et al., 2006; Takahashi et al., 
2005), which lead to the hypothesis that chromate cancer cells express the 
mutator phenotype, i.e., a tendency to undergo a cascade of further mutations 
caused by the loss of the MMR system (Loeb et al., 2008; Salnikow and Zhitkovich, 
2008). Our findings, however, did not sustain this hypothesis, as the malignant 
RenG2 system expressed high levels of the MLH1 transcript and did not exhibit 
MSI. Nevertheless, our observations were in agreement with previous ones indi-
cating that reduced DNMT1 activity correlated with increased MSI development 
(Kim et al., 2004), which seemed to happen due to loss of efficiency of the MMR 
system (Loughery et al., 2011). Moreover, increased DNMT1 transcript levels were 
previously reported to correlate with increased MYC mRNA levels in gastric can-
cers (Fang et al., 2004), as well as with transformation of NIH 3T3 cells (Wu et al., 
1993).  
The absence of neoplastic transformation of BEAS-2B cells after prolonged 
exposure to Cr(VI) at normal cell density indicates that low density culture provid-
ed the adequate conditions for the selection of transformation-susceptible Cr(VI) 
variants. We believe that those conditions relay on the physiology of cellular Cr(VI) 
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uptake. Previous studies showed that this uptake represents a very fast and effi-
cient process that reaches a maximum load within the first 3 h of exposure (Xie et 
al., 2004). Besides, it seems to be limited by the ratio Cr(VI)/cell (Xie et al., 2004). 
By increasing this ratio, the low density conditions influenced the rate of Cr(VI) up-
take, and consequently, imposed a stronger environmental pressure on BEAS-2B 
cells being cultured at unfavorable low densities. As a natural Darwinian response, 
only the cells with the most resistant cellular phenotypes survived the adverse 
conditions. Similarly to the acquisition of drug resistance, the selection process 
may has encompassed multi-stages and resulted in GI development, which then 
provided a supply of mutants for another round of natural selection (Blagosklonny, 
2002). This theory is in agreement with the actual thinking according to which mu-
tations themselves are irrelevant if there is not a microenvironment change that 
selects the cells carrying such mutations (Barcellos-Hoff et al., 2013). 
6.4 Conclusion 
Similarly to chronic contact to cigarette smoke, prolonged exposure to 
Cr(VI) induces sustained DNA damage and growth inhibition, thus driving the ma-
lignant transformation of the bronchial epithelium. These direct effects of the ox-
yanion over cells’ DNA set the conditions for the selection of cytotoxicity-resistant 
altered cells. It seems that the development of Cr(VI) resistance, more than the 
mutagenic potential of Cr(VI), paved the way for the accumulation of mutations 
through the selection of the most resistant variants. It is thus possible that this 
process of selection may drive the onset of chromate lung tumors through the ac-
tivation of the resistance phenotype pathway. 
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Note 
The results presented in this chapter are already published as an original paper:  
Rodrigues CFD, Urbano AM, Matoso E, Carreira IM, Almeida A, Santos P, Botelho MF, Carvalho L, 
Alves M, Monteiro C, Costa A, Moreno V and Alpoim MC. Cr(VI)-induced malignant transformation 
of a human bronchial epithelial cell line. Mutat. Res 670(1-2):42-52. 
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Chapter 7  
Derivation and Characterization of 
RenG2 cells  
1.1. Introduction 
Cancer is typically characterized by series of progressive alterations that disrupt 
cell and tissue homeostasis. Though, whereas many of those alterations can be induced 
by gene-specific mutations, faulty signals from the microenvironment are now assumed 
to act as inducers of tumor development and progression (Hanahan and Coussens, 
2012). 
As presented in Chapter 3, it is now generally accepted that a tumor is a hetero-
geneous entity composed of a wide range of cell populations in different stages of dif-
ferentiation. One such population is comprised of CSCs, and recent findings indicated 
them as the only tumor fraction able to self-renew and produce phenotypically diverse 
populations (Marjanovic et al., 2013). The biology of CSCs has been exhaustively dissect-
ed during the last decades. It is now accepted that CSCs have a slower cell cycle and an 
asymmetric pattern of cellular division. These two characteristics, besides being very 
simple, are actually responsible for most of the malignant potential of this tumor popu-
lation. Asymmetric division allows CSCs to keep providing the tumor with progenitor 
cells it may need, while keeping the pool of CSCs. On the other hand, the slower cell 
cycle protects these cells of DNA damage and increases their resistance to chemothera-
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py. In fact, conventional chemo- and radiotherapy programs are designed to target pro-
liferating cells, thus requiring active cycling to induce cellular apoptosis (Moore and Lyle, 
2011). The origins of CSCs are still debatable, and it now seems that they may form from 
different sources. The most recently described strategy for CSCs formation was present-
ed by Chaffer and colleagues, who provided the first experimental facts attesting that 
CSCs may arise by dedifferentiation of differentiated tumor cells. Besides authors 
popped the hypothesis that the formation of CSCs by dedifferentiation may involve EMT 
programs, this hypothesis has not, to the best of our knowledge, yet been assessed. 
The main purpose of this study was to increase the malignant potential of the 
RenG2 system in order to exacerbate Cr(VI)-induced features as well as to fully charac-
terized the attained systems. Finally, we want to scrutinize the involvement of CSCs on 
Cr(VI)-driven BEAS-2B cells’ malignization.  
7.1 Results 
7.1.1 Increasing the malignant potential of the RenG2 
cell line: the attainment of DRenG2 and DDRenG2 cel-
lular systems 
The in vivo studies performed to unveil the tumorigenic potential of 
RenG2 cell line showed that although the system was malignant, its poten-
tial was still very low, as it took circa two months for tumors to form.  
To increase the malignant potential of RenG2 cells and thus exacer-
bate Cr(VI)-imprinted features, we decided to in vivo derive the RenG2 cell 
line as described in section 5.8 of Chapter 5. DRenG2 cells, the cells at-
tained from the RenG2-induced tumor, turned out to be significantly more 
malignant than RenG2 cells as a tumor was already visible 30 days after in-
jection. Tumors’ resection was made when they reached a diameter of ap-
proximately 1 cm. Following resection, tumor was split and half of it was 
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sent to histopathological analysis, while the remaining specimen was used 
to establish the DDRenG2 system. 
To prove that DDRenG2 cells were indeed more malignant than the 
DRenG2 system, the same number of cells from both cell lines was simul-
taneously injected into the subcutaneous compartment of two mice and al-
lowed to grow. After 30 days both mice harbored tumors, even though the 
volume of the tumor induced by DDRenG2 cells was twice of that induced 
by DRenG2 (Figure 7.1).  
 
 
Figure 7.1 - Different tumorigenic potential of the 
derivative cellular systems. The size of the tumor in-
duced by the same number of cells of the DDRenG2 sys-
tem clearly depicts its higher malignant potential when 
compared to DRenG2 cells. 
 
The time needed for tumor development was thus progressively 
lower as systems’ malignancy increased, confirming their different tumor-
igenic potential. 
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7.1.2 Karyotypic study of the derivative systems 
Similarly to what was done for the non-malignant and the RenG2 
systems, the karyotype of both DRenG2 and DDRenG2 were also assessed. 
Not surprisingly, additional chromosomal alterations were observed, thus 
supporting the observations that GI accompanies malignant transformation 
(Potapova et al., 2013) and most importantly, Cr(VI)-induced transfor-
mation (Wise and Wise, 2012). 
The alterations found in DRenG2 cells sum those already present in 
RenG2 cells. Moreover, besides the loss of the Y chromosome, which was 
found in all the analyzed cells, the other alterations were present as mosa-
ics. From the 20 constructed karyotypes 60 % of them showed an 
isochromosome 9q with extra material at the terminal part of the chromo-
some [i(9)(q+)], 40 % showed a deletion of the terminal part of the short 
arm of chromosome 7 (7p-), 20 % presented a similar alteration on the long 
arm of chromosome 7 (7q-) and finally, 30 % had a chromosome 6 with ad-
ditional material attached to its short arm (6p+). 
As to DDRenG2 cellular system, the observed alterations again sum 
to those found in the previous systems, exception made for 7q-. Moreover, 
the prevalence of 7p- increased slightly to 27 %, the same percentage at 
which the chromosome 17 can be found with additional material on its 
short arm (17p+). Finally, a translocation between chromosomes 7 and 14 
[t(7;14)] was found in 40 % of the analyzed cells, while a derivative chro-
mosome 12 [der(12)] only appeared in 20 %. Representative karyotypes of 
both cell lines are shown in Figure 7.2.  
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Figure 7.2 - Representative karyotypes of the DRenG2 and DDRenG2 de-
rivative systems at #33. Karyotypes illustrated the new structural alterations 
present on DRenG2 (upper) cells, namely the i(9)(q+) and the 7p-, and which were 
passed along to DDRenG2 cells (down). Moreover, they allowed the identification 
of 6p+ and 7q- structural alterations as exclusive from DRenG2 cells and of 17p+, 
t(7;14) and der(12) as exclusive from the DDRenG2 system. At least 20 karyotypes 
were constructed for each cell passage analysed. 
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Independently of the alterations found, the chromosome number of 
both cell lines changed in comparison to RenG2 cells, as both carry 76 
chromosomes. The number of chromosomes did not varied significantly 
among the analyzed cells. 
7.1.3 Metabolic Studies using 18FDG Uptake 
Metabolic studies were performed in the five cell lines in order to 
highlight any differences that Cr(VI)-induced malignant transformation may 
have imprinted in the cells (Figure 7.3).  
 
 
Figure 7.3 - 18FDG uptake by malignant and non-malignant 
cellular systems. Malignant cells showed a considerably 
higher glucose uptake than non-malignant cells. Unexpect-
edly, however, as malignancy increased the glucose uptake 
decreased. Bars represent means ± SEM. Differences between the cell 
lines’ means were evaluated by one-way ANOVA followed by a Bonferroni post 
test. n.s., no significant; 
*
, P≤0.05; 
**
, P≤0.01; 
***
, P≤0.001.  
 
The malignant cells under study (RenG2, DRenG2 and DDRenG2) 
showed a much higher glucose uptake than their non-malignant common 
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progenitor, BEAS-2B, and the RenG2 non-malignant control, Cont1. This 
observation is believed to mirror their increased energetic demands, which 
is a common feature of malignant cells (Martins-Neves et al., 2012; Ren et 
al., 2013). In fact, the increased dependency of tumor cells upon glucose, 
even under high oxygen tensions, is known as the Warburg Effect and was 
recently considered an hallmark of cancer cells (Hanahan and Weinberg, 
2011).  
Surprisingly, however, was the progressive decrease of glucose con-
sumption observed along the malignant systems (Figure 7.3). As a matter 
of fact, the DDRenG2 cell line showed a glucose uptake that, besides being 
considerably greater than that of BEAS-2B and Cont1 cells, was almost half 
of the uptake registered for RenG2 malignant cells. The glucose uptake of 
DRenG2 cells was situated between that of RenG2 and DDRenG2. 
7.1.4 Doubling Times (DTs)  
The DT calculation for all cell lines constituted a requirement to bet-
ter understand the glucose-uptake results. Figure 7.4 illustrates each cell 
DT and highlights significant differences. 
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Figure 7.4 - Cellular duplication times. Malignant cells repli-
cated significantly faster than their non-malignant progenitors. 
RenG2 DT was significantly different from that of DRenG2 cells, 
while no significance was observed when comparing DDRenG2 to 
its malignant counterparts. Data represent means ± SE. Differences between 
the means were evaluated by one-way ANOVA followed by a Bonferroni post test. 
n.s., no significant; 
*
,P≤0.05; 
**
, P≤0.01; 
***
, P≤0.001.  
 
BEAS-2B cells showed a DT of approximately 23 h, which is in 
agreement with the observations of Costa and colleagues (Costa et al., 
2010). Moreover, Cont1 cells showed no statistically significant differences 
in their DTs when compared to BEAS-2B cells’ DT, thus corroborating their 
non-malignant nature. Malignant cell lines, however, were shown to repli-
cate faster than non-malignant systems, particularly DRenG2 cells which 
showed a DT of roughly 18.5 h. No statistically significant differences were 
observed between DDRenG2 and either RenG2 or DRenG2 cells. 
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7.1.5 Clonogenic Ability of the Different Cellular     
Systems 
To establish the portrait of cells’ malignant signature, clonogenic 
assays were performed and the attained results are depicted at Table II.  
 
 Table II - Plating efficiency (PE) of the different cellular systems. 
 BEAS-2B Cont1 RenG2 DRenG2 DDRenG2 
PE 0.37 ± 0.09 0.51 ± 0.17 3.41 ± 0.17*** 3.78 ± 0.29*** 3.87 ± 0.05*** 
Data are presented as mean ± SEM and one-way ANOVA followed by a Dunnett post test were used 
to identify differences between the cell lines. 
*
,P≤0.05; 
**
, P≤0.01; 
***
, P≤0.001. 
 
The PE results from both BEAS-2B and Cont1 cell lines revealed little 
capacity to survive low density growth, further supporting their non-
malignant nature. Conversely, BEAS-2B malignant progeny revealed single-
cell independent growth ability, since all malignant cell lines were able to 
form colonies. Furthermore, the attained colonies, alike the ones from 
which RenG2 cells were isolated, displayed altered morphologies and a 
disordered growth pattern, thus corroborating the cells’ malignant pheno-
type. 
7.1.6 Migration Assay 
A major characteristic of highly malignant cells is their enhanced 
migratory phenotype. In order to evaluate whether the derivative systems 
portrayed more pronounced migration ability than RenG2 and the non-
malignant BEAS-2B and Cont1 cell lines, scratch assays were performed. 
Figure 7.5 combines several of the best photographs attained at key time 
points. 
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In agreement with their non-malignant phenotype, both BEAS-2B 
and Cont1 cell lines failed to close the wound after 200 h of the beginning 
of the assay, even though they displayed some residual migration ability. 
Comparatively, RenG2 cells displayed higher migration capacity even 
though by the end of the assay the wound closure was incomplete and 
gaps could still be observed. In contrast, the more malignant derivative sys-
tems closed the wound very fast. In fact, the wound made in the DRenG2 
cells’ monolayer was clearly closed 82 h after the beginning of the assay, 
while at 73 h timepoint the wound in DDRenG2 cells’ monolayer was al-
ready closed. 
7.1.7 Immunocytochemistry  
The expression of α-SMA and Vimentin is widely used to monitor 
EMT. In fact, as reviewed by Kalluri and Weinberg, the lost of epithelial fea-
tures towards a mesenchymal phenotype triggers the expression of α-SMA 
and increases that of Vimentin (Kalluri and Weinberg, 2009). To assess 
whether the more malignant cell lines portrayed a mesenchymal pheno-
type, immunocytochemistry analysis was performed using the abovemen-
tioned markers, and the results are illustrated in Figure 7.6. 
 
 
Figure 7.6 - Immunocytochemistry study of Vimentin and α-SMA. Both 
BEAS-2B and Cont1 non-malignant systems displayed a basal staining for 
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Vimentin. Conversely, α-SMA staining was negative in these cell lines. All the 
malignant systems, however, presented a strong staining for both Vimentin and 
α-SMA. A magnification of 400x was used in all panels. VIM, Vimentin. 
 
Basal levels of Vimentin staining were found in BEAS-2B and Cont1 
cells while BEAS-2B malignant progeny revealed an increased expression of 
this protein. As to α-SMA, not surprisingly this protein was only expressed 
in the malignant cell lines. Altogether, these results corroborated the ob-
servations of Weinberg’s laboratory (Kalluri and Weinberg, 2009). 
7.1.8 Therapy Resistance Studies 
A widely accepted feature of cancer cells is that they are more re-
sistant to conventional therapeutic drugs than normal cells. As a conse-
quence, drug resistance assays are often performed to sustain cells’ malig-
nancy. 
Applying a similar reasoning, drug resistance studies were per-
formed in both the non-malignant and malignant cell lines under study. We 
selected three drugs that were normally used in the treatment of lung car-
cinomas, methotrexate (MTX), cisplatin (Cis) and gemcitabine (Gem). Fol-
lowing exposure of our cell lines to tree different concentrations of the 
drug, the cellular viability was measured by the MMT assay. Obtained re-
sults are shown in Figure 7.7. 
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Figure 7.7 - Cell survival following drug treatment. The higher the degree 
of malignancy, the higher the resistance to the different drugs at all tested con-
centrations Derivative cell lines, in particular, were shown to be more sensitive 
to methotrexate than their non-malignant progenitor cells. Data represents mean ± 
SEM. When not visible error bars are smaller than the symbols. MTX, methotrexate; Cis, cisplatin; 
Gem, Gemcitabine.  
 
The non-malignant BEAS-2B and Cont1 cell lines were shown to be 
very sensitive to the complete range of concentrations and drugs tested. 
However, Cont1 cells showed a more robust phenotype, as it took 72 h for 
both Cis and Gem drugs to eradicate these cells. Regarding BEAS-2B cells, 
results indicated that they were more resistant to MTX than to the other 
drugs under test. 
Regarding BEAS-2B malignant progeny, none of the therapeutic reg-
imens succeeded in completely eradicating them. Moreover, the higher the 
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malignancy of the system, the higher was the resistance to drugs. In fact, 
RenG2 cells showed a considerably lower resistance to the therapeutic reg-
imens than the derivative systems, further supporting the hypothesis that 
RenG2 cells were only mildly malignant. In contrast, both the derivative 
systems distinctively succeed in surviving the entire repertoire of adopted 
therapeutic strategies, particularly DDRenG2 which was clearly more re-
sistant than DRenG2. This observation further supported the premise that 
DDRenG2 cells were the more malignant cells under study. Finally, the re-
sults indicated that best therapeutic effectiveness was attained using MTX, 
while Gem and Cis showed less effectiveness and similar behavior. 
7.1.9 CSCs Search using the Sphere-forming Assay 
Medema’s laboratory proposed that only CSCs are endowed with 
tumorigenic capacity and the ability to resist chemotherapy (Vermeulen et 
al., 2008b). By interpreting our results in light of Medema’s theory, it be-
came plausible to hypothesize that CSCs mediated BEAS-2B cells’ 
malignization, and were liable for the malignant features of RenG2, 
DRenG2 and DDRenG2 cell lines. To test our hypothesis the sphere-forming 
assay was used as, according to Eramo and collaborators, it has the ability 
to specifically isolate CSCs from inside a an heterogeneous mixture of cells 
(Eramo et al., 2008, 2010).  
The attained results were rather surprising as spheres only formed 
when DRenG2 and DDRenG2 cell lines were cultured at the restraining 
conditions of the sphere-forming assay (Figure 7.8). Moreover, the spheres 
attained with DDRenG2 cells were not only larger but also more numerous 
than those formed by DRenG2. This observation unveiled the higher stem 
potential of the DDRenG2 cellular system. 
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Figure 7.8 - Comparison of the spheres isolated from the derivative sys-
tems. DDRenG2 cell line formed more and larger spheres than its progenitor 
DRenG2 cell line. A magnification of 100x was used in both photographs. 
 
The resulting DRenG2 and DDRenG2 spheres were then purified as 
described in section 5.16 of Chapter 5, in order to establish the CSC lines of 
each of the derivative systems, named SC-DRenG2 and SC-DDRenG2, re-
spectively. 
7.2 Discussion 
The process of malignant transformation greatly differs among tissue 
types, even when the same set of genes is involved. For instance, KRAS-driven to-
bacco-induced lung adenocarcinomas need circa 30 years to evolve from pre-
neoplastic lesions to the metastatic disease stage (Umar et al., 2012), while pan-
creatic adenocarcinomas, similarly driven by KRAS mutations, normally take less 
than 20 years to form metastasis (Yachida et al., 2010). These observations impose 
a great necessity of better understanding and characterizing the cellular physiol-
ogy of the different tumors in order to design more adequate and effective thera-
peutic strategies against them. 
Cells’ aggressiveness and malignant potential are usually measured based 
on a wide range of factors, namely the time cells need to induce tumors in immu-
nosuppressed mice, the volume of the tumors formed, and the extent of tissue 
damage observed in the tumor neighbourhoods (Musteanu et al., 2012). In light of 
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these observations, the results attained following in vivo derivation of the RenG2 
system suggested that the malignant potential of these cells was successfully in-
creased. Moreover, this assertion was further corroborated by the karyotypic 
studies on the derivative systems.  
GI is recognized as a hallmark of malignant cells, which are usually re-
garded as having intricate genomes (Hanahan and Weinberg, 2011). GI is defined 
by the presence of gross structural chromosome alterations in the cells, and it may 
drive the formation of polyploid genomes (Fujiwara et al., 2005). As discussed in 
Chapter 6, Pellman’s laboratory observed that tetraploid intermediates are fre-
quently the reservoirs of this GI as they usually form during malignant transforma-
tion, subsequently evolving into aneuploid instable genomes (Ganem et al., 2009). 
Similarly, the results attained in the karyotypic study of BEAS-2B’s malignant prog-
eny corroborated Pellman’s theory as all the malignant cell lines carried aneuploid 
genomes suggestive of being derived from a tetraploid intermediate. Moreover, 
they also confirmed that all the cell lines descended from BEAS-2B cells, as a 
chromosome signature was transversally present in BEAS-2B’s progeny. Finally, 
derivative cells’ karyotypes definitively supported their higher malignancy in com-
parison to RenG2 and the non-malignant cells, since some of the alterations found 
had already been associated to cancer. For instance, deletions of chromosome 7p 
have been identified in paediatric leukemias (Woo et al., 2009), while loss of 
chromosome Y as long been linked to LC (Center et al., 1993). Likewise, the dele-
tion of chromosome 7q was already observed in breast cancer cells (Kristjansson 
et al., 1997) and the t(7;14) present in DDRenG2 cells’ karyotype has very recently 
been found to be related with EGFR overexpression in multiple myeloma (Walker 
et al., 2013). It would be very interesting to assess whether EGFR alterations were 
involved in Cr(VI)-induced BEAS-2B malignization, as mutations in this gene were 
one of many drivers of lung carcinogenesis (da Cunha Santos et al., 2011). 
Cells are social entities; they inhabit tissues, and they actually depend on 
their microenvironment to survive and sustain their physiology. As demonstrated 
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by Sassoli and collaborators using cardiac cells, paracrine and juxtacrine signaliza-
tions regulate tissues’ homeostasis and fate (Sassoli et al., 2011). When normal 
cells are deprived of intercellular contacts, their internal circuitries are deregu-
lated and the apoptotic cascades are triggered (Nelson and Bissell, 2006). Malig-
nant cells, however, grow independently of these signalizations, and thus are able 
to survive following single-cell culture (Hanahan and Weinberg, 2011; Nelson and 
Bissell, 2006). The clonogenic assays’ results evidenced the malignant nature of 
BEAS-2B’s malignant progeny, as those cell lines were shown to give rise to 
significantly more cellular colonies than BEAS-2B and Cont1 cell lines. The capacity 
of these non-malignant systems to form colonies, although significantly lower than 
that of the malignant systems, potentially results from the immortalization with 
the SV40 virus, as was suggested by Yilmaz who observed similar features in im-
mortalized human milk epithelial cells (Yilmaz et al., 1993). 
The augmented clonogenic ability of the malignant systems sumed to their 
increased cellular motility, helping sustaining their malignant phenotype. Cellular 
motility is normally restrained to determined cellular populations in the body. As 
can easily be understood, lung bronchial epithelial cells are not one of those 
(Dertsiz et al., 2005). However, following malignization, these cells become motile 
in order to intravasate and disseminate throughout the organism (Joyce and 
Pollard, 2009). Paraphrasing Liang and colleagues, a scratch assay is a straightfor-
ward and economical method to study cell migration in vitro (Liang et al., 2007) 
and it is widely used in different cellular systems (Belo et al., 2013; Lee et al., 
2013). In 2004, a high throughput platform was even designed to distinguish envi-
ronmental perturbations that can affect cell migration, morphology, and division 
during the assay timeframe (Yarrow et al., 2004). The results attained in the 
scratch assay supported the assumption that RenG2 cells are the least malignant 
of BEAS-2B’s progeny, as these cells only partially and disorderly closed the wound 
after 200 h. The fast wound closure observed in the derivative systems may sug-
gest that wound closure relayed on cell division rather than on cell motility; how-
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ever, the erratic pattern of closure along with the DTs calculated by the MTT assay 
strongly favored the migration theory. As a matter of fact, DDRenG2 cells showed 
no significant differences in DT when compared to RenG2 cells, yet they closed the 
wound in less than the half time and in a more ordered way then its progenitors. 
The filamentous protein Vimentin, although often associated with 
mesenchymal cells, integrates the cytoskeleton of virtually all eukaryotic cells 
(Leader et al., 1987). Thus, its expression in BEAS-2B and Cont1 systems only illus-
trated its ubiquitousness. The absence of α-SMA staining in these non-malignant 
epithelial cells corroborated their epithelial nature. Conversely, the expression of 
α-SMA in the malignant systems sustained the EMT involvement in their for-
mation. In agreement with Kalluri and Weinberg, this process of EMT is involved in 
the acquisition of motility properties by the malignant epithelial cells (Kalluri and 
Weinberg, 2009). Mendez and collaborators further identified Vimentin has the 
element responsible for the motility acquisition, through induction of the assem-
bly of Vimentin intermediate filaments (Mendez et al., 2010). In light of these ob-
servations, immunocytochemistry results further supported scratch assay’s re-
sults, as the more motile derivative cells showed a compatible mesenchymal phe-
notype.  
Considering all the above mentioned results, the outcome of the therapy 
resistance studies was relatively predictable. Reflecting their non-malignant na-
ture, both BEAS-2B and Cont1 cells succumbed to the employed therapeutic regi-
mens and were killed soon after 48 h of treatment. The exceptional resistance 
shown by BEAS-2B cells to MTX treatment, rather than really meaning resistance, 
it most likely illustrated the different mechanism of action of the drugs used in this 
study. In fact, both Cis and Gem are predominantly cytotoxic agents while MTX is a 
cytostatic one. As cytotoxic agents, Gem and Cis affect cells at any stage of their 
cycle. MTX, on contrary, specifically interferes with DNA and RNA synthesis, acting 
preferably during the S-phase of the cell cycle during which these processes are 
crucial. As a consequence, cells cannot replicate their DNA and fail to divide 
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(Patanè et al., 2013). Overlapping the drug resistance results with those of the 
DTs, it became plausible to accept that slow-dividing non-malignant cells needed 
more time to progress through the cell cycle, thus delaying the entrance into S-
phase and consequently, the toxic effects of MTX.  This cycle phase-specificity of 
MTX may also justify its increased effectiveness in killing the cells of the derivative 
systems. 
Highly proliferative cells such as cancer cells rely on glycolysis to support 
oxidative generation of ATP, regardless of oxygen availability, in a process called 
the Warburg effect (Warburg, 1956). Corroborating this observation, 18FDG studies 
revealed that the malignant systems had a much higher demand of glucose than 
the non-malignant BEAS-2B and Cont1 cell lines (Vander Heiden et al., 2009). 
However, 18FDG studies also unexpectedly revealed that the two derivative sys-
tems uptake significantly less glucose than RenG2 malignant cells, in spite of their 
higher malignant potential. These results indicated that DDRenG2 cells may need 
approximately half the energy required by RenG2 cells to sustain their malignant 
physiology. Moreover, because MTT assays showed that the three malignant sys-
tems have comparable DTs, the lower glucose demands cannot be ascribed to a 
slower proliferation. Instead, the metabolic profile of the more malignant cell lines 
suggested the existence of slow cycling and less glucose-requiring cellular sub-
populations inside our derivative systems. Similar observations have been recently 
reported by Martins-Neves and collaborators using a human osteosarcoma cell 
line (Martins-Neves et al., 2012).  
As discussed in Chapter 3, CSCs are characterized as being very tumorigenic 
and resistant to chemotherapy (Medema, 2013). Moreover, several other studies 
also showed that these cells also have lower glucose requirements, higher clono-
genic efficiency and increased cellular mobility (Gottschling et al., 2012; Moore 
and Lyle, 2011; Visvader, 2011). Considering that we were able to find all these 
features in the derivative systems, it was hypothesized that CSCs mediated Cr(VI)-
induced BEAS-2B cells’ malignization. In line with the current literature, our initial 
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hypothesis was that a residual population of basal-like cells would have been re-
tained in the BEAS-2B cell line during its immortalization. Subsequently, following 
exposure to Cr(VI), this population of cells would have been transformed into CSCs 
which had then driven the malignization process. Nonetheless, immunohisto-
chemistry results did not corroborate the existence of such a basal-like cell popu-
lation within BEAS-2B cells, and the sphere-forming revealed that only the deriva-
tive systems were able to produce spheres. Moreover, the fact that DDRenG2 cells 
formed more and bigger spheres, besides supporting the idea of their increased 
malignant potential, further suggested that the CSCs isolated from DRenG2 cul-
tures were obtained through dedifferentiation of RenG2 cells and not by trans-
formation of endogenous stem-like cells.  
This hypothesis of dedifferentiation, although very appealing and not new, 
has only very recently been observed in vitro by Chaffer and colleagues (Chaffer et 
al., 2011). This group observed that differentiated mammary epithelial cells can 
reconvert to a stem-like state, in their opinion through an apparent stochastic 
process (Chaffer et al., 2011). Even though not excluding a random process, we 
rather believe that microenvironment cues were the major players in the dediffer-
entiation process. With that in mind it was reasoned that following injection of 
RenG2 cells in immunosuppressed mice a paracrine communication with mice 
subcutaneous stromal cells may have been established. This interaction with the 
microenvironment, as dissected in Chapter 3, is rather common among growing 
tumors and often results in microenvironment co-option and tumor outgrowth 
(Hanahan and Coussens, 2012). According to our rational, the soluble factors re-
leased by the mouse cells would have driven RenG2 cells dedifferentiation, thus 
leading to the formation of a CSC pool inside the DRenG2 system. Figure 7.9 pre-
sents the model proposed for CSCs-driven BEAS-2B cells’ malignization following 
Cr(VI)-exposure.  
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Figure 7.9 - Model for Cr(VI)-induced BEAS-2B cells' malignant transformation. 
Cr(VI) and low density culture rendered BEAS-2B malignant. According to our hypothe-
sis, a subsequent communication between RenG2 cells and the subcutaneous mouse 
stromal cells would have driven the dedifferentiation of RenG2 cells with a specific set of 
Cr(VI)-induced mutations, and consequently, the formation of a CSC population inside 
DRenG2 cells. Further derivation of the system in a new mouse would have boosted the 
CSC sub-population in the DDRenG2 cell line. 
 
The subsequent derivation of DRenG2 cells in a singenic mouse model 
would then have boosted the CSC sub-population, thus justifying the results at-
tained in the sphere-forming assay. The comparative characterization of the at-
tained stem systems would allow to clarify this hypothesis and understand the 
overall mechanism of Cr(VI)-induced BEAS-2B cells’ malignization. 
7.3 Conclusion 
The process of in vivo derivation of the RenG2 cell line succeeded at in-
creasing the malignant potential of the system. Moreover, it became evident that 
CSCs drove the boosted aggressiveness of the more malignant cell lines as a CSC 
sub-population was isolated from each of the derivative cell lines. Finally, the in-
capacity of RenG2 cells to yield spheres when cultured in restraining conditions 
indicated that CSCs were formed by dedifferentiation of the RenG2 cells while in 
the mouse subcutaneous compartment. The global chain of events further sug-
gested that a paracrine communication between RenG2 and the mouse stromal 
cells may have driven the process of dedifferentiation. 
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Note 
The results presented in this chapter are part of a manuscript in preparation: 
Rodrigues, CFD, Val, M, Rodrigues IP, Fonseca, J, Gomes CMF, Abrunhosa, AJ, Paiva, A, Carvalho, L, 
Botelho, MF, Carreira, IM and Alpoim, MC. Stromal cells-released IL-6, G-CSF and Activin-A induce 
dedifferentiation of lung carcinoma cells into cancer stem cells. 
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Chapter 8  
CSCs’ Isolation and Characterization 
8.1 Introduction 
Intercellular crosstalk is probably the most important cellular event. In fact, 
it is through this process that cells keep their normal physiology, thus maintaining 
tissues’ architecture and function, ultimately allowing the entire body homeosta-
sis. As a consequence, it came as no surprise that this biological process is deeply 
affected by the malignant transformation course. 
There are many ways through which cells may communicate; however, the 
most commonly employed strategies relay on paracrine and juxtacrine processes, 
and in the case of malignant cells, autocrine loops are also common. Regarding the 
mediators of the cellular dialogs, they mostly depend on the type of communica-
tion established. For instance, juxtacrine communication relays on intercellular 
membrane interaction through membrane-anchored molecules. Paracrine and 
autocrine loops, on contrary, depend upon the interaction of membrane-anchored 
cellular receptors with released soluble factors. Cytokines are often the mediators 
of paracrine and autocrine loops; these small molecules, although with different 
chemical structures, act over specific cellular receptors, activating intracellular sig-
naling pathways that most frequently affect cells’ expressome.  
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Co-culture strategies have been widely used to assess intercellular com-
munication. There are many devices that can be used to co-culture cells, and their 
choice mostly depends upon the ultimate goal to be attained with the culture. 
When paracrine signalization is to be analyzed, Transwell® devices represent a 
good option as they may allow two different cellular populations to communicate 
without inter-population contact. As a consequence, soluble factors which enrich 
the correspondent conditioned media can subsequently be searched for using mo-
lecular biology techniques. 
The aim of this study was to uncover the molecular mechanisms underlying 
CSCs-formation in the in DRenG2 and DDRenG2 cell lines, as a way of completing 
the molecular portrait of Cr(VI)-induced malignant transformation of BEAS-2B 
cells. High throughput strategies were used to identify the paracrine orchestrators 
of RenG2 cells’ dedifferentiation, as well as the Cr(VI) role in the overall process. 
8.2 Results 
8.2.1 Karyotypic study of CSCs 
To compare CSCs lines with their progenitors and identify genomic 
hallmarks of the dedifferentiation process, 20 karyotypes were constructed 
for both SC-DRenG2 and SC-DDRenG2 cells. 
The karyotypic study of SC-DRenG2 cells revealed that, similarly to 
what was observed for DRenG2 and DDRenG2 cell lines, they harbored in 
all the analyzed karyotypes some of the features that were present in their 
progenitors, namely the 6p+ and the i(9)(q+). In addition, this CSCs line 
showed a reciprocal derivative of the short arms of chromosomes 1 and 2 
(der 1p/2p) in 70 % of the analyzed cells, a similar derivative involving the 
long arms of the same chromosomes (der 1q/2q) in 33.3 % and a terminal 
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deletion in the long arm of chromosome 1 (1q-) in 70 %, in the analyzed 
karyotypes (Figure 8.1). 
 
 
Figure 8.1 - Representative karyotype of SC-DRenG2 at #6. The karyotype 
showed new structural alterations relative to DRenG2 cells, namely the 
der(1p/2p), the der(1q/2q) and the 1p-. At least 20 karyotypes were constructed for 
each cell passage analysed. 
 
SC-DDRenG2 cells also retained similar percentages of the 6p+, 7p- 
and 17q+ from DDRenG2 cells. In addition, these cells’ karyotype also 
showed an isochromosome of the short arm of chromosome 5 [i(5)(p10)] 
as well as a derivative chromosome involving parts of both chromosomes 5 
and 7 (der5/7) in 100 % and 80 % of all the analyzed metaphases, respec-
tively (Figure 8.2). 
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Figure 8.2 - Representative karyotype of SC-DDRenG2 at #6. The karyo-
type showed new structural alterations relative DDRenG2 cells, namely the 
i(5)(p10) and the der(5/7). At least 20 karyotypes were constructed for each cell pas-
sage analysed. 
 
In terms of ploidy, both the CSC lines presented a reduced number 
of chromosomes when compared to their progenitors. As a matter of fact, 
SC-DRenG2 cells showed an average of 74 chromosomes, while SC-
DDRenG2 normally presented circa 62 chromosomes. 
8.2.2 Metabolic Studies using 18FDG Uptake 
CSCs are described as quiescent, slow dividing cell populations that 
consume less glucose than differentiated tumor cells (Moore and Lyle, 
2011; Vlashi et al., 2011). Driven by these observations, the glucose uptake 
of both CSCs systems was assessed using 18FDG (Figure 8.3). 
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Figure 8.3 - Comparative analysis of 18FDG uptake. Both           
SC-DRenG2 and SC-DDRenG2 cell lines uptake significantly less 18FDG 
in comparison to the other malignant cell lines. Bars represent means 
± SEM. Differences between the cell lines’ means were evaluated by one-way 
ANOVA followed by a Bonferroni post test. n.s., no significant; 
*
,P≤0.05; 
**
, P≤0.01; 
***
, P≤0.001.  
 
The attained results further corroborated the observations of Vlashi 
and colleagues as they showed that both our CSC systems had significantly 
lower glucose needs than RenG2, DRenG2 and DDRenG2 cell lines (Vlashi 
et al., 2011). In fact, the registered values of 18FDG uptake for the stem cell 
lines were actually very close to those attained for the non-malignant 
BEAS-2B and Cont1 systems. 
 
1.1.1. Doubling Times by MTT 
To assess if the lower glucose requirements of the CSC systems par-
alleled an increased DT, MTT assay was performed as previously described. 
The attained results are summarized in Figure 8.4. 
 
  
    
154 Carlos F. D. Rodrigues │ University of Coimbra  
 
Figure 8.4 - Comparative study of cellular duplication times. Both 
SC-DRenG2 and SC-DDRenG2 had considerably higher replication times 
than their derivative progenitors. Moreover, SC-DDRenG2 needed even 
more time to replicate than SC-DRenG2. Data represent means ± SEM. Differ-
ences between the means were evaluated by one-way ANOVA followed by a Bonferroni 
post test. n.s., no significant; 
*
,P≤0.05; 
**
, P≤0.01; 
***
, P≤0.001.  
 
Corroborating previous observations from other laboratories, the 
isolated CSCs populations had a longer cell cycle progression than the cell 
lines from which they were isolated (Dembinski and Krauss, 2010; Roesch 
et al., 2010). Moreover, trypan blue direct cell counting further confirmed 
that the increase observed in cellular viability did not result from an in-
crease in cell number. Finally, the results attained in preliminary cell cycle 
studies with PI do corroborated the observations of Mackenzie and col-
leagues, according to whom CSCs isolated from epithelial tumors have a 
higher percentage of cells in G2 cell cycle phase (Harper et al., 2010). 
8.2.3 Therapy Resistance Studies 
Tumor resistance and consequent relapse is generally ascribed to 
CSCs as these cells show enhanced resistance to common therapeutic ap-
proaches. To test whether SC-DRenG2 and SC-DDRenG2 also had increased 
drug resistance, studies were performed using different concentrations of 
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MTX.  The viability of the cell lines exposed to MTX was assessed along 72 h 
by the MTT assay (Figure 8.5).  
 
 
Figure 8.5 - CSCs’ survival following MTX treatment. MTX not only failed at 
killing CSCs, but also was unable to block their division, as both SC-DRenG2 and 
SC-DDRenG2 grew in the presence of the drug. Data represents means ± SEM. When not 
visible error bars are smaller than the symbols. 
 
On contrary to what was observed on Chapter 7 with the RenG2, 
DRenG2 and DDRenG2 malignant systems (see Figure 7.7), MTX failed to 
abrogate CSCs’ cycle progression as the cells not only did not die, but kept 
dividing in the presence of the drug. This observation is consistent with 
previous studies demonstrating the higher resistance of CSCs to therapy 
(Barr et al., 2013; Gupta et al., 2009; Lee et al., 2011; Naujokata and 
Lauferc, 2013). Note that in both CSCs systems the drug treatment seemed 
to have had some degree of effectiveness 24 h following exposure, but this 
effectiveness was immediately abolished since 48 h following exposure 
cells were actively dividing again. 
8.2.4 Gene expression profile by RT-qPCR 
The gene expression analysis used to follow up BEAS-2B cells’ 
malignization was globally recapitulated for the RenG2 progeny and for the 
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isolated CSCs systems, to highlight differences among them. The attained 
results are illustrated in Figure 8.6. 
 
 
Figure 8.6 - Gene expression analysis of derivative and CSC systems. Alto-
gether the results confirmed the higher malignancy of the derivative DRenG2 and 
DDRenG2 systems, as well as the stem nature of their isolated CSCs sub-populations. 
See text for specific analysis. Bars represent means ± SEM.  
 
CCNB1 expression was significantly reduced in the CSCs systems, 
thus corroborating the cell cycle studies, according to which both SC-
DRenG2 and SC-DDRenG2 divide slower than their progenitor derivative 
cells. As to LDHA gene, it was consistently overexpressed in CSCs in opposi-
tion to HIF1α gene, which was downregulated in both the derivative sys-
tems and in their isolated sub-populations. Moreover, HIF1α suppression 
was greater in the most malignant cell line (DDRenG2) and in its respective 
CSCs sub-population (SC-DDRenG2) (Figure 8.6). 
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DNA repair genes were globally downregulated, with the exception 
of MSH2 and XRCC1 in the derivative systems and CAV1 in the DDRenG2 
and CSCs systems. As to the genes involved in malignant transformation, all 
MAPKs tended to be downregulated in all the cell lines, in relation to the 
less malignant RenG2 cells, excepting MAP2K4 which was slightly 
upregulated in DDRenG2 cells. MYC oncogene was greatly expressed in the 
more malignant systems, when compared to RenG2 cells. Surprisingly, 
however, its levels reached a peak in the derivative systems and were then 
inferior in both SC-DRenG2 and SC-DDRenG2 cells. SPARC showed a very 
significant up-regulation in the SC-CSCs, while the MMR system turned out 
to be silenced, as revealed by DNMT1 and MLH1 evident downregulation. 
8.2.5 Comparative genomic analysis of all systems 
Following karyotypic studies, aCGH was used to attained better un-
derstand the malignization process induced by Cr(VI). Using the Agilent 180 
K platform, all our systems were compared to BEAS-2B cells. The results are 
illustrated in Figure 8.7. 
An overview of the attained results allowed us to identify various 
genes potentially involved in the different steps of the cell lines’ develop-
ment. It was even possible to identify chromosome imbalances potentially 
correlated with viral-based BEAS-2B immortalization, like the observed 
point deletion at 1q34 in BEAS-2B, involving the zinc finger CCCH-type anti-
viral 1 (ZC3HAV1) gene, which codes for an anti-retroviral protein that in-
hibits viral replication (Cagliani et al., 2012). The low-density culture proto-
col did induced some degree of GI, as can be observed by the chromosome 
deletions at the distal part of the short arm of chromosome 4 and at the 
distal part of the long arm of chromosome 16 in both Cont1 and RenG2 
cells (Figure 8.7).  
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Figure 8-7 - Ideogram representing chromosome imbalances in all cel-
lular systems. It was possible to identify chromosome regions affected by low 
density culture, namely in chromosomes 4 and 16. A high degree of GI was 
found in the CSCs systems. Coloured lines represent the cell lines where imbalances 
occurred. When placed on the left of the chromosome they represent deletions, on 
contrary, when located on the right they represent amplifications. Dark blue BEAS-2B, 
light blue Cont1, black RenG2, green DRenG2, yellow DDRenG2, red SC-DRenG2 and 
violet SC-DDRenG2. The analysis software normalized the results to the most frequent 
ploidy displayed in each cell line in comparison to BEAS-2B cells. 
 
In agreement with Borodyansky and Yang, the isolated CSCs sys-
tems showed a higher degree of GI when compared to the cell lines from 
which they were isolated (Li et al., 2009). In fact, analysis of the attained 
results revealed that both CSCs lines carried deletions on tumor suppressor 
genes, namely TP53BP2, LIN9 and RPS29. Additionally, WDR26 and CDKL3, 
two important genes in cell cycle progression were also shown to be delet-
ed in both CSCs systems. Mitocondrial metabolism also seemed to be im-
paired as genes involved in mitochondria respiratory chain complexes’ as-
sembly were deleted. This was actually the case of BCS1L, involved in the 
assembly of complex III (Fernandez-Vizarra et al., 2007), NUBPL, involved in 
the assembly of complex I (Calvo et al., 2010; Kevelam et al., 2013), and 
ATP5S, needed for the regulation of ATP synthase (Belogrudov and Hatefi, 
2002). Also deleted in both CSCs systems were various genes involved in in-
tracellular MAPK-mediated signaling pathways, a gene involved in cellular 
differentiation, ARID4B, and two controllers of EMT, TWIST2 and PTPN14. 
Regarding gene amplifications, they were shown to be significantly less 
frequent than deletions in the CSCs systems. Of relevance was the amplifi-
cation of a wide range of cytokine genes (CCL1, CCL2, CCL7, CCL8C, CCL11 
and CCL13), of the SKI proto-oncogene and of genes involved in intercellu-
lar signal transduction affecting, for instance, NFKB pathway (PLEKHG5), 
p53 pathway (TP73), PI3K pathway (PRKCZ) and RAF pathway (KSR1). 
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In addition to the above mentioned deletions and amplifications SC-
DDRenG2 cells portrayed an even higher degree of GI when compared with 
SC-DRenG2. Especially relevant was the amplification of the genes SRC, Au-
rora kinase A and B (AURKA and AURKB), Hypoxia-inducible factor 1β      
(HIF-1β), Snail homolog 3 (SNAI3), Nuclear factor of activated T-cells, cyto-
plasmic, calcineurin-dependent 2 (NFATC1 also known as NFAT2) and Ela-C 
homolog 2 (ELAC2). 
8.2.6 Co-culture of RenG2 and FR: the last cue! 
Following the confirmation of SC-DRenG2 and SC-DDRenG2 stem 
potential, it became evident that the mouse subcutaneous compartment 
drove RenG2 cells’ dedifferentiation. To assess this hypothesis RenG2 cells 
were co-cultured with cirurgically isolated mouse FR cells for two months, 
and isolated RenG2 cells (iRenG2) were subsequently tested for their ability 
to grow under restraining conditions using the sphere-forming assay. 
Spheres formed soon after cells were plated in low-adherent wells, similar-
ly to what was observed during the isolation of SC-DRenG2 and SC-
DDRenG2 systems (section 7.1.9 of Chapter 7). To highlight differences and 
similarities between iRenG2 and RenG2, DRenG2 and SC-DRenG2, a gene 
expression analysis was performed using the same candidates. The ob-
tained results are depicted at Figure 8.8. 
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Figure 8.8 - Comparative gene expression analysis of iRenG2 cells. Glob-
ally, iRenG2 cells lost the expressome signature of RenG2 cells and adopted a new 
signature that lay in between those of DRenG2 and SC-DRenG2. Bars represent means 
± SEM. 
 
The attained results showed that iRenG2 cells no longer have 
RenG2’s signature but rather adopted one that is somewhere in between 
those of DRenG2 and SC-DRenG2 cells. Furthermore, these observations 
were corroborated by the flow cytometry studies that used a selected pan-
el of markers to compare the abovementioned cellular systems (Figure 
8.9). 
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Figure 8.9 - Flow cytometry scattering plots comparing the iRenG2 cell 
line to both RenG2, DRenG2 and SC-DRenG2. In both tubes the                    
yellow-represented iRenG2 cells were more close to both DRenG2 and SC-DRenG2 
than to RenG2, illustrating their closer identity. Colored dots represent individual cells. 
RenG2 green, DRenG2 light blue, SC-DRenG2 red and iRenG2 yellow.  
 
The scattering plots resulted from an integrative software analysis 
that combined the information of all the markers studied to assess the mo-
lecular signature of the cells. These plots revealed that iRenG2 cells are 
very close to both DRenG2 and SC-DRenG2 cells, but rather different from 
RenG2 cells. These observations prompted the hypothesis that a paracrine 
crosstalk may have driven the dedifferentiation of iRenG2 cells. To validate 
this hypothesis, additional control co- and monocultures were performed, 
as depicted in Figure 5.6 from Chapter 5. Subsequently, cytokine multiplex 
array and ELISA were carried out in the conditioned media of the different 
cultures (Figures 8.10 and 8.11).  
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Figure 8.10 - IL-6 and G-CSF levels in the conditioned media 
of the RenG2-FR co-culture. The levels of both cytokines were 
significantly increased in the co-cultures relative to the controls. 
The use of an anti-mouse Ab allowed the detection of FR-produced 
cytokines in the upper compartment. Data represent means ± SEM. Differ-
ences between the means were evaluated by one-way ANOVA followed by a 
Bonferroni post test. Mo, mouse; mFR, monocultured FR cells; cFR, FR cells co-
cultured with RenG2 cells; cRenG2, RenG2 cells co-cultured with FR cells; mRenG2, 
monocultured RenG2 cells; w/, co-cultured with; n.s., no significant; 
*
,P≤0.05; 
**
, 
P≤0.01; 
***
, P≤0.001. 
 
Multiplex cytokine array is a very powerful and sensitive assay that 
allows detecting very low levels of cytokines. Non-significant variations 
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were detected in a wide range of cytokines, however, only the IL-6 and G-
CSF levels in the co-culture conditioned media turned out to be elevated at 
a statistically significant level. Moreover, the specie-specificity of the Abs 
allowed to confirm that the FR-secreted cytokines were able to trespass 
the Transwell® membrane into the upper compartment, thus being availa-
ble to affect RenG2 cells’ physiology. 
 
 
Figure 8.11 - Activin-A levels in the conditioned media of the 
RenG2-FR co-culture. A statistically significant increase on Ac-
tivin-A levels was observed in the co-cultures relative to the con-
trols. Data represent means ± SEM. Differences between the means were evalu-
ated by one-way ANOVA followed by a Bonferroni post test. n.s., no significant; 
*
,P≤0.05;
 **
, P≤0.01; 
***
, P≤0.001. 
 
The ELISA assay used to search for Activin-A in the co-cultures’ con-
ditioned media also suggested the involvement of this cytokine in RenG2 
cells’ dedifferentiation, as its levels were significantly increased compared 
to the one attained in control cultures. Nonetheless, although the inter-
species cross-reactivity of the Ab used does not allow affirming definitely 
that Activin-A was produced by the FR feeder layer, the negligible produc-
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tion of this molecule by RenG2 monocultures strongly supports this hy-
pothesis. 
8.3 Discussion 
Independently of the tissue of origin and of the pathophysiology of the dis-
ease, malignant cells share a group of features that characterize them. The extent 
to which each of these characteristics is developed and their relative proportion 
further determines tumors’ behavior. Gene expression usually underlies the de-
velopment and expression of these characteristics, and it is actually believed to be 
their underlying driving force. 
Alterations in cells’ karyotype were commonly found in malignant cells as 
they very efficiently modulate gene expression. In fact, chromosome rearrange-
ments may activate, silence, amplify or delete genes. For instance, MYC amplifica-
tion was long encountered in a wide range of tumor cells (Collins and Groudine, 
1982; Little et al., 1983), while TP53 was found to be either deleted (Nigro et al., 
1989) or mutated (Nigro et al., 1989). In both situations, malignant transformation 
was promoted either by the increased expression of an oncogene or by silencing 
of a tumor suppressor gene. Alternatively, the translocation of chromosome frag-
ments, or even entire chromosome arms, may also be used by malignant cells to 
modulate their expressome. For example, acute lymphoblastic leukemias carrying 
a translocation affecting the mixed-lineage leukemia gene (MLL) portray a distinct 
gene expression profile that renders cells more resistant to chemotherapy 
(Armstrong et al., 2002). 
aCGH is a very potent tool to assess numeric alterations in cancer cells. 
Nevertheless, the complexity of the chromosome rearrangements is such that 
sometimes it becomes very difficult to interpret and contextualize the results at-
tained in the study of malignant cells. This task is further complicated by the soft-
ware analysis which masks polyploid cells by transforming the probe intensity data 
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to a virtually diploid state (Gardina et al., 2008; Yau et al., 2010). As a conse-
quence, the scrutiny of aCGH data needs special care and criticism. This fact justi-
fied the amplification/deletion of entire chromosomes attained in the present 
comparative study of the cell lines relative to their progenitor BEAS-2B cells. 
According to manufacturer’s instructions, the aCGH study of BEAS-2B cells 
was performed against a commercial control male genome. The control genome 
combines an average of the alterations found in the population, so it provides a 
standardized model against to which other male genomes can be compared. Fol-
lowing comparison to the control genome, BEAS-2B cells were shown to display a 
deletion at the q34 region of chromosome 7. Among the deleted genes was the 
ZC3HAV1, which encodes an antiretroviral protein. Although both SV40 and AD12 
are DNA viruses, we reasoned that the specific deletion of this intrachromosomal 
region may have favored BEAS-2B immortalization. 
The fact that the aCGH analysis was made against BEAS-2B cells, allowed 
the understanding of what alterations were introduced into the system by our 
manipulations. For example, the terminal deletions found in chromosomes 4 and 
16 could be ascribed to low-density culture as they appeared in at least Cont1 and 
RenG2 cells, but not in BEAS-2B. An overview of the genes located in these re-
gions, although identified genes that could have indirectly favored malignization, 
did not provide any real target for future dissection. Similarly, Cr(VI) also seemed 
to have had little GI-prone activity. In fact, contradicting the reports on the litera-
ture that described Cr(VI) as a highly mutagenic and genotoxic agent, the aCGH 
analysis only identified two small regions on chromosomes 10 and 21 that were 
amplified and deleted in RenG2 cells, respectively. The amplified region contained 
SORCS1 that encodes for a family member of Vacuolar protein sorting 10 (VPS10), 
highly expressed in the central nervous system and which had been associated 
with diabetes (Goodarzi et al., 2007), Alzheimer (Lane et al., 2013) and more re-
cently, renal disease (Lazar et al., 2013). Nonetheless, we were unable to find any 
link between SORCS1, VPS10 and cancer, so far. Regarding the deleted region on 
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chromosome 21, it contained only two genes, TPT2, which function is still un-
known, and B melanoma antigen (BAGE), a tumor antigen discovered by Boël and 
collaborators in human melanoma samples (Boël et al., 1995). Later on, the pro-
tein coded by this gene was also found in benign and malignant neoplasms of the 
salivary glands (Nagel et al., 2003) and in ovarian cancer samples (Zhang et al., 
2010). Although no relation was found between BAGE and either Cr(VI) and LC, it 
is rather surprising that this gene was shown to be deleted in RenG2 cells. 
RenG2 cells’ derivation in nude mice did not seem to have induced GI. In 
fact, the loss of entire chromosomes shown by aCGH for the cell lines is rather vir-
tual and reflected the normalization performed by the software analysis (Yau et 
al., 2010). This observation further supported the theory presented in Chapter 6, 
according to which increased ploidy and consequent variations in gene dosage 
levels are mediators of malignant transformation (Duesberg and Li, 2003; Nguyen 
and Ravid, 2006). Nonetheless, and in agreement with their higher malignant po-
tential, DDRenG2 cells did present some additional alterations, particularly in 
chromosome 6. Following analysis, the amplified regions in chromosome 6 re-
vealed to contain genes that were potentially involved in the increased malignancy 
of the system. Among others we managed to found CD83, commonly expressed in 
human neoplasias (Ananiev et al., 2011; Zhang et al., 2007); the seventh member 
of the TBC1 domain family (TBC1D7) gene, whose activation is associated with 
lung carcinogenesis (Sato et al., 2010); endothelin-1 (EDN1), whose involvement is 
cancer has been recently reviewed by Rosanò and colleagues (Rosanò et al., 2013); 
the transcription factor AP-2α (TFAP2A) gene that seems to collaborate with MYC 
on the regulation of cell cycle progression (Wong et al., 2012a) and the MYC target 
1 (MYCT1) gene that encodes the protein responsible for mediating many of MYC’s 
actions (Yin et al., 2002). 
Metabolic studies using 18FDG revealed that the glucose requirements of 
CSC systems were comparable to those of non-malignant BEAS-2B and Cont1 cells, 
and thus significantly lower than that of RenG2, DRenG2 and DDRenG2 cells. 
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When interpreting these results in light of those from MTT-based cell DTs study, it 
became evident that the modest glucose necessities of CSCs portrayed their qui-
escent status, as these cell populations have a considerably longer cell cycle. Qui-
escence as long been associated with CSCs (Blanpain, 2012; Visvader and 
Lindeman, 2008), and it actually partially justifies their increased resistance to 
therapy, particularly to the agents that depend upon the cell cycle progression to 
target cells (Gottschling et al., 2012). SC-DRenG2 and SC-DDRenG2 cells’ quies-
cence settlement was subsequently supported by RT-qPCR analysis showing 
underexpression of the Cyclin B gene (Figure 8.6), as well as by aCGH results re-
vealing the deletion of genes involved in mitochondria oxidative metabolism (Fig-
ure 8.7). In fact, a dysfunctional mitochondria respiratory chain would render cells 
more dependent upon glycolysis as energy source. As a consequence, HIF-1α 
would have to be expressed and its levels stabilized to conjugate with HIF-1β, to 
induce the expression of target genes like SLC2A1, GLUT3 and LDHA. Although 
aerobic respiration was not assessed, gene expression analysis of HIF-1α gene did 
not show its upregulation in the CSCs systems in comparison to the other malig-
nant cell lines (Figure 8.6). LDHA, however, showed a marked overexpression, par-
ticularly in SC-DDRenG2 cells, as did SLC2A1. 
The increase in the expression of the enzyme that catalyses the 
interconversion of pyruvate and lactate as been previously observed in bovine 
blastocyst development, and was correlated with the overexpression of SLC2A1 
but not HIF-1α (Harvey et al., 2007). Authors reasoned that the increased expres-
sion of these two genes depended upon HIF-2α-mediated response to oxygen 
concentration, sensed independently of HIF-1α (Harvey et al., 2007). Although this 
could have happened in DDRenG2 and SC-DDRenG2 systems, regarding the first 
derivative, only LDHA was shown to be overexpressed (Figure 8.6). In this case, the 
observed LDHA overexpression may have resulted from direct MYC stimulation, 
corroborating the observations of Dang’s laboratory (Shim et al., 1997). In fact, 
MYC is able to activate LDHA, driving pyruvate away from mitochondria towards 
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the production of lactate (Gordan et al., 2007). This process allows regenerating 
nicotinamide adenine dinucleotide (NAD+) from NADH, and provides a route for 
discarding the glucose-derived carbon molecules that are then extruded through 
lactate efflux, with the consequent lowering of the extracellular pH (Gordan et al., 
2007; Shim et al., 1997). Although further experiments will be needed to directly 
assess MYC and HIF-1β involvement in gene expression regulation of our systems, 
upregulation of MYC expression in both CSC systems, along with the amplification 
of HIF-2β gene identified by aCGH in SC-DDRenG2 cells strongly support our hy-
pothesis. 
The increased ability of both SC-DRenG2 and SC-DDRenG2 to survive ad-
verse growth conditions and methotrexate treatment further highlighted their 
CSCs signature. Furthermore, the very well established increased resistance of 
CSCs (Bertolini et al., 2009) laid the foundations of the theory of CSCs-driven tu-
mor relapse (Frank et al., 2010). More recently, Visvader and Lindeman further in-
troduced the concept of dormant CSCs, which seem to co-inhabit the tumors along 
with non-dormant CSCs, and are resistant to even targeted therapies (Visvader 
and Lindeman, 2012). This robustness of CSCs apparently relays on a very efficient 
activation of the DNA repair genes, as well as on the overexpression of drug efflux 
pumps like P-glycoprotein (Medema, 2013; Naujokata and Lauferc, 2013; Wilson 
et al., 2011a). However, whether other mechanisms are involved is still to be elu-
cidated. In the present study RenG2’s progeny showed a generalized 
underexpression of the DNA repair genes when cultured under normal conditions. 
This was not surprising, as they were kept under suitable conditions of nutrients 
and oxygen. Nonetheless, it would be interesting to assess the expression of those 
same genes following methotrexate treatment, and to evaluate the P-glycoprotein 
expression status. 
The results attained regarding MYC expression may seem rather controver-
sial. In fact, one would expect to find a progressively higher MYC overexpression 
along the malignant systems and not the opposite (Figure 8.6). However, Bártová’s 
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laboratory recently showed that the same colony of mouse embryonic SCs 
(mESCs) harbored cells with distinct levels of OCT4 and MYC, resultant from dif-
ferent ratios of mono- and bi-allelic gene expression controlled by epigenetic mod-
ifications (Sustáčková et al., 2012). Earlier on, Niwa and collaborators further 
demonstrated that mESCs’ pluripotency was dependent on a certain level of OCT4 
expression, and was lost whenever the gene was either up or downregulated 
(Niwa et al., 2000). Most probably, after a necessary initial boost to malignantly 
transform and derive BEAS-2B and RenG2 cells, respectively, MYC expression lev-
els were then reduced to the values required by the CSC systems’ to preserve a 
pluripotent phenotype. Furthermore, the group of Medema recently showed that 
WNT-pathway target genes are shown methylated in late stages of colon carcino-
genesis, after a period of sustained overexpression (de Sousa E Melo et al., 2011), 
suggesting that gene expression signature alone is not enough to infer on CSCs’ 
malignancy or even proportion inside tumors. 
Conversely to MYC, SPARC showed a strong tendency for upregulation as 
malignancy increased (Figure 8.6). This same observation, already reported by 
other laboratories, was associated to decreased intercellular attachment and an 
increased metastatic ability (Jiang et al., 2013; Neuzillet et al., 2013; Said et al., 
2013). The increased metastatic ability of the CSCs systems was also suggested by 
the aCGH results, as both TWIST2 and PTPN14 were equally amplified in the CSCs 
lines, and the SCR, NFATC1 and MMP9 were amplified solely in the more malig-
nant SC-DDRenG2 cells. As amply dissected in Chapter 1, in order to intravasate 
tumor cells must acquire the ability to move and to destroy ECM and the intercel-
lular connections. This capacity is acquired mainly by upregulating the expression 
of metalloproteinase genes, as shown in NSCLC (Safranek et al., 2009; Zheng et al., 
2010). As revealed by Long and collaborators, SRC protein seems to have a key 
role in the process, as it interacts with specific transcription factors driving MMP 
genes’ upregulation (Long et al., 2012). This observation may thus justify SRC ex-
pression found in nearly 60 % of all lung carcinomas (Mazurenko et al., 1992). 
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The involvement of NFAT genes in cancer has long been proposed. In 2006 
Yiu and Toker demonstrated that NFTA induces the upregulation of cyclooxygen-
ase-2 (COX-2) gene and the synthesis of prostaglandins’, driving breast cancer 
cells’ invasion (Yiu and Toker, 2006). More recently, Oikawa and collaborators 
showed that the increased metastatic potential induced by NFATC1 is mediated by 
TGF-β-independent upregulation of SNAIL and ZEB1, which subsequently 
downregulate E-cadherin, thus favoring EMT and a migratory phenotype (Oikawa 
et al., 2013).  Additionally, AURKA and AURKB were also shown to be amplified in 
SC-DDRenG2 cells.  According to Ice and colleagues, AURKA is overexpressed in 96 
% of human cancers and is considered an independent marker of poor prognosis 
(Ice et al., 2013). Very recently, both these genes have been shown to be activated 
by C-Abl Oncogene 1, Non-Receptor Tyrosine Kinase (BCR-ABL) in leukemic cells 
(Yang et al., 2013), a gene from a 9q chromosome region that was amplified in 
both SC-DRenG2 and SC-DDRenG2 cells (Figure 8.7). In tumor cells AURK genes 
have already been associated with cell cycle alterations (Zhu et al., 2005), therapy 
resistance (Agnese et al., 2007), EMT and enhanced migration (Wan et al., 2008). 
Furthermore, Liu’s group discovered that the increased metastatic ability of cells 
overexpressing AURKA relayed on MAPK downregulation (Wan et al., 2008). Taken 
together, these observations further support the higher malignant potential of SC-
DDRenG2 cells’, as they harbor both amplified AURKA and downregulated MAPK1. 
Finally, the groups of Scagliotti and Wang verified that particularly AURKA expres-
sion was associated with lung cancer histopathological classification, and more 
importantly with tumor dedifferentiation (Lo Iacono et al., 2011; Xu et al., 2006). 
In fact, both laboratories observed that AURKA amplification was associated with 
highly aggressive tumors that carry cells with less differentiated phenotypes. 
Once confirmed the stem nature of SC-DRenG2 and SC-DDRenG2 isolated 
from DRenG2 and DDRenG2, respectively, it became unquestionable that a dedif-
ferentiation process featured CSCs formation inside RenG2 cells while they were in 
the mouse lumbar subcutaneous compartment. This hypothesis was further sus-
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tained by the progressive increment in CSCs sub-populations found along the de-
rivative systems (DRenG2 and DDRenG2) (Figure 7.8, Chapter 7). Co-culture stud-
ies provided the final confirmation of this hypothesis, as iRenG2 cells, generated 
following co-culture of RenG2 with mouse stromal fibroblasts, portrayed the abil-
ity to form spheres when cultured in restraining conditions. Subsequent RT-qPCR 
and flow cytometry studies revealed that iRenG2 cells’ signature, unlike their pro-
genitor RenG2, was more similar to both DRenG2 and SC-DRenG2 signatures (Fig-
ures 8.8 and 8.9). 
The multiplex array and ELISA experiments ultimately identified the drivers 
of RenG2 cells’ dedifferentiation as being IL-6, G-CSF and Activin-A (Figures 8.10 
and 8.11). The involvement of IL-6 in CSCs’ formation have been previously sug-
gested by the works of Levina and colleagues, who showed that CSC-derived tu-
mors have increased levels this cytokine (Levina et al., 2008). The group of Struhl 
further sustained these suspicions by showing that IL-6 is sufficient to convert 
non-CSCs to CSCs in genetically different breast and prostate cell lines, and 
demonstrating that tumor heterogeneity involves an IL-6-mediated dynamic equi-
librium between CSCs and non-CSCs (Iliopoulos et al., 2011). More recently, Xie 
and collaborators observed that EMT was involved in IL-6 driven CSCs’ formation 
in breast cancer (Xie et al., 2012), while Kao’s laboratory proved that IL-6-treated 
BEAS-2B cells displayed increased motility due to the activation of the AKT-
pathway (Wang et al., 2012). Very recently, Kim and colleagues showed that 
breast cancer cells’ dedifferentiation yielding CSCs relays on the activation of the 
IL-6-JAK1-STAT3-OCT-4 pathway (Kim et al., 2013b). 
IL-6 is a pleiotropic cytokine produced by a myriad of cells with important 
roles in inflammatory response-based host defense (Kishimoto, 2010). It acts 
through its receptor (IL6R) activating JAK and subsequently STAT. STAT3, in partic-
ular, was shown to mediate the expression of various important genes in the con-
text of cancer, namely OCT-4, TWIST, SNAIL, VEGF and MMP-9 (Kim et al., 2013b). 
In addition, IL-6 was also shown to activate PI3K, NFKB and MAPKs pathways (Kim 
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et al., 2013b; Lee et al., 2007). It is thus very plausible to admit the role of IL-6 in 
RenG2 cells’ dedifferentiation, probably assisted by the amplification of MMP-9, 
SNAI3, PRKCZ, PLEKHG5 and TWIST2 genes revealed by aCGH study of the CSC sys-
tems (Figure 8.7). 
Regarding G-CSF, it is considered a hematopoietic growth factor with im-
portant roles in neutrophils’ differentiation (Baumann et al., 2005) and in response 
against bacterial infections (Nguyen-Jackson et al., 2010). Like IL-6, it is produced 
by a wide range of cells, including fibroblats, and is commonly present in tumors’ 
stroma (Mueller and Fusenig, 2004). G-CSF was revealed to stimulate tumor angi-
ogenesis (Shojaei et al., 2009) and, along with GM-CSF, to promote the malignant 
growth of some carcinomas (Gutschalk et al., 2006). Nonetheless, and perhaps 
more important in light of the attained results, IL-6 and G-CSF apparently work to-
gether on controlling the angiogenic potential of bone marrow resident mono-
cytes. In agreement, Gregory and collaborators showed that tissue ischemia in-
duced an increase of the systemic levels of both IL-6 and G-CSF (Gregory et al., 
2010). As a consequence, these cytokines act over BM monocytes inducing their 
differentiation towards a TAM phenotype by stimulating the STAT3 pathway 
(Gregory et al., 2010; Yan et al., 2013). As presented in Chapter 1, hypoxia charac-
terizes the majority of the tumors and represents one of body’s great defenses 
against cancer (Denko, 2008). Tumor cells respond to hypoxia by releasing into cir-
culation high levels of chemical mediators that will act over the endothelium and 
the BM to activate angiogenesis (Semenza, 2010). It is thus very likely that tumors 
also hijack this normal IL-6 and G-CSF-based physiological response to hypoxia to 
promote the angiogenic switch.  
When cultured under the restraining sphere-forming assay condition, both 
the derivative cells underwent oxygen deprivation mainly as a consequence of the 
tridimensional sphere-form growth. It is plausible that G-CSF and IL-6 had been 
produced as a consequence of the hypoxic environment, ending up driving cells’ 
dedifferentiation. Supporting this hypothesis, a group of the Baylor College of 
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Medicine showed that pancreatic cancer cells release high amounts of both IL-6 
and G-CSF to their cell culture medium. Culture of CD4+ monocytes in pancreatic 
cell-conditioned medium abrogated their differentiation into dendritic cells, thus 
favoring an undifferentiated phenotype (Bharadwaj et al., 2007). 
Activin-A was identified as a mediator of RenG2 cells´ dedifferentiation. 
This TGF-β superfamily member acts in various biological processes ranging from 
cellular proliferation to differentiation and survival (Massague and Wotton, 2000). 
Its actions are mediated by the activin receptors I and II, each of which with two 
different isoforms. These receptors activate the SMAD2/SMAD3 intracellular com-
plex, allowing its translocation into the nucleus and the activation of target genes 
(Tsuchida et al., 2009). With the discovery of SCs and iPS cells, new cell culture 
techniques were developed to maintain the stem potential of cells in culture. In 
the meantime, Beattie and colleagues discovered that Activin-A, abundantly se-
creted by fibroblasts feeder layers, had a potent stem-promoting action over hu-
man embryonic stem cells (hESCs) co-cultured with fibroblasts (Beattie et al., 
2005). The same authors observed that supplementation of culture medium with 
Activin-A would avoid the need of a feeder layer on hESCs’ culture. Rather simul-
taneously, the group of Pedersen showed that FGF pathway acts synergistically 
with Activin-A in mediating hESCs stemness under culture (Vallier et al., 2005). In 
pancreatic CSCs the upregulation of Activin-A pathway prompted CSCs’ asymmet-
ric division, thus contributing to their stem and increased malignant potential 
(Lonardo et al., 2011). Nonetheless, because the available literature reports pro-
vide antagonistic results, the role of this cytokine in tumor progression is still quite 
misunderstood. In fact, Activin-A has already been presented as a tumor suppres-
sor and tumor promoting protein (reviewed by Antsiferova and Werner, 2012), 
and its function in tumor inflammation is rather controversial: while Zipori’s labor-
atory observed that Activin-A actually antagonizes IL-6 pro-inflammatory actions 
(Zauberman et al., 2001), Jones and collaborators presented it as essential in tu-
mor-promoting inflammatory responses (Jones et al., 2007). More recently, Hedg-
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er and collaborators tried to meet consensus by proposing that Activin-A may be 
necessary to initiate inflammatory responses, but becomes dispensable during 
sustained inflammation (Hedger et al., 2011). Apart controversies, a strong corre-
lation between increased systemic Activin-A levels and metastasis formation was 
reported in prostate and breast cancer patients (Incorvaia et al., 2007; Leto et al., 
2006). Finally, previous work from Taketani’s laboratory showed that some com-
mon tumor cytokines were able to mediate Activin-A overexpression in tumor 
cells, which in turn promoted IL-6 overexpression (Yoshino et al., 2011). As to G-
CSF, no correlation was found between that cytokine and Activin-A. 
The present results on the involvement of Activin-A in RenG2 cells’ dedif-
ferentiation, along with findings of Heeschen’s and Taketani’s groups, support a 
crucial role for Activin-A in cancer progression (Lonardo et al., 2011, Yoshino et al., 
2011). Moreover, ELAC2 amplification, a mediator of SMAD2 protein in Activin-A 
pathway (Noda et al., 2006), further consolidated the idea of a central role of this 
cytokine in RenG2 cells’ dedifferentiation. Apparently, the Activin-A and IL-6 in-
creased levels in the FR-RenG2 co-cultured cells were not arbitrary but rather a 
cause-consequence event. 
8.4 Conclusion 
The integrative strategy employed to characterize the SC-DRenG2 and SC-
DDRenG2 systems yield a myriad of results that together provided clues on their 
formation and ultimately on the role played by Cr(VI) in the overall process. It is, 
to the best of our knowledge, the first time that increased Activin-A levels were 
associated with CSCs’ formation, most particularly in lung cancer. Moreover, it 
now seems that Activin-A combined with IL-6 and G-CSF strongly shielded RenG2 
cells from the attack of the aggressive mouse subcutaneous compartment envi-
ronment. Acting cooperatively, these cytokines drove RenG2 cells’ dedifferentia-
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tion and rendered the resultant derivative systems considerably more resistant to 
hypoxia, starvation and death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note 
The results presented in this chapter are part of a manuscript in preparation: 
Rodrigues, CFD, Val, M, Rodrigues IP, Fonseca, J, Gomes CMF, Abrunhosa, AJ, Paiva, A, Carvalho, L, 
Botelho, MF, Carreira, IM and Alpoim, MC. Stromal cells-released IL-6, G-CSF and Activin-A induce 
dedifferentiation of lung carcinoma cells into cancer stem cells. 
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Chapter 9  
Final Integration                                
and Concluding Remarks 
Even though chromium carcinogenesis is a very active field of research, no major 
steps have been taken in the recent years towards having an effective medical protocol 
to approach Cr(VI)-induced LC patients. In fact, despite the numerous reports in the lit-
erature indicating the fundamentally different genetic and pathophysiologic nature of 
chromate tumors, these neoplasias keep on being treated exactly the same way as to-
bacco or other carcinogen-induced LC. 
Clinical advances relay on scientific knowledge generation and that, in turn, de-
pends on the use of adequate laboratory disease models. As the rudimentary clinical 
approaches used in the treatment of chromate LC result from the inexistence of a relia-
ble model for the study of such neoplasias, and consequently, from a bad bench-bedside 
correlation of the results attained in vitro, this project focused on developing a disease 
model. It was decided to depart from the immortalized normal human bronchial epithe-
lial BEAS-2B cell line, as it better suited the present study, and to simply expose the cells 
to the sub-cytotoxic concentration of 1.0 µM Cr(VI). Nevertheless, as shown by Xie and 
collaborators, the Cr(VI)/cell ratio greatly limits Cr(VI)-uptake by the cells, which in turn 
modulates the carcinogenic actions of the oxyanion (Xie et al., 2004). As a consequence, 
it became evident that BEAS-2B would not be malignantly transformed by the first pro-
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tocol we used, and therefore, a new low-density culture protocol was developed. Under 
these conditions, BEAS-2B cells’ morphology deeply changed towards a malignant phe-
notype, being accompanied by the adoption of an expressome characteristic of malig-
nant cells. 
Against the observations of Zhitkovich’s laboratory, Cr(VI)-driven BEAS-2B 
malignization did not involve MMR system inactivation nor MSI development (Reynolds 
et al., 2009). On contrary, BEAS-2B cells answered to the presence of Cr(VI) by overex-
pressing the genes coding for proteins of the DNA repair systems, thus indicating that 
the mutagenic effects of the oxyanion were at least approached by cellular repair ma-
chinery. Nonetheless, the near tetraploid karyotype of RenG2 cells suggested that cells 
may have taken too much time in repairing DNA lesions during S-phase, thus leading to 
cell division abrogation and formation of tetraploid cells carrying duplicated centro-
somes. Most likely, the subsequent division of these cells drove the formation of the 
RenG2 cellular system, closely mimicking the results attained by Wise’s group (Holmes 
et al., 2006). Preliminary immunocytochemistry results using a pericentrin Ab appear to 
validate this hypothesis, even though more studies are needed to assess centrosomes’ 
role in BEAS-2B cells’ malignization. 
Tumorigenicity assays performed using RenG2 cells indicated that this cell line, 
though tumorigenic, was only mildly malignant. Following serial rounds of injection in 
athymic nude mice the derivative DRenG2 and DDRenG2 systems were attained. It was 
our rational that, by increasing RenG2 cells’ malignant potential, Cr(VI) features imprint-
ed in the cells would be exacerbated and thus better suitable for analysis. In fact, the 
derivation process per si promptly revealed the boosted malignant potential of the ma-
lignant systems as cells needed progressively less time to form tumors. Subsequently, 
the combination of assays selected in this project provided a group of results that alto-
gether suggested the involvement of CSCs in BEAS-2B malignant transformation 
(Gottschling et al., 2012; Medema, 2013). Especially relevant were the glucose uptake 
studies performed using 18FDG, which unveiled the lower glucose requirements of the 
more malignant derivative cell lines. Equally important were the drug resistance and the 
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migration assays that postulated the boosted resistance and migration ability of the 
newly attained cellular systems in comparison to RenG2 and the non-malignant BEAS-2B 
and Cont1 cell lines. The ultimate confirmation of CSCs’ involvement was provided by 
the sphere-forming assay that showed that only the derivative systems (DRenG2 and 
DDRenG2) had the ability to form spheres under growth restraining conditions, particu-
larly the DDRenG2 cell line. Moreover, these results also implied that a dedifferentiation 
process was involved in the formation of a CSC sub-population within the RenG2 system, 
although they provided no hint about the mechanisms or the orchestrators of this pro-
cess. 
After revisiting RenG2’s formation protocol, it became evident that the dediffer-
entiation of RenG2 cells could only have occurred in the mice subcutaneous lumbar 
compartment, as it was the last place where RenG2 cells have been before giving rise to 
the DRenG2 cellular system. To validate this hypothesis a mouse lumbar fibroblasts’ 
primary FR cell line was produced and co-culture experiments involving RenG2 and FR 
cells were performed using Transwell® devices. Once again, the sphere forming assay 
provided the final confirmation of FR-driven RenG2 cells’ dedifferentiation, since this 
mildly malignant cellular population acquired the ability to form spheres following co-
culture with FR cells.  
Finally, beyond all experiments made to prove the similarities between iRenG2 
cells and the DRenG2 and SC-DRenG2 cellular systems, the main efforts aimed at identi-
fying the molecular orchestrators of the dedifferentiation process. As the protocol cho-
sen to co-culture RenG2 and FR cells prevented physical contact between the two cellu-
lar populations, these orchestrators had to be paracrine soluble factors released by FR 
cells cultured in the bottom compartment. As paracrine communications are a potent 
weapon commonly hijacked by tumor cells to modulate their microenvironment, it was 
no surprise that such a mechanism was involved in RenG2 cells’ dedifferentiation. The 
subsequent search for the guilty used sensitive molecular biology techniques and identi-
fied the IL-6, G-CSF and Activin-A cytokines as the molecular orchestrators of CSCs’ for-
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mation inside the RenG2 system. Mechanistically, literature hints suggest that IL-6 and 
Activin-A may have worked together to boost the survival of RenG2 cells’ while they 
were inside the mice subcutaneous compartment, accidentally driving the activation of 
the IL-6-JAK1-STAT3-OCT-4 pathway, and consequently, their dedifferentiation (Kim et 
al., 2013b). 
Altogether, the integrative strategy used in this process succeeded in attaining 
most of the initially established goals, namely: 
 
- A new platform specifically tailored to examine the mechanisms underlying 
Cr(VI)-induced LC was produced; 
 
- It became evident that the malignant transformation process triggered by low 
concentrations of soluble Cr(VI) rather involve the selection of Cr(VI)-resistant 
variants than the induction of DNA mutations; 
 
- A dedifferentiation process leading to CSCs’ formation was involved in the in vi-
vo progression towards a more malignant phenotype of the first                       
Cr(VI)-induced malignant system; 
 
- The central role of the microenvironment in tumor biology was reinforced;   
 
-  IL-6 and Activin-A were identified as paracrine mediators of CSCs’ formation, 
corroborating the observations made by other groups; 
 
- G-CSF was implicated for the first time in the formation and maintenance of a 
CSC population; 
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- The dedifferentiation process was essentially chemical and specie-unspecific, as 
human cells can respond to mice cells-released molecules. 
 
In conclusion, our results indicated that Cr(VI)-induced lung carcinogenesis is a very 
complex process that involves the activation of different cellular pathways and eventual-
ly the formation of CSCs. Unlike other neoplasias, ploidy unbalances rather than muta-
tions seem to drive the transformation process, at least when low concentrations of 
chromium are used. Finally, the microenvironment plays a pivotal role in the overall 
process, acting like a maestro in mediating intercellular communications. 
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Chapter 10  
Future Perspectives 
The use of high throughput screenings for the analysis of biological samples 
usually provides an arsenal of information that more than delivering answers, opens 
new and numerous avenues of research. In fact, although a reliable model for the 
study of Cr(VI)-lung carcinogenesis has been established, it still has some edges that 
need to be polished. To that end, it would be very interesting to: 
 
- Complete the characterization of the CSCs systems. Assess the presence of 
common CSCs markers of LC in SC-DRenG2 and SC-DDRenG2 cell lines, for in-
stance CD133 and ALDH. In case they are not found, investigate new markers 
that may characterize Cr(VI)-induced malignant transformation. Evaluate the 
tumorigenic potential of all the cellular systems. 
 
- Scrutinize the IL-6, G-CSF and Activin-A involvement in CSCs’ formation. Dis-
sect the IL-6-JAK1-STAT3-OCT-4 and Nodal-Activin pathways, and others that 
may seem relevant in CSCs’ biology, perhaps by using iRNA technology to si-
lence some of their  key-players;  
 
- Study the therapy-resistant cells. Preliminary observations made in our labo-
ratory indicate that the cells that survived drug treatment have a boosted stem 
phenotype. Moreover, RenG2 cells appear to have acquired sphere-forming 
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ability following methotrexate treatment. Understanding the mechanisms of 
therapy resistance will most probably result in the design of a therapeutic ap-
proach for Cr(VI)-induced lung neoplasias; 
 
- Deepen the analysis of aCGH results. Assess the role of some of the affected 
genes and understand how their deletion/amplification affected CSCs’ dediffer-
entiation and the overall transformation process; 
-  Assess the metastatic potential of our entire repertoire of cellular systems. 
Confirm the hints provided by the many of the attaining results suggesting that 
the derivative systems are endowed with a higher migratory ability; 
 
- Investigate the involvement of epigenetic events in BEAS-2B’s malignization. 
According to the literature, epigenetic modulation of gene expression is an al-
ternative avenue to attain malignant transformation. Considering that the 
Cr(VI) used in this study only induced a couple of chromosome alterations, it is 
plausible to admit that the epigenetic machinery may have contributed to the 
Cr(VI)-driven malignization process; 
 
 Finally, considering some promissory results attained using primary human 
bronchial fibroblats, it would be very interesting to reproduce at least parts of this pro-
ject with a non-immortalized human bronchial epithelial system. Through this ap-
proach the distance between bench and bedside would be diminished and eventually 
patients’ welfare would be ameliorated. 
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Solutions’ Preparation 
2.5 mM K2Cr2O7 stock solution 
This stock solution was prepared by dissolving 73,5 mg of K2Cr2O7 in 100 ml of 
milli-Q water. Syringe filtration was subsequently used to guarantee the steriliza-
tion of the solution. 
 
2 % BSA solution 
This solution was prepared by diluting 2 g of BSA in 100 ml of milli-Q water 
under mild agitation. Syringe filtration was subsequently used to guarantee the 
sterilization of the solution. 
 
Progesterone solution 
Dissolve 0.003 g of progesterone in 1 ml of water in order to prepare an initial 
stock solution of 10 mM. The final 10 mM solution used in cell culture medium’s 
preparation is made by mixing 100 µl of the stock solution with 900 µl of water. 
 
2 % methylcellulose solution 
To prepare 300 ml of a 2 % methylcellulose solution pre-heat 100 ml of water 
until it reaches the final temperature of 80 ºC, always keeping a mild stirring. Then 
dissolve 6 g of methylcellulose on the warm water and wait until the cellulose par-
ticles are dispersed to add the remaining 200 ml of water. This turn the water 
should has been previously cold until 4 ºC. The temperature of the solution should 
be brought to around 4 ºC, which is aided by placing the solution cup into ice. Af-
ter reaching the desired temperature, agitation should be kept for approximately 
20 min in order to ensure complete dissolution of the methylcellulose particles. 
Sterilization is attained by conventional autoclaving. 
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RT-qPCR primers’ information 
Table III - RT-qPCR primers’ information. 
Gene Primer Catalogue number 
GAPDH_2_SG QT 01192646 
TOP1_1_SG QT 00068915 
CCNB1_1_SG QT 00006615 
LDHA_1_SG QT 00001687 
HIF1α_1_SG QT 00083664 
SLC2A1_1_SG QT 00068957 
MYC_1_SG QT 00035406 
SPARC_1_SG QT 00018620 
EGFR_1_SG QT 00085701 
MAPK14_1_SG QT 00079345 
MAP2K4_1_SG QT 00082530 
MAPK1_1_SG QT 00065933 
XRCC1_1_SG QT 00016688 
XRCC3_1_SG QT 00095921 
XRCC5_1_SG QT 00052731 
RAD51_1_SG QT 00072688 
MSH2_1_SG QT 00032466 
CAV1_1_SG QT 00012607 
DNMT1_1_SG QT 00034335 
MLH1_1_SG QT 00028833 
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a b s t r a c t
Hexavalent chromium [Cr(VI)] is a well-recognized human lung carcinogen. In order to gain further insight
into Cr(VI)-induced carcinogenesis, we have established an adequate in vitro cellular model for the study
of this process. To this end, BEAS-2B cells were used. Chronic exposure of cells to 1M Cr(VI) induced
changes in the cells’ ploidy and a decrease in cloning efficiency, although cultures continued to progress to
confluence. After prolonged exposure (12 passages), the culture became heterogeneous, exhibiting areas
where apparently normal epithelial cells and morphologically altered cells coexisted. Subsequent culture
at a very low density strongly accentuated the Cr(VI)-induced changes in morphology and pattern of
growth. Three individual colonies were then ring-cloned and expanded into three subclonal aneuploid cell
lines. These subclonal cell lines showed changes in growth pattern and morphology, as well as a karyotype
drift concomitant with the overexpression of genes commonly involved in malignant transformation (c-alignant transformation
icrosatellite instability
ismatch repair system
MYC, EGFR, HIF-1 and LDH-A). Moreover, when one of these cell lines (RenG2) was injected into nude
mice, it showed the ability to induce tumors. This cell line revealed no microsatellite instability (MSI),
which points to the expression of a functional MLH1 protein and an active mismatch repair (MMR) system.
Therefore, the progression to malignancy of the BEAS-2B cells involved Cr(VI)-induced transformants that
retained the ability to repair DNA damage, suggesting that genotoxicity underlies the ongoing carcinogenic
process.
. Introduction
Epidemiologic studies revealed that there is a direct relation-
hip between chronic exposure to Cr(VI) compounds (chromates)
nd lung cancer development [1]. Occupational exposure to Cr(VI)
ffects several million workers worldwide and non-occupational
xposures to particulate chromates are increasing, due to industrial
aste disposal, concrete pavement and fuel combustion, among
ther uses of Cr(VI). Important studies on Cr(VI) biochemistry
evealed that the chromate structural affinity to sulphate and phos-
∗ Corresponding author at: Departamento de Bioquímica, Faculdade de Ciências e
ecnologia, Universidade de Coimbra, Apartado 3126, 3001-401 Coimbra, Portugal.
el.: +351 239853603; fax: +351 239853607.
E-mail address: mcalpoim@gmail.com (M.C. Alpoim).
027-5107/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
oi:10.1016/j.mrfmmm.2009.07.004© 2009 Elsevier B.V. All rights reserved.
phate allows its quick movement across the cell membrane [2].
Once inside the cells, Cr(VI) is rapidly reduced to Cr(III) through
mechanisms dependent on the reducing conditions [3,4]. Binary
and ternary Cr(III)–DNA adducts were the most important DNA
lesions detected in in vitro experiments [3]. Other forms of Cr(VI)-
induced DNA damage include Cr(III)–DNA–protein crosslinks, DNA
interstrand crosslinks, as well as DNA–protein crosslinks (DPCs) [2],
which apparently represent the major obstacle for the replication
and transcription processes [5]. In cellular systems, Cr(VI)-induced
DNA lesions can easily generate not only single-strand breaks, but
also the very mutagenic double-strand breaks, due to an abnor-
mal procession of primary lesions by DNA repair systems, such as
nucleotide excision repair (NER) and the methyl directed mismatch
repair (MMR) [4], genome-surveillance systems that maintain the
genomic integrity of mammalian organisms [6]. Accumulation of
unrepaired double-strand breaks usually leads to apoptosis, while
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heir abnormal processing by the non-homologous end joining
ystem (NHEJ) generates chromosome rearrangements and thus
enomic instability [7]. Cr(VI)-induced genomic instability can also
esult from uncoupling of centrosome duplication from the cell
ycle, as a consequence of prolonged arrest at either S or G2 phases
o repair double-strand breaks [8].
As revealed by post-mortem studies, the squamous lung can-
er induced by inhalation of Cr(VI) compounds is different from
he lung cancer induced by cigarette smoke and asbestos [9–11]. In
act, in contrast to other squamous lung carcinomas, Cr(VI)-induced
ung cancer exhibits MSI, loss of expression of MLH1, aberrant
ethylation of p16INK4 and low incidence of p53 mutations [9–11].
urthermore, whenever p53 appeared mutated, it was found that
t presented an unusual mutation pattern [9].
Recently, following the observation that MMR-deficient cells
ere highly tolerant to Cr(VI), another path has been evoked as
he major pathway leading to Cr(VI)-induced lung cancers [4].
ccording to the proposal, chronic exposure to toxic doses of Cr(VI)
ay result in the selective outgrowth of MMR-deficient cells. Since
MR-deficient cells exhibit very high rates of spontaneous muta-
enesis [12] and impaired MMR can give rise to malignancies
xhibiting MSI [13], this model can account for the lack of expres-
ion of MLH1, a key protein of the MMR system, and the high
ncidence of MSI found in chromate lung cancers [9,10,14].
In spite of relevant studies on Cr(VI)-induced lung carcinogen-
sis that yielded important information on this subject (see, for
nstance, references [15–17]), it must be noted that very few utilized
pithelial lung cells, the main targets of Cr(VI) carcinogenicity, and
hat, to the best of our knowledge, none of them involved continu-
us, long-term exposure to this carcinogen. Ideally, one should use
rimary cultures. However, the short lifespan of these cultures is not
ompatible with prolonged exposures to sub-lethal Cr(VI)-doses.
or this reason the option for the BEAS-2B cell line (SV40 immor-
alized) [18] used in the present study to evaluate: (i) if the in vivo
rocess of malignancy induced by chronic exposure to Cr(VI) could
e mimicked in vitro; (ii) if the malignant transformation induced
y Cr(VI) exposure was due to a process of selection of MMR-
eficient, Cr(VI)-resistant and genetically unstable populations; (iii)
f MSI was involved on Cr(VI)-induced malignant transformation;
iv) if this process of malignant transformation involved changes in
he expression of genes commonly associated with carcinogenesis,
amely, c-MYC [19], HIF-1 [20], LDH-A [21], EGFR [22], DNMT1 [23],
he cyclins CCND1 and CCNB1 [24], the MaP kinases JNK, ERK and
38 [2,25], and the proteins involved in DNA repair MLH1, RAD51,
RCC5, XRCC1, XRCC3 and OGG1 [8,10,26,27]. Our study revealed
hat it is possible to induce in vitro the malignant transformation of
ronchial epithelial cells by Cr(VI), and that this process was accom-
lished by a large karyotype drift and the overexpression of all genes
nder scrutiny, including MLH1. In spite of the extensive genomic
nstability induced by Cr(VI), the absence of MSI clearly showed that
he progression to malignancy of the BEAS-2B cells did not involve
he selection of MLH1-deficient cells.
. Materials and methods
.1. Cells and cell culture
BEAS-2B cells were obtained from the European Collection of Animal Cell Cul-
ures (Salisbury, UK; ECCAC no. 95102433). Cells, grown as adherent monolayers,
ere maintained in Clonetics® BEGM medium supplemented with bovine insulin,
ovine pituitary extract, epinephrine, human epidermal growth factor, hydrocorti-
one, retinoic acid, triiodothyronine, transferrin and the antibiotics amphotericin-B
ulphate and gentamicin (Lonza, Barcelona, Spain) at 37 ◦C in a 95% air/5% CO2 incu-
ator. Vented culture flasks (Corning, Lowell, MA) were covered with a solution of
ype-B gelatin from bovine skin (Sigma–Aldrich, Sintra, Portugal) 2 h before use.
xcept otherwise stated, cells were seeded at an initial density of 4 × 103 cells/cm2
nd sub-cultured with a 0.25% trypsin–1 mM EDTA solution (Sigma–Aldrich, Sintra,
ortugal) when cultures reached 80% confluence. Continuous cultivation in the pres-
nce of 1.0M Cr(VI) started at passage (#) 4. Cr(VI) was added as a 50M potassiumesearch 670 (2009) 42–52 43
dichromate aqueous solution, which was filter sterilized before use. Control cultures,
grown in the absence of Cr(VI), were maintained in parallel.
2.2. Clonogenic assays
Cr(VI)-exposed cells from different passages were seeded onto 100 mm Petri
dishes (Corning, Lowell, MA) at a cell density of 13 cells/cm2. Cultures were
then allowed to grow for 10 days both in the absence and in the presence of
1M Cr(VI). Control cells were subjected to the same treatment, except that
Cr(VI) was always absent from the medium. Surviving colonies (containing more
than 10 cells) were scored to assess cloning efficiency. Dense clumps, present
in Cr(VI)-treated cultures, were also scored. Cells from these clumps exhibited
clearly altered morphologies. Clonogenic experiments were repeated at least three
times.
2.3. Generation of subclonal cell lines
For the generation of subclonal cell lines, several dense clumps obtained when
passage 12 cultures were submitted to the clonogenic assay in the presence of Cr(VI)
were isolated, using glass cloning rings (Sigma–Aldrich, Sintra, Portugal), reseeded
onto 150 mm Petri dishes (Corning, Lowell, MA) and cultured again in the presence
of 1M Cr(VI). Ten days later, three morphologically altered colonies were isolated
and transferred into 3 different wells of a 6-well plate (Corning, Lowell, MA). When
cultures reached near 80% confluence, cells were trypsinized and reseeded onto
25 cm2 culture flasks (Corning, Lowell, MA), again in the presence of 1M Cr(VI). In
the case of control cultures, where no dense clumps formed during the clonogenic
assays, the cloning rings were used to isolate randomly chosen colonies. The cells
thus isolated were subjected to the same treatment as the Cr(VI)-treated cells, except
that Cr(VI) was always absent from the medium. All subclonal cell lines obtained
were maintained as previously described.
2.4. Cytogenetic analysis
For cytogenetic analysis, cells were cultivated in 75 cm2 flasks and allowed to
reach approximately 75% confluence. The preparation of metaphase chromosomes
was carried out according to standard procedures optimized to our cultures [28].
Metaphase spreads were GTG-banded and, for each passage, at least 30
metaphases were analyzed and 15 karyotypes constructed using a Nikon microscope
(Nikon Portugal, Lisbon, Portugal) coupled with Applied Imaging® CytoVision® soft-
ware (Genetix, New Milton, UK).
2.5. Gene expression analysis
For RNA isolation, 1 × 106 cells were initially collected in RNAlater® RNA Sta-
bilization Reagent (Qiagen, Madrid, Spain) and stored at −20 ◦C. RNA isolation was
then carried out using the RNeasy® Mini Kit (Qiagen, Madrid, Spain), which allows
for the isolation of total RNA from animal cells. To quantify the RNA extracted and
verify its integrity, samples were analyzed using the RNA 6000 Nano Chip® Kit in
an Agilent 2100 Bioanalyzer with the 2100 Expert Software (Agilent Technologies,
Böblingen, Germany), according to the manufacturer’s instructions.
One microgram of total RNA was reverse transcribed using the SuperScriptTM III
First-Strand Synthesis System for RT-PCR (Invitrogen, Barcelona, Spain). The reac-
tions were carried out in a GeneAmp PCR System 9600 Thermal Cycler (PerkinElmer,
Waltham, MA). Reaction products were digested with 1l RNase H and finally eluted
with 30l Rnase-free water and stored at −20 ◦C.
Relative quantification of gene expression by Real-Time PCR was performed in
a 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). For
normalization purposes, optimal housekeeping genes for this study were selected
using the geNormTM Housekeeping Gene Selection Kit (PrimerDesign, Southampton,
UK) and the geNormTM software (Ghent University Hospital, Ghent, Belgium). Real-
time PCR reactions used QuantiTect® Primer Assays (Qiagen, Madrid, Spain) for each
of the different genes. Real-time PCR reactions were carried using 100 ng of cDNA
sample, 1× QuantiTect® Primer Assay and 1× QuantiTect® SYBR Green PCR Master
Mix (Qiagen, Madrid, Spain), in a total volume of 50l, using the following thermal
profile: 15 min at 95 ◦C (PCR initial activation step) and 40 cycles of 15 s at 94 ◦C,
30 s at 55 ◦C and 30 s at 72 ◦C. Real-time PCR results were analyzed with the SDS
2.1 Software (Applied Biosystems, Foster City, CA) and quantified using the 2−Ct
method [29].
2.6. Microsatellite analysis
Five mononucleotide repeats (NR-21, NR-24, NR-27, BAT-25 and BAT-26) were
amplified in a pentaplex PCR reaction using a Biometra T3 Thermocycler (Göttin-
gen, Germany). Primer sequences were as previously described [30]. All the reverse
primers (Thermo Scientific, Ulm, Germany) were 5′-labelled with a fluorescent tag –
HEX for markers NR-24, NR-27 and BAT-26, and 6-FAM for markers NR-21 and BAT-
25 – to allow for microsatellite detection using an Applied Biosystems 3730XL DNA
Analyzer (Applied Biosystems, Foster City, CA). The PCR reaction was carried out in a
total volume of 25l that contained 1× GoTaq® Flexi Buffer (Promega, Madison, WI),
0.2 mM dNTPs, 2.5 mM MgCl2, 8 pmol of primers NR-21, NR-24 and NR-27, 10 pmol of
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Fig. 1. Effect of Cr(VI) on the morphology and growth pattern of BEAS-2B cells. (A) Representative image of BEAS-2B cultures that were cultivated for 8 passages in the
p trol cu
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Sresence of 1M Cr(VI). (B) As (A), but with cells grown in the absence of Cr(VI) (con
epresented in (A) were cultivated at very low density (13 cells/cm2) in the presence
epresented in (B) were cultivated at very low density (13 cells/cm2) in the absenc
mage of a control subclonal culture.
rimer BAT-25, 12 pmol of primer BAT-26, 0.75 U of GoTaq® Flexi A DNA Polymerase
Promega, Madison, WI) and 5l of genomic DNA. Genomic DNA was extracted
rom the cells with the Puregene® DNA Isolation Kit (Gentra Systems, Minneapolis,
N), according to the manufacturer’s instructions. After an initial denaturation at
5 ◦C for 5 min, PCR steps were as follows: 35 cycles of denaturation at 94 ◦C for 30 s,
nnealing at 54 ◦C for 45 s and extension at 72 ◦C for 30 s. Final extension was carried
ut at 72 ◦C for 10 min. Successful amplification was confirmed by electrophoresis
n a 3.5% agarose gel and PCR products were sent to Macrogen Inc. (Seoul, Republic
f Korea) (http://www.macrogen.com) for fragment analysis. Allelic sizes estima-
ion and MSI analysis were made using the GeneMarker® software (SoftGenetics,
tate College, PA). The Cr(VI)-exposed cell line would be considered MSI positive if,ltures). (C) Representative image of colonies obtained when cells from the cultures
Cr(VI). (D) Representative image of colonies obtained when cells from the cultures
r(VI). (E) Representative image of the RenG2 subclonal cell line. (F) Representative
at least, 2 out of 5 markers showed band shifting, when compared to the control,
non-exposed one.
2.7. In vivo tumorigenicity assayAll experiments were performed according to EU guidelines on the ethical use
of experimental animals (86/609/EEC). The tumorigenicity assay was performed by
s.c. injection of 107 cells suspended in 100l of sterile saline solution into four 6
weeks old BALB/c-nu/nu mice. Animals were inspected weekly for the appearance of
tumors. Two months after the injection, tumors were removed and fixed in formalin.
Two additional mice were s.c. injected with 107 and 2 × 107 BEAS-2B control cells.
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Fig. 2. Representative karyotype of BEAS-2B cells (at passage 7). (A) Cultures grown in the absence of Cr(VI). (B) Cultures grown in the presence of 1M Cr(VI), showing
alterations in various chromosomes: i(5)(q10), 14p+, 15p+, 16p+, trisomy 20, 22p+ and Xp− . (A1) Evolution of the karyotype along time in culture for control BEAS-2B cells. (B1)
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n increase on der(2) as well as i(5)(q10)del(5)(qter) both in control and Cr(VI)-treate
n (A) and (B). (C) Representative karyotype of Cr(VI)-transformed subclonal cell lin
ine. The presented percentages were calculated from the evaluation of 20 karyotyp
For the determination of their histological classification, tumors were embedded
n paraffin. Three micrometer sections were stained with hematoxylin and eosin for
icroscopic evaluation and were examined by a pathologist. Immunohistochem-
stry was performed for LCA (lymphoma marker; clone 2B11 + PD7/26), HMB-45
melanosome marker), MNF116 (cytokeratin antibody marker for carcinomas; clone
NF116), and vimentin (mesenchymal marker; clone Vim 3B4). All clones were
btained from Dako Corporation (Carpinteria, CA).
.8. Digital image
Throughout this study, cell morphology and growth pattern were continuously
onitored by microscopic observation. Inverted phase micrographs were obtained
sing a Sony Cyber Shot digital camera DSC-S600.
. Results
.1. Establishment of subclonal cell lines
In an attempt to establish malignantly transformed subclonal
ell lines, we have continuously exposed BEAS-2B cells to 1M
r(VI), a dose previously found by us to be only slightly cytotoxic
submitted for publication).Up to ca.10 passages in culture, both control and Cr(VI)-treated
EAS-2B cells displayed similar morphologies when cultivated at
he regular cell density (4000 cells/cm2). However, upon Cr(VI)
xposure, cells became increasingly less resistant to trypsinization,
s compared to control cells. By passage 12, the Cr(VI)-exposed cul-It was observed a gradual disappearance of trisomy 20 and of the 14 mosaicism and
S-2B cells. Percentages were relative to the initial karyotype variations documented
G2 (#4). (C1) Percentage of trisomies for different chromosomes in the RenG2 cell
he RenG2 cell line.
ture became non-homogeneous (Fig. 1A), with discrete collections
of cells displaying a growth pattern and/or morphologic appear-
ance distinct from those of the normal diamond-shaped epithelial
cells (Fig. 1B), a behaviour identical to that observed by our group
on a previous study (submitted for publication).
Clonogenicity assays carried out at different passages (between
5 and 13) confirmed the low cytotoxicity of the Cr(VI) dose used in
this study. In fact, when the assay was carried out in the absence of
Cr(VI), the clonogenic survival of Cr(VI)-exposed BEAS-2B cells was
only slightly lower (by less that 10% at all passages tested) than that
of the control cells. Addition of Cr(VI) to the growth medium during
the assay resulted in a higher decrease of the clonogenic survival of
Cr(VI)-treated cells (results not shown). This decreased clonogenic
efficiency was likely the result of the reported higher duplication
time exhibited by BEAS-2B cells exposed to 1M Cr(VI) (submit-
ted for publication), as prolonged exposure to this Cr(VI) dose did
not result in significant cell death (submitted for publication). Cul-
tivation of these Cr(VI)-treated cells at a very low cell density (13
cells/cm2), again in the presence of Cr(VI), deeply accentuated the
observed Cr(VI) effects, with cultures showing many areas of cells
with profoundly changed morphologies and with growth pattern
features resembling those of malignantly transformed cells. It was
also possible to observe several dense clumps containing cells with
clearly altered morphologies (Fig. 1C). Cultivation of control cells
at the same low cell density had no effect on the morphology
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Fig. 3. Representative changes in cells’ ploidy along time in culture. (A) BEAS-2B
cells grown in the absence of Cr(VI). (B) BEAS-2B cells grown in the presence of
1M Cr(VI) (B). Although a similar pattern was observed for both control and Cr(VI)-
exposed BEAS-2B cells, Cr(VI) treatment exacerbated the increase in the percentage
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Unequivocal evidence from numerous cellular experimentalf hyperdiploid metaphases (between 46 and 96) in early passages and the increase
n the number of hypodiploid metaphases (less than 46 chromosomes) in late pas-
ages. At least 30 metaphases were analyzed for each passage.
nd pattern of growth of the cells (Fig. 1D). Thus, cultivation at a
ery low density and in the presence of Cr(VI) of cells that were
eing chronically exposed to this carcinogen set the stage for the
mergence and evolution of cells portraying some of the biologi-
al hallmarks of tumor progression (e.g. foci formation, decreased
ell–cell interactions). Three subclonal cell lines [RenG1, RenG2
Fig. 1E) and CrossG1] were established from these Cr(VI)-exposed
ultures (see the Materials and Methods section for the detailed
rotocol). Control cultures also gave rise to three control subclonal
ell lines [Cont1 (Fig. 1F), Cont2 and Cont3].
.2. Karyotype evolution
Lack of detailed information on the cytogenetic constitution of
EAS-2B cells prompted the study of the evolution of the karyotype
f this cell line along time in culture. At the beginning of this study,
ith cultures at very low passages, all cells analyzed showed an
sochromosome 5 [i(5)(q10)], a terminal deletion of the short arm
f chromosome X (Xp−) and additional material on the short arm of
hromosomes 15 (15p+), 16 (16p+) and 22 (22p+) (Fig. 2A). In addi-
ion, this cell line exhibited a trisomy of chromosome 20 in nearly
0% of the metaphases analyzed, the presence of a derivative chro-
osome 14 with additional material on the short arm [der(14)]
n 70% of the metaphases, as well as structural alterations of the
anding pattern along the long arm of chromosome 2 [der(2)] on
0% of the metaphases. Karyotype evolution along the time in cul-
ure (up to #42) showed a decrease in the percentage of cells with
risomy 20 and with der(14). Increases in the percentage of cells
ith der(2) and the emergence of a terminal deletion on i(5)(q10)
i(5)(q10)del(qter)] were also observed (Fig. 2A1).esearch 670 (2009) 42–52
As illustrated in Fig. 3, in the early stages of exposure to Cr(VI),
there was an increase in the number of hyperdiploid cells relative
to the control. However, the evolution pattern of the cell line kary-
otype in the presence of Cr(VI) (Figs. 2B and 3B) was quite similar
to that observed in control cells (Figs. 2A and 3A), i.e. there was a
decrease in the number of cells with trisomy 20 and chromosome
14 mosaicism, as well as an increase in der(2) and i(5)(q10)del(qter)
(Fig. 2B and B1). More prolonged cultivation (>#25) in the presence
of Cr(VI) lead to an increase in hypodiploid cells (Fig. 3B), similar to
what was found in human bronchial fibroblasts exposed to Cr(VI)
[31]. The control subclonal cell line had a karyotype rather similar
to that of the initial cell line. In contrast, the subclonal cell lines
derived from Cr(VI)-exposed BEAS-2B cultures showed a marked
karyotypic change. Fig. 2C and C1 illustrates the aneuploid pheno-
type (ca. 80 chromosomes in over 90% of the metaphases analyzed)
of one of these subclonal cell lines (RenG2) at passage 4. Between
passages 1 and 4, a duplication of the chromosome complement of
the RenG2 subclonal cell line must have taken place, followed by
a gradual loss of chromosomes towards the aneuploid phenotype
observed at passage 4. This latter phenotype remained stable along
time in culture. It has been suggested that this chromosomal evolu-
tion reflects the earliest steps on a long process toward malignancy
[32–34]. As karyotype analysis revealed that all Cr(VI)-subclonal
cell lines were identical, only one of them (RenG2) was selected for
subsequent studies.
3.3. Evolution of the expression of biomarkers of malignant
transformation
In non-small cell lung cancer (NSCLC), as well as in bronchial pre-
neoplasia, the epidermal growth factor receptor (EGFR) is frequently
overexpressed, and its autocrine loop is considered fundamental
in regulating epithelial carcinogenesis [22,35]. CCND1 (cyclin D1)
is also frequently overexpressed in the early stages of lung car-
cinogenesis in vivo [24] and several studies revealed that CCND1
transcriptional activation in response to EGFR activation is mediated
by diverse pathways, such as the mitogen-activated protein kinase
(MaP kinase) pathway [25]. Therefore, it was reasonable to hypoth-
esize that during the process of BEAS-2B malignant transformation
these genes would be constitutively up-regulated.
The Warburg effect, the ability of cancer cells to overproduce lac-
tic acid aerobically as a consequence of exacerbated glycolysis, was
recognized long ago [36]. The basis for the Warburg effect is likely
to include activated oncogenes, inactivated tumor suppressors and
the hypoxia-inducible transcription factor HIF-1, a heterodimeric
transcription factor composed of HIF-1 and HIF-1/aryl hydro-
carbon nuclear translocator subunits [21]. HIF-1 is the regulatory
component of the HIF-1 complex and is unique to the hypoxic
response and metal stress [37]. Under normoxic conditions, HIF-1
is virtually undetectable in many normal cells [38]. However, HIF-1
is induced by the expression of oncogenes such as v-SRC, RAS and c-
MYC [39] and is overexpressed in many human cancers [21]. In fact,
its activity in cells correlates with tumorigenicity and angiogene-
sis [40]. HIF-1 regulates the expression of many genes, including
lactate dehydrogenase A (LDH-A) [21]. LDH-A, which participates in
normal anaerobic glycolysis, has been used as a marker of neoplas-
tic transformation [21]. The LDH-A gene, frequently overexpressed
in human cancers, was identified as a c-MYC-responsive target [19].
Transgenic animals constructed to overexpress c-MYC in the liver
have increased levels of glycolytic liver enzymes and overproduce
lactic acid [41].systems indicates that oncogenic factors including c-MYC [19], HIF-
1 [20] and LDH-A [21] are prevalent in many types of cancers,
being associated with cellular response to stress and demonstrating
pleiotropic properties. As illustrated in Fig. 4A cultivation of BEAS-
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B cells in the presence of Cr(VI) yielded no consistent changes
n the overall expression of genes c-MYC, HIF-1 and LDH-A, as
ell as of genes such as EGFR, CCND1 and of the MaP kinases JNK
MAP2K4), ERK (MAPK1) and p38 (MAPK14). However, in the RenG2
ubclonal cell line, the expression of all these genes was consistently
p-regulated along time in culture (Fig. 4B).
.4. Evolution of the expression of the genes that code for proteins
f the DNA repair systems and of DNMT1
As mentioned before, it has been suggested that deficiencies
n DNA repair due to inactivation of DNA repair systems and/or
o their abnormal processing of DNA lesions may be implicatedell line. These images establish a parallel between the expression profiles of CCNB1,
1, XRCC3, XRCC1 and XRCC5 genes in both Cr(VI)-exposed BEAS-2B and RenG2 cells.
rpretation of the references to color in this figure legend, the reader is referred to
in Cr(VI)-induced lung cancer. DNA methyltransferases (DNMTs),
which catalyze the covalent addition of methyl groups to cytosines
in the CpG dinucleotide context, were reported to play an impor-
tant role in the inactivation of DNA repair systems [42], in genomic
instability with increased loss of heterozygosity [43], in the acti-
vation of tumor suppressors and in the activation of oncogenes
[44]. Moreover, they have been directly implicated in the epigenetic
drift observed in malignant transformed tissues [44]. Therefore, it
was important to explore their involvement in Cr(VI)-induced lung
cancer.
In BEAS-2B cells exposed to Cr(VI), the expression of the genes
that code for proteins involved on DNA repair, namely RAD51, XRCC3
and OGG1 [homologous recombination (HR)], XRCC1 [base excision
48 C.F.D. Rodrigues et al. / Mutation Research 670 (2009) 42–52
Fig. 5. Chromatograms showing absence of instability for the microsatellite markers (A) NR-21, (B) NR-24, (C) NR-27, (D) BAT-25 and (E) BAT-26. Red peaks correspond to
the BEAS-2B control cell line whereas blue/green correspond to the RenG2 Cr(VI)-transformed subclonal cell line. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of the article.)
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cig. 6. Immunohistological analysis of the tumors induced by RenG2 cells upon s.c
B) and the positive staining for MNF116 (400×) (C) revealed the malignant epithel
f this protein, typical of normal tissue, confirming the epithelial origin of the tumo
epair (BER)], XRCC5 (NHEJ) and MLH1 (MMR), as well as that of
he DNMT1, changed randomly with exposure time (Fig. 4A). The
ontinuous and random variation of the expression of the afore-
entioned genes possibly reflects the phenotypic diversity that
esulted from exposure to Cr(VI). In contrast, the expression of all
he above mentioned genes in RenG2 was consistently up-regulated
Fig. 4B).
.5. Microsatellite analysis
Microsatellites are short, tandemly repeated nucleotide
equences that are widely distributed throughout the genome [45].
ecause of their repetitive nature, microsatellites are particularly
rone to errors during replication. Length alterations in microsatel-
ite repeats are termed MSI [45]. Frequent somatic variations in
he size of microsatellites is a characteristic of the replication
rror phenotype (RER) [46], which is most commonly caused by a
eficiency of the DNA MMR system attributable to mutation in one
f the human DNA MMR genes: hMLH1, hMSH2, hMSH3, hMSH6,
PMS1 and hPMS2 [42,45]. The recently introduced pentaplex
olymerase chain reaction of five mononucleotide repeats to
stablish the MSI status of human tumors was shown to be 100%
ensitive and specific [30]. In the present study, the microsatellite
nalysis of the RenG2 cell line with the pentaplex mononucleotide
anel showed no MSI at any marker, when compared with control
EAS-2B cells (Fig. 5). All electrophoretograms of mononucleotide
arkers showed a number of less intense stutter peaks at 1 bp
ntervals from the true allele peak, due to polymerase slippage
uring PCR amplification of each STR marker. Therefore, the RenG2
ell line does not have an MSI phenotype because, according to the
onsensus meeting guidelines, a tumor is considered MSI-H (MSItion into nude mice. The negative staining for LCA (400×) (A) and HMB45 (400×)
ture of the tumors. Vimentin staining (400×) (D) showed a ubiquitous distribution
phenotype) when at least 3 out of 5 mononucleotide repeats show
instability [30].
3.6. Tumorigenicity results
None of the two male nude mice s.c. injected with control BEAS-
2B cells developed tumors, which is in agreement with what was
previously reported by Reddel et al. [18]. Concerning the RenG2
subclonal cell line, 3 out of 4 injected mice developed one tumor
each. The immunohistological analysis of the tumor cells induced
by RenG2 in nude mice revealed negative staining for LCA and
HMB45, and positive staining for MNF116 (Fig. 6), clearly showing
characteristics of carcinoma.
4. Discussion
In the present work, a tumorigenic cell line was established by
cultivating at a very low density and in the presence of 1M Cr(VI)
cells that had been exposed to this dose of the carcinogen for several
passages. Such treatment did not induce microsatellite instability,
but lead to changes in chromosome number, to decreased cell–cell
interactions, as well as to alterations in the cells’ morphology and
growth pattern and in the expression of genes commonly associated
with malignant transformation. Moreover, when cells from one of
the subclonal cell lines obtained were injected into nude mice, it
induced tumors.Frequently, the diploid to aneuploid transition is associated with
the biological progression from phenotypically normal to malig-
nant cells [32–34]. The induction of aneuploidy and the correlated
ability to induce morphological transformation observed in this
study parallels the results obtained with other human and rodent
5 ation R
S
m
fi
t
t
m
i
f
m
p
D
c
a
r
q
r
s
t
f
i
d
o
t
o
l
C
s
t
X
s
i
i
C
c
d
p
t
t
p
(
fi
s
M
r
h
l
t
t
m
d
h
a
s
m
t
M
t
e
[
D
s
o0 C.F.D. Rodrigues et al. / Mut
V40-immortalized cells [47,48] and with a SV40-transgenic mouse
odel [49] following exposure to a chemical carcinogen. These
ndings may suggest that immortalization by SV40, which leads
o the sequestration of p53 [50], a protein that has been correlated
o the onset of tetraploidy [33], may induce malignant transfor-
ation. Nevertheless, the results of the present work confirm that
mmortalization by SV40 is not sufficient for the neoplastic trans-
ormation of BEAS-2B cells, as non-treated BEAS-2B cells are not
alignant. However, we cannot exclude that p53 deficiency may
re-dispose Cr(VI)-damaged cells to aneuploidy because cells with
NA damage may continue to divide, being subject to asymmetric
hromosome segregation every time this happens [51].
Even though the mutagenic effect of carcinogens is generally
ccepted as the driving force of transformation, a new theory has
ecently emerged pointing that changes in ploidy and the conse-
uent imbalance in gene expression may also play an important
ole [52]. As recent work showed, in cell lines with relatively high
pontaneous rates of chromosome non-disjunction in late mitosis,
he fate of the majority of cells is to become tetraploid [32]. There-
ore, cancer development may not necessarily require mutations
n cancer related genes at the DNA level, but an imbalance in the
osage of thousands of normal genes, caused by chromosomal gains
r losses by random aneuploidization [53]. Thus, cells may become
ransformed before mutations on tumor suppressor genes and/or
ncogenes occur [52].
The malignant transformation of BEAS-2B cells following pro-
onged exposure and low density cultivation in the presence of
r(VI) cannot be ascribed solely to Cr(VI) effects on chromosome
egregation and genetic instability. The finding that the transcrip-
ion of genes that code for proteins involved in DNA repair (RAD51,
RCC3, OGG1, XRCC1, XRCC5 and MLH1) is up-regulated in the
ubclonal RenG2 cell line suggests that DNA damage played an
mportant role in the process of transformation. This assumption
s reinforced by the fact that chronic exposure of BEAS-2B cells to
r(VI) increased their duplication time (results submitted to publi-
ation), which may reflect the time spent by the cells repairing DNA
amage. Additionally, BEAS-2B cells exposed for lower periods (5
assages) to Cr(VI) preserved a normal phenotype even when cul-
ivated at a very low cell density (results not shown), supporting
he premise that prolonged DNA damage is a major event in the
rogression to malignancy.
Recent data obtained with human epithelial colon HCT116 cells
MLH1−/− and MLH1+/+) and also with MMR-deficient human lung
broblasts and epithelial cells strongly suggested that chronic expo-
ure to toxic doses of Cr(VI) may result in the selective outgrowth of
MR-deficient cells [4,7]. As MMR-deficient cells exhibit very high
ates of spontaneous mutagenesis, this model could explain the
igh incidence of MSI found in chromate cancers [9,10,14], thereby
eading to the hypothesis that Cr(VI)-associated cancer cells express
he mutator phenotype (the tendency to undergo a cascade of fur-
her mutations) [54] caused by the loss of the DNA most important
utation prevention system, MMR [4]. However, our data contra-
icts this hypothesis, since the malignant RenG2 subclonal cell line
as high MLH1 transcript levels and does not exhibit MSI. Addition-
lly, the findings that the DNMT1 gene is overexpressed in RenG2
ubclonal cell line further confirms that the pathway involved in
alignant transformation of BEAS-2B by Cr(VI) does not appoint
o MSI, since reduction of DNMT1 activity was reported to reduce
MR efficiency and to increase MSI [55]. Besides, increased DNMT1
ranscript levels were reported to correlate with c-MYC mRNA lev-
ls in gastric cancers [56] and to transformation of NIH 3T3 cells
23].
In the RenG2 subclonal cell line, the genes of the most important
NA repair systems (BER, HR and NHEJ) were also actively tran-
cribed, which goes against the assertion that genomic instability
nly builds up in cells whose DNA repair pathways are seriouslyesearch 670 (2009) 42–52
compromised, as was the case with HR- [26], BER- [27] and FANCA-
(Falconi anemia) [57] deficient cells exposed to Cr(VI), which exhib-
ited increased chromosomal damage and aberrations.
The absence of neoplastic transformation of BEAS-2B cells after
prolonged exposure (>#12) to Cr(VI) at normal cell density indi-
cates that the low cell density setting provided adequate conditions
for selection of variants that were susceptible to Cr(VI) trans-
formation. Cellular Cr(VI) uptake has been reported to be very
fast, with a maximum load being reached within the first 3 h of
exposure [58]. In this study, we observed that Cr(VI)-treatment
weakened cell adhesion to the substratum. The ratio Cr(VI)/cell
was much lower at normal cell density than in the low density
cultures. Thus, in low density cultures, Cr(VI) pressure selects the
most resistant phenotypes, through a multi-stage process which,
similarly to the acquisition of drug resistance, is associated with
genomic instability. In fact, genetic instability provides a supply of
mutants from which the environment selects favourable variants
to its growth-limiting conditions [59]. As recently emerged, muta-
tions themselves are irrelevant if there is not a microenvironment
change that selects the cells carrying such mutations [60]. Thus, the
nature of the cellular microenvironment must have determined the
cells to be selected.
Activation of MaP kinases pathways has a pivotal function in
controlling cell growth, survival, differentiation and apoptosis [61].
The results obtained in the present study are in agreement with a
critical role for ERK in mitogenesis and differentiation [62]. As to
JNK and p38, our data revealed that their activation does not corre-
late with cytotoxicity. JNK and p38 were also persistently activated
[63] in human lung carcinoma cells continuously exposed to Cr(VI),
which raises the hypothesis that activation of these kinases may
support cell survival and carcinogenesis. This goes against the com-
mon association of their activation to growth arrest and apoptosis
[64].
Finally, our data indicates that in vitro Cr(VI)-induced malignant
transformation of BEAS-2B is mediated by EGFR activation, similarly
to what was reported in in vivo human bronchial pre-neoplastic and
malignant lung lesions [24].
In conclusion, similarly to chronic exposure to cigarette smoke,
the effects of prolonged exposure to Cr(VI) may also include DNA
damage and growth inhibition. These effects run in parallel with
the emergence of altered cells resistant to cytotoxicity. The devel-
opment of Cr(VI) resistance, more than the mutagenic potential of
Cr(VI), paves the way to the accumulation of mutations through the
selection of the most resistant variants. Thus, our findings in fact
suggest that the resistance phenotype pathway plays an important
role in the onset of the chromate lung cancer.
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